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Summary
With the discovery of AIDS (and the HIV virus) in the 1970’s it has become 
increasingly apparent that AIDS and other immuno-compromised patients are 
particularly vulnerable to viral and fungal infections. If left untreated these 
infections which may only cause minor discomfort in a healthy individual can 
ultimately lead to the death of the immuno-compromised patient. The disease 
trichomoniasis found in humans and caused by the anaerobic flagellate protozoa 
Trichomonas vaginalis is one such infection.
In the past trichomonal infections, including trichomoniasis, have been treated 
using 5-nitroimidazoles. However these agents can give rise to resistant strains 
of the parasite and are suspected of having mutagenic effects. The drawbacks of 
these existing treatments demonstrate the need to identify new pro-drugs of 
greater specificity towards the disease processes of viral and fungal infections.
In the case of the organism Trichomonas vaginalis, we already know that the 
organism contains the enzyme L-methionine^y-lyase and that this enzyme 
performs a function peculiar to T. vaginalis. This peculiarity is a potential source 
of increased specificity for this organism’s particular disease process and as 
such the enzyme L-methionine-y-lyase presents itself as a target for therapeutic 
attack. If the suggested role of the enzyme is correct, then specific inhibitors of 
L-methionine^y-lyase could significantly reduce or even cure the pathogenicity of 
T. vaginalis.
In recent years a large number of compounds have been found to function as 
enzyme activated suicide substrates, through loss of a halide or other good 
leaving group. The vigorous development of organofluorine chemistry together 
with further advances in the understanding of biochemical processes have led to 
an increased level of interest and research in the area of fluorine containing
aminoacids. Many fluorinated amino acids are now proving to be highly 
selective inhibitors of pyridoxal-5’-phosphate dependent enzymes.
Following a rational drug design (RDD) approach, it was our aim to synthesise 
potential anti-metabolites for the therapeutic treatment of infections arising from 
anaerobic micro-organisms and helminths, in particular focusing our attention on 
the treatment of infections arising from the anaerobic flagellate protozoa 
T. vaginalis.
The sulfur containing amino acid L-methionine plays diverse biochemical and 
physiological roles not only as a constituent of peptides and proteins but also as 
a precursor in the biosynthesis of the DNA methylating agent 
5-adenosylmethionine. In addition to its importance in both biochemical and 
physiological processes, L- methionine is a natural substrate for L-methionine^y- 
lyase. Our experimental starting point has been to try to exploit this enzyme- 
substrate binding specificity. To do this we synthesised and biologically tested 
fluorinated analogues of L-methionine for growth inhibiting properties and or 
selective toxicity in T. vaginalis, an organism known to contain 
L-methionine-y-lyase.
In addition and for comparison with L-trifluoromethionine we undertook to 
synthesise and biologically test the trifluoromethyl analogues of L-cysteine and 
D-penicillamine.
In an alternative attempt to identify a selectively toxic compound for T. vaginalis 
we also explored a mechanism based enzyme inactivation approach involving the 
2,3-sigmatropic rearrangement of an allyl sulfoxide to an allyl sulfenate ester in 
the enzyme active site. Via this approach the allyl sulfenate ester situated in the 
enzyme active site serves to derivatise and deactivate the target enzyme. This 
approach required the synthesis of 2-amino-4-chloro-5-(p-tolylsu!finyl) pentanoic 
acid from allylglycine. In an effort to extend our chemical and biological 
understanding of this alternative approach we also attempted to synthesise
analogous chloro, fluoromethyl (sulfinyl) pentanoic acid compounds. It was 
hoped that these new compounds would create more favourable equilibrium 
concentrations of the sulfenate ester in the active site and that the presence of 
fluorine would convey an increased level of toxicity through improved lipophilicity 
and susceptibility to nucleophilic attack.
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Chapter 1
The Discovery of the Role of Micro-organisms in the 
Causation of Disease
1.1 Human disease
Micro-organisms as agents of disease 
Control of bacteriological disease 
The modern era of medicinal chemistry
1.2
1.3
1.4
1.1 Human disease
A disease is a condition that impairs the proper function of the body or of one of 
its parts. Every living thing, both plants and animals, can succumb to disease. 
Hundreds of different diseases exist. Each has its own particular set of 
symptoms and signs that enable a diagnosis. Every disease has a cause, 
although the cause of some diseases still remains to be discovered. Every 
disease displays a cycle of onset, course of affliction and end, when it 
disappears or it partially disables or kills its victim.
As far back as history can be traced, including Egyptian hieroglyphics, there 
have been references made to medicinal remedies for the treatment of various 
diseases (1 ).
1.2 Micro-organisms as agents of infectious disease
Microbes are ubiquitous organisms, they are found in the soil, the air and our 
own bodies. In most individuals they can co-exist without causing any harm to
their unwitting host. However as we now know microbes can act as agents of 
infectious disease.
The discovery of the role of micro-organisms in the causation of disease was 
not made until Louis Pasteur’s studies on fermentation, carried out between 
1857 -1876. Ever conscious of the practical applications of his work, he 
devoted considerable attention to the spoilage of beer and wine, demonstrating 
that spoilage was a result of the growth of undesirable micro-organisms. 
Pasteur used a peculiar and significant term to describe these microbial 
induced spoilage processes, he called them “diseases” of beer and wine. In 
fact he was already considering the possibility that micro-organisms may act as 
agents of infectious disease in higher organisms. Some evidence in support of 
his hypothesis already existed. It had been shown in 1813 that a specific 
fungus caused diseases of wheat and rye and in 1845 M.J. Berkeley had 
proven that the great potato blight of Ireland, a natural disaster that deeply 
influenced Irish history, was caused by a fungus (2).
The first recognition that fungi may be specifically associated with a disease of 
animals came in 1836 through the work of A. Bassi in Italy on fungal diseases 
in silkworms. A few years later J.L. Schonlein showed certain skin diseases in 
man were caused by fungal infections. Despite these indications, very few 
medical scientists were willing to entertain the notion that major infectious 
diseases in man could be caused by micro-organisms, and fewer still believed 
that organisms as small and apparently simple as the bacteria could act as 
agents of disease.
Some years later a young British surgeon, J. Lister, who was deeply impressed 
by the work of Pasteur, reasoned that surgical sepsis, a serious problem of the 
day, might well result from microbial infections of the tissue exposed during 
operation. Around 1864 Lister developed procedures of antiseptic surgery and 
although these procedures were initially greeted with considerable scepticism, 
once their success in the prevention of surgical sepsis was widely recognised
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they eventually became common practice. This discovery provided powerful, 
albeit indirect, evidence for the ‘germ theory’ of disease.
The breakthrough in linking bacteria as specific agents of infectious disease in 
animals was made during the study of anthrax, a serious infection of domestic 
animals that is transmissible to humans. R. Koch, a German country doctor, 
demonstrated conclusively in 1876 that mice could be infected with material 
from a diseased domestic animal. He transmitted the disease through a series 
of 2 0  mice by successive inoculation; at each transfer the characteristic 
symptoms were observed. He then proceeded to cultivate the bacterium by 
introducing minute heavily infected particles of spleen from a diseased animal 
into drops of sterile serum. Observing hour after hour the growth of the micro­
organisms in this culture medium he saw the rods change into long filaments 
within which ovoid, retractile bodies eventually appeared, now know as Bacillus 
anthracis (2 ).
Koch carried out another series of experiments that demonstrated the biological 
specificity of disease agents. He showed that another spore forming 
bacterium, the hay bacillus, does not cause the disease anthrax upon injection. 
From this and other studies he concluded that only one kind of bacillus is able 
to cause the specific disease process anthrax, while other bacteria either do 
not produce disease following inoculation or give rise to other kinds of disease. 
This work marked the start of the golden age of medicinal bacteriology (3).
1.3 Control of bacteriological disease
The importance of acquiring immunity as a means of protection against specific 
bacteriological diseases was recognised shortly after the discovery of the role 
of micro-organisms as the agents of infectious disease. For several decades 
thereafter (from the late 1880’s to the early 1900’s) control of infectious disease 
was based exclusively on the use of antisera and vaccines, and was largely 
preventative. Usually little could be done to cure an infection once it appeared.
A different kind of approach to the control of infectious disease was developed 
in 1908 by the German physician-chemist P. Erhlich. Erhlich initiated an 
empirical search for synthetic chemicals that possess selective toxicity for 
pathogenic micro-organisms. He coined the word ‘chemotherapy’ to describe 
this approach. A few years earlier, in 1905, H. Thompson discovered that an 
arsenic containing organic compound ‘atoxyl’ was effective in treating 
trypanosomiasis, a protozoal disease common in parts of Africa and South 
America. Erhlich set out to modify atoxyl systematically in the hope of finding a 
compound which would be selectively toxic to pathogens. His efforts produced 
one success; Salvarsan (arsphenamine) which proved to be effective in the 
treatment of syphilis, caused by the protozoa Spirochaeta pallida, and other 
spirochaetal infections. Even though Salvarsan produced severe side effects, 
it remained the only treatment of spirochaetal infections and the only example 
of chemotherapy of infectious disease until the late 1920’s and the introduction 
of antibiotics (4).
The years between 1928 and 1940 were the most fruitful in the discovery and 
development of anti-microbial drugs. In 1928 a British scientist, Sir Alexander 
Fleming, noticed that a mold growing in one of his laboratory cultures was able 
to destroy that culture’s microbes. Since the mold was a species of Penicillium, 
he named the germ-killing substance penicillin. In 1941 and thanks to the 
pioneering efforts of Florey and coworkers, penicillin was used to treat serious 
infections. The results were dramatic with patients who received the drug 
making rapid and complete recoveries (5).
AsCh
arsphenamine (Salvarsan)
The next significant advance in chemotherapy came in 1935 and was also 
made empirically. Large numbers of aniline dyes were screened for anti­
bacterial chemotherapeutic activity. In this class of compounds one substance 
Prontosil, discovered by G. Domagk, was found to be effective. Its anti­
bacterial activity in infected animals was attributed to a colourless breakdown 
product sulfanilamide, formed in the animal’s body. D.D. Woods observed that 
the inhibition of bacterial growth by sulfanilamide can be reversed by the 
structural analogue p-aminobenzoic acid. Woods deduced that p- 
aminobenzoic acid is both a normal constituent of the bacterial cell and also a 
biosynthetic precursor of the coenzyme folic acid. While mammals obtain folic 
acid from dietary sources, most bacteria synthesise folic acid from p- 
aminobenzoic acid. Sulfanilamide blocks the conversion of p-aminobenzoic 
acid to folic acid by ‘tricking’ the bacteria into using it instead of the close 
structural relation p-aminobenzoic acid that it really needs. In this way 
sulfanilamide is selectively toxic to bacteria (4).
penicillin
0 = S = 0
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p-aminobenzoic acid. Sulfanilamide
1.4 The modem era of medicinal chemistry
Woods’ work in the 1930’s and 1940’s on sulfanilamide appeared to offer a 
rational approach to chemotherapy through the synthesis of analogues of 
known essential metabolites. Woods’ work marks the beginning of the modern 
era of medicinal chemistry and a shift in the medicinal chemist’s attention from 
endogenous metabolites to the biochemical processes which control the flux of 
metabolites and to the rational drug design approach.
The first step in a rational drug design process is the careful selection of a 
crucial metabolite of a key biological process believed to be critical to a 
“disease process”. The second step is to effect the conversion of the crucial 
metabolite into an anti-metabolite, that is into a compound which will as closely 
as possible mimic the metabolite whilst at the same time be different enough to 
effect inhibition of the key chemical or physico-chemical process.
CRUCIAL METABOLITE
TRANSFORMATION
f
ANTIMETABOLITE 
Summary of the rational drug design approach
Many of the important biochemical processes are enzyme catalysed reactions 
of biosynthesis and catabolism. In the years since Woods’ work on 
sulfanilamide thousands of structural analogues of amino acids, purines, 
pyrimidines and vitamins have been synthesised and tested and a number of 
useful chemotherapeutic agents discovered. One such example is 
methotrexate discovered in the 1940’s. Although the mechanism of action was 
not fully appreciated at the time of discovery, methotrexate, in its role as an
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antimetabolite, inhibits cancer tumour growth by preventing DNA synthesis. As 
a structural analogue of folic acid, methotrexate acts as a competitive inhibitor 
of the enzyme dihydrofolate reductase and prevents the formation of the 
reduced folate required for DNA synthesis (6 ).
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folic acid (methotrexate)
In the following chapter we will concentrate our discussion on enzymes as 
targets for medicinal chemistry.
Chapter 2
Enzymes in Medicine
2.1 Enzymes
2.1.1. What is an enzyme?
2.1.2 Enzymic reactions
2.2 Enzymes as targets for drug design
2.3 Substrate stereospecificity
2.4 Enzyme specific inactivation
2.5 irreversible enzyme inhibition
2.5.1 Mechanism based irreversible enzyme inactivation
2.6 Halogenated substrates
2.1 Allylic compounds
In the field of molecular sciences, enzyme chemistry occupies a special niche 
as one of the major contact points between the chemical and biological 
disciplines. The special properties of enzymes as selective and highly efficient 
catalysts are so central to current medical and chemical challenges that the 
development of enzyme chemistry over the past 40 years has been a major 
stimulus to chemical research in general.
2.1 Enzymes
Enzymes were already prompting a great deal of interest and chemical 
research in the first half of the 19th century. When we look back in the literature 
we find as early as 1833 observations had been made of the phenomenon of 
the natural hydrolysis of potato starch. At this time the idea that enzymes are
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chemicals was treated with a great deal of scepticism and controversy. Two 
conflicting views were held. The first view, held by amongst others L. Pasteur, 
believed that enzymatic activity was a property inseparable from living cells. 
Pasteur believed that living yeast cells were necessary for the fermentation 
process, hence the name ‘Enzyme’ meaning yeast was born. The second and 
opposing view, held by the prominent chemists J. Liebig and F. Wohler, 
regarded enzymes as chemical catalysts, which could be separated from cells. 
In 1897 Buchner settled the dispute by experiment. He demonstrated that a 
yeast extract was capable of sustaining the fermentation of sugar. A few years 
earlier in 1894 a series of papers published by E. Fischer discussed the 
stereoselectivity in enzyme catalysis (7). By experiment Fischer showed that 
the enzyme which hydrolyses sucrose, called ‘invertin’ by Fischer, acts only 
upon a-D-glucosides: p-D-glucosides and L-glucosides were completely 
untouched. This result along with other complementary experimental data 
proved conclusively that enzymes are discriminatory with respect to the 
configuration of their substrate. The ability of enzymes to select between 
stereoisomers still remains one of their most important and alluring properties.
The first steps in the synthetic use of enzymes were made when Croft-Hill 
demonstrated that yeast enzymes could be used synthetically and Emmerling 
reported the synthesis of amydalin using enzymes. So even at the turn of the 
century we knew many of the fundamental properties of enzymes.
2.1.1 What is an enzyme?
So what is an enzyme? This question was answered in the 1920’s after the 
successful isolation of the enzyme urease by J.B. Sumner (8 ). The purification 
and crystallisation of this enzyme and others that followed showed clearly that 
enzymes are proteins. Since then our knowledge of enzymes has greatly 
increased and we now know they act as excellent catalysts in biochemical 
reactions, accelerating reactions by factors of at least a million. In many 
biological systems the reactions do not occur at perceptible rates in the
absence of enzymes. A survey of the different types of reaction catalysed by 
enzymes reveals that the common categories of organic and inorganic 
reactions apply.
These categories include for example:
i) substitution ii) addition Hi) elimination iv) oxidation v) reduction
Although the enzyme-catalysed reaction types are very often obvious the 
mechanism by which they occur can often only be speculated since the 
structure of many enzymes are still unknown.
The mechanistic nature of enzyme chemistry has increased awareness in the 
principles of physical organic chemistry. The physical organic chemist is 
concerned with the properties of organic molecules in systematic relationship to 
their structure and reactivity. Enzyme chemistry is a logical extension of this 
interest since catalysis and specificity, the central features of enzyme 
reactions, are already very familiar concepts to the physical organic chemist.
Enzymes are much larger than any usual reaction substrate and as such 
provide the environment of the reaction. This environment is often referred to 
as the active site of the enzyme. The active site of an enzyme is a 
3-dimensional entity formed by groups that come together from different parts 
of the amino acid sequence. The non-covalent binding in the enzyme- 
substrate complex involves irreversible interactions mediated by electrostatic 
interactions, hydrogen bonds, van der Waals forces and hydrophobic 
interactions. Active sites tend to be clefts or crevices and in order to fit into a 
cleft or crevice the substrate must have a matching shape. The biological 
activity of a substrate originates from the enzyme-substrate binding.
E. Fischer’s analogy of a lock and key expressed in 1890 gives a good visual 
interpretation of enzyme substrate binding. This process of dynamic 
recognition is called ‘induced fit’. Once bound a cascade of events amplifies 
the original molecular interaction via the biological activity of different factors 
such as steric hindirance, electronegativity, dipole interactions, lipophilicity etc. 
all of which contribute to the overall process of molecular recognition.
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Schematic Representation of Enzvme-Substrate Binding 
(Fischer’s Lock and Key analogy)
Substrate
(key)
Enzyme Active Site 
(lock)
Enzyme-Substrate Binding 
(lock + key)
However it is now known that the physical rigidity of a lock and key do not 
appropriately describe the mobile enzyme-substrate interaction and that the 
active sites of some enzymes are modified by the binding of a substrate.
Enzymatic activity is influenced by:
each of which must lie within a certain range for the enzyme to function. 
Selectivity in catalysis, as Fischer surmised, is of immense importance in that it 
can be applied in a direct sense to perform both regioselective and 
stereoselective transformations in organic synthesis.
2.1.2 Enzymic reactions
Each enzyme is specific to a particular reaction or group of similar reactions 
and many enzymes will require the association of certain cofactors in order to 
function. A cofactor is the non-protein portion of the enzyme and can be a 
simple metal ion; for example copper ion is the cofactor for the enzyme 
ascorbic acid oxidase. Other enzymes contain non-protein organic molecules 
as cofactors. An organic prosthetic group is frequently referred to as a co­
enzyme. Two examples are given below (table 1). If an organism cannot 
synthesis a necessary cofactor then the cofactor must be present in small 
amounts in the diet.
i) Substrate Concentration ii) Temperature iii) pH
Table 1 - Examples of Co-enzvmes
cofactor vitamin required by organism 
to provide cofactor
structure o f vitamin
NAD+ nicotinic acid (niacin)
N
pyridoxal phosphate
pyridoxine
CH2 0 H
HO ^ CH20H
H3 c ' 7 r
In effect enzymes catalyse reactions by stabilising transition states in reaction 
pathways. By doing this selectively an enzyme determines which of several 
potential chemical reactions actually occurs.
2.2 Enzymes as targets for drug design
By elucidating the mechanism by which an enzyme catalyses a reaction we can 
further our understanding of how enzymes accomplish their tasks. With this 
knowledge we can either i) begin to design or modify molecules to become 
useful catalysts or ii) use enzymes themselves as catalysts for reactions 
outside their normal metabolic functions. It is this second possibility with which 
we will concern ourselves in the remainder of this chapter. In particular we will 
focus on the role of enzymes in the selective inhibition of key metabolic 
pathways and how this type of inhibition can be utilised in the treatment of 
medical conditions such as microbial and viral infections.
The history of medicinal chemistry is full of examples of drug searches in which 
recognition that the target at the molecular level was an enzyme came long 
after the drug was discovered. Often it was the case that a clear understanding 
of the biochemical mechanism of a particular disease only became possible 
after the drug was available. The discovery of the non-steroidal anti­
inflammatory drugs (NSAIDs) is an excellent example of this. These drugs
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were the product of extensive research programmes aimed at alleviating 
rheumatoid arthritis through the use of steroids (rheumatoid arthritis is a 
chronic crippling disease of the connective tissue which deforms the bone 
joints). Aspirin had been used in the treatment of rheumatoid arthritis for about 
half a century before the introduction in the 1950s of the powerful anti­
inflammatory steroids. These steroids, of which cortisone is an example, 
although highly effective as anti-inflammatory drugs had a tendency to induce 
hormonal and metabolic side effects and as such proved to be of only limited 
medical use. However the discovery of the anti-inflammatory steroids provided 
the stimulus in the scientific community to search for other compounds of novel 
structure with anti-inflammatory activity. These efforts led to the discovery of 
indomethacin in 1961 and shortly after ibuprofen. However it was not until 
1971 that J.R. Vane (9) was able to demonstrate that both indomethacin and 
aspirin inhibit the biosynthesis of prostaglandins, some of which are important 
mediators of inflammation. Prostaglandins are produced from the metabolism 
of arachidonic acid and their production is controlled by the enzyme cyclo- 
oxygenase.
Me OH
OHMe
cortisone
aspirin indomethacin
/ ==V /==V ^ / c°2H 
\=A=AAy
arachidonic acid
2.3 Substrate stereospecificitv
For many years it was considered that the racemic form of any chiral compound 
should in the worst case have only half the activity of the more active 
enantiomer. It is only in the last 30 years that the scientific community and the 
drug regulatory authorities have fully recognised the relevance of chirality to 
biological activity and molecular recognition (10,11). It is now commonly 
accepted that there are often likely to be differences in the uptake and 
transportation of 2 complementary enantiomers. Two antipodes can also 
exhibit different affinities and / or intrinsic activities at receptor sites, which can 
result in different responses.
e.g. the historical example of thalidomide (C13H10N2O4)
(once referred to as the safest drug ever)
Between 1959 and 1962 thousands of deformed babies were bom to West 
German and British mothers who had taken the sedative thalidomide while they 
were pregnant to alleviate morning sickness. It is now known that although the 
L-enantiomer of thalidomide acts as a sedative the D-enantiomer interferes with 
foetal growth and in particular formation of the arms and legs. (1 2 )
Me.
Me
Me
C02H
ibuprofen
H H
I I
(D) (L)
L and D enantiomers of thalidomide
It is a great challenge for chemists to understand the chemical basis for 
enzymatic catalysis and a still greater one to mimic it effectively.
2.4 Enzyme specific inactivation
Over the last couple of decades a variety of molecules, both naturally occurring 
as well as synthetic, has been shown to cause specific inactivation of some 
target enzyme. The outcome of this chemical intervention of the biological 
system can be beneficial, as in the blockage of microbial growth, or it can as is 
often the case produce toxic effects.
An understanding at a molecular level of these phenomena in chemical terms 
can be useful in elucidating how chemical transformations are effected by 
nature’s macromolecular protein catalysts, the enzymes, and in the rational 
design of drugs with maximal in vivo specificity.
At the outset we can divide chemical agents that inhibit specific enzymes into 
two categories: (i) reversible and (ii) irreversible inhibitors:
(i) Reversible inhibition is characterised by a rapid dissociation of the enzyme- 
inhibitor complex, and in general requires no chemical transformation by the 
target system to have their effect.
(ii) Irreversible inhibitors dissociate only very slowly, if at all, from their target 
enzyme. This slow dissociation is a consequence of the inhibitor binding 
tightly to the active site of the enzyme usually through covalent bonding.
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Table 2 - Common enzyme Inactivating functional groups
Types of enzyme inactivating functional groups
Acetylenes 
Halogenated substrates 
Cyclopropanes 
Thionosulfur compounds 
Quinones 
Allylic compounds 
Carbonium ion precursors
It is irreversible enzyme inhibition with which we will concern ourselves in the 
remainder of this chapter.
2.5 Irreversible enzyme inhibition
In the broad category of irreversible inhibitors of target enzymes, we can 
distinguish two groups. The first group are active site directed reagents. 
These are structural analogues of normal substrates of the target enzyme with 
one important difference, in that they have a built in reactive group (see table
2) (13). The reactive group could include any of the following:
O
terminal halogenated substrate 
e.g. tosyl phenyl chloromethylketone
epoxide
e.g. phosphonomycin
tnz
phosphorylhalide
e.g. diisopropylfluorophosphate
<
O
sulfonylhalide
e.g.phenylmethanesulfonylfluoride
These molecules take advantage of binding specificity and the predetermined 
position of some nucleophilic aminoacid side chain present in the active site of 
the target enzyme. Once in place the reactive group sets up a displacement 
reaction for covalent modification and inactivation of the enzyme.
Although useful for active site structural mapping of purified enzymes, these 
compounds are in general too indiscriminate. The reactive functional groups, 
are already present in the cellular solution and will tend to react with the first 
nucleophile they come in contact with. This is often not the target enzyme.
Due to the indiscriminate nature of this group of structural analogues they do 
not have widespread applications except in extreme situations. Some anti­
cancer drugs such as cyclophosphamide and phenylalanine mustard fall into 
this group.
The second group of enzyme specific and irreversible inactivation reagents has 
been in medical use for about the last 20 years. They differ from the first group 
in that the reactive functional group is latent while the molecule is in cellular 
solution. Only after binding to the target enzyme and subsequent to the 
enzyme beginning catalysis is the reactive chemical group uncovered. The
cyclophosphamide phenylalanine mustard
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inactivators are enzyme specific with the inactivation occurring only in the 
precise micro-environment of the target enzyme, the active site. If covalent 
capture is efficient, then only the conscripted enzyme molecule is modified and 
its catalytic activity destroyed. This class of inactivation has received several 
terminologies including; mechanism based enzyme inactivation, kcat inhibitors, 
and suicide substrates (14-19). Although the term suicidal inactivation conveys 
the role of the enzyme molecule in catalysing its own destruction, it is a 
misnomer in so far as the enzyme is not doing this deed willingly, but rather by 
mistake (2 0 ).
2.5.1 Mechanism based irreversible enzyme inactivation
In order for a compound to fall into the category of a mechanism-based enzyme
inactivator it must meet certain chemical and kinetic criteria:
i) As with any substrate where physical binding to the enzyme active site 
precedes catalysis, the inactivator should follow the simple minimal scheme, 
where a binding equilibrium following first order kinetics leads to 
inactivation.
ii) If the covalent modification that leads to enzyme activity destruction is a 
mechanism-based process that derivatises a key aminoacid residue of the 
enzyme, the chemical stoichiometry of modification should be a 1 :1  adduct / 
enzyme ratio.
In the case of some multimeric enzymes, substoichiometric labelling can cause 
complete activity loss. Thus when the bacterial enzyme methionine^y-lyase is 
inactivated by propargylglycine, 2  labels per tetramer block all activity. 
Presumably the two modified sub units show altered conformations that are 
transmitted by inter-subunit contacts to the unmodified subunits (21). Higher 
stoichiometry values probably reflect non-specific alkylation processes (2 2 ).
iii) A final criterion which is both useful mechanistically in identifying the nature 
of the inactivating species and also in the evaluation of any in vivo
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therapeutic potential is the partition ratio, the simple M  k* This represents 
the number of times a suicide substrate is processed by the enzyme to 
produce a product (P) without harming the enzyme, for every inactivation 
that occurs.
The mechanism-based class of activators requires the enzyme go at least part 
way through its normal chemical catalytic cycle before the latent functionality is 
uncovered. Therefore in designing a drug we would require to know how often 
the catalytic cycle is completed compared to how often it is re-routed into 
covalent derivatisation of the enzyme. Maximal specificity will be represented 
by complete derivatisation of the enzyme.
When route k3 is followed molecules of P produced and released are unlike the 
latent groups in the substrate and are fully uncovered and reactive. These 
reactive product molecules can then diffuse to other cellular components and 
alkylate or acylate them. This on a microscopic scale is a loss of specificity 
and on a macroscopic scale would be a source of side effects or toxicity.
In the drug design approach of mechanism based enzyme inactivation, the two 
classes of functional groups with which we will concern ourselves are 
halogenated substrates and allylic compounds.
2.6 Halogenated substrates
In recent years a large number of compounds have been found to function as 
suicide substrates through loss of a halide or other good leaving group. The 
mechanism of enzyme inactivation involves carbanion formation, at a site
E +
covalent
inactivation
adjacent to the leaving group, generating a conjugated allylic system. This 
conjugated system then undergoes Michael addition to release the leaving 
group and yield the alkylated and deactivated enzyme (23). Since pyridoxal 
dependent enzymes specialise in generating a- and (3-carbanion equivalents 
during catalysis, almost all the target enzymes in this group are pyridoxal 
dependent enzymes. Since aminoacids are substrates of pyridoxal phosphate 
dependent enzymes, (3-halo-a-amino acids can act as suicide substrates for 
this class of enzymes.
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Mechanism of pyridoxal phosphate dependent enzyme inactivation
e.g. Replacing the leaving group X with F (fluorine) in the above scheme 
demonstrates the method by which (3-fluoroalanine inactivates the bacterial 
enzyme alanine racemase on a molecular level (24, 25).
2.7 Allvlic compounds
Although some enzymes are able to process ally lie functionalities most cannot. 
By introducing a reactive allylic bond in the active site of an enzyme which 
does not routinely encounter any it is possible to trigger mechanism based 
alkylative inactivation of the enzyme. To demonstrate allylic bond deactivation 
we can look to the y-substituted a-amino acid vinylglycine. In the 
transamination pathway when vinylglycine is transaminated by a pyridoxal 
phosphate dependent transaminase, the bound product can then either be 
released or captured in an inactivating Michael attack as shown (26, 27).
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22
Chapter 3
Fluorine in Medicine in the Twentieth Century
3.1 Fluoroorganic chemistry - a brief history
3.1.1 Biochemical applications of fluorine
3.2 Fluorine the enabler
3.3 Fluorine-containing anti-viral and anti-bacterial agents
3.3.1 Fluorine-containing anti-viral agents
3.3.2 Fluorine-containing anti-fungal agents
3.3.3 Fluorine-containing amino acids
The unique properties of fluorine make it a very useful addition to the medicinal 
chemist’s toolbox. The importance of fluorine in successful drug design and in 
the pharmaceutical industry in general is increasingly reflected in the growing 
proportion of new drugs containing fluorine.
3.1 Fluoroorganic chemistry - a brief history 
Fluoroorganic chemistry is almost entirely a man-made subject and the 
fluorocarbon branch of chemistry has jokingly been described as ‘unnatural 
product chemistry’.
Only 10 naturally occurring fluoro metabolites have been discovered so far and 
they are all monofluorides. Monofluoroacetic acid was the first to be 
discovered in 1944 and isolated from the South African plant Dichapetalum 
cymosum (28, 29, 30). Monofluoroacetic acid is now known to occur in more
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than 30 other plant species and is produced by the bacterium, Streptomyces 
cattleya. Another naturally occurring fluorine containing product is the 
antibiotic fluoro sugar nucleocidin, produced by the soil bacterium 
Actinomycete of the genus Streptomyces.
H2 N—S—0
OH OH
nucleocidin (natural product used as an antibiotic)
Bench chemists have easily outstripped nature (31), having so far reported in 
the region of 7 X 105 compounds containing one or more C-F bond. The first 
and simplest fluoroorganic compound, methyl fluoride, was synthesised in 1835 
by Dumas and Peligot (32). Dumas and Peligot described the reaction as a 
displacement of the sulphate group by fluorine, a reaction of the type now 
described as an SN2 displacement.
2KF + (CH30)2S02 2 CH3F + K2S04
Sn2  displacement reactions using fluoride are now amongst the most widely 
used methods of synthesising aliphatic C-F bonds.
The next major step forward in organo fluorine chemistry did not come until the 
early 1880’s, when Palemd and Oleveri synthesised monofluorobenzene 
utilising the then emerging arenediazonium mediated methodology.
ArN2+ + F' ->  ArF + N2
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In 1898 the Belgian chemist Swarts reported the conversion of phenyl 
trichloromethane (C6H5CCI3) to phenyl trifluoromethane (C6H5CF3) now a fluoro 
aromatic building block of great commercial value (32). At this time Swarts was 
already considering ways of incorporating fluorine into aliphatic hydrocarbons. 
By the turn of the century and via aliphatic halogen exchange reactions 
involving metal fluorides and in particular antimony fluorides, e.g. SbF3 now 
known as Swarts reaction reagents, Swarts was able to synthesis the first 
fluorinated aliphatic hydrocarbons. Swarts’ discoveries provided the impetus in 
the 1930’s for the production of chlorofluorocarbon refrigerants (brand name 
Freon), marking the first commercial application of organo fluorine chemistry. 
This was quickly followed by the discovery by Plunkett and Rebok of the 
polymer poly(tetrafluoroethylene) which was produced for use in World War II 
but not fully commercialised until 1950 under Dupont’s Teflon brand and ICI’s 
Fluon brand in 1956 (32). It was also around this time that the first real 
progress in biochemical applications of fluorine were made.
3.1.1 Biochemical applications of fluorine
In the mid 1880’s Peter Griess prepared the first fluorine analogue of a natural 
product, fluorohippuric acid C6H4FCONHCH2CO2H, but it was not until 1948 
during World War II that the first real progress in biochemical applications was 
made. During World War II the prominent biochemist Sir Rudolph Peters, 
through his pioneering work on fluoroorganic compounds, demonstrated the 
toxic effects of monofluoroacetic acid. He showed that monofluoroacetic acid 
has no effect on acetate metabolism, but induces the toxic accumulation of 
acetic acid in the kidneys and liver of a guinea pig (33). This discovery led to 
the concept of ‘lethal synthesis’. In this case monofluoroacetic acid is 
converted metabolically to a 2-fluorocitrate diastereoisomer (2R, 3R) which is 
thought to exert its toxic effect through inhibiting the enzyme mediated 
isomerisation of citrate to iso-citrate in the mitochondria (34).
CH2FC02'Na* LDso™* = 0.2mg/Kg
Note: The lethal dosage for a 70kg man is ca 400mgs.
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Therefore in any drug design approach careful attention must always be given 
to metabolic pathways to ensure monofluoroacetic acid is never a byproduct.
A well known and striking example of fluorotoxicity is found in 
w-fluoroalkylcarboxylic acids. H2CF(CH2)xC02H. When X is an even number; 
X = 2,4,6, etc. the carboxylic acid is toxic. When X is an odd number;
X = 1,3,5, etc. the carboxylic acid is non toxic. This example has been hailed 
as a beautiful verification of the theory of p-oxidation of fatty acids.
Because they are biosynthesised from the 2 carbon acetyl groups in acetyl 
coenzyme A, almost all naturally occurring fatty acids have an even number of 
carbon atoms.
Example:
cy-monofluoropalmitic acid is toxic
From the late 1950’s to the present day represents a period of major 
advancement in the history of medicine. Fluorine containing medicines, 
frequently made available by the use of new reagents and improved handling 
techniques for the introduction of fluorine, have contributed greatly to these 
advances. Notable historical events during this time include the first 
commercial fluorinated inhalation anaesthetics Fluoroxene (1953) and 
halothane (1956) (35, 36) and the pioneering work of Fried and Sabo in 1954 
on the preparation of 9a-fluorohydrocortisone acetate (37). Fried and Sabo’s 
work led to the first significant reporting of a useful, not harmful, modification of 
biological activity through selective fluorination. In tests on rat liver glycogen 
Fried and Sabo found that 9a-fluorohydrocortisone acetate possesses 11 times 
the activity of hydrocortisone acetate.
O C k X F s
F3C ir
HO
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"OH
fluorooxene halothane 9,a-fluorohydrocortisone
historical inhalation anaesthetics first fluorinated steroid analogue
C. Heidelberger and coworkers in 1956, through their investigations on the 
fluorinated pyrimidine 5-fluorouracil made significant advances in the treatment 
of cancer (38). Since then a great deal of the medicinal chemists’ time has 
been spent synthesising and screening fluorinated pyrimidines for tumour 
inhibiting anticancer and antiviral activity.
O
I
H
5-fluorouracil (1956), nucleic acid antagonist
Over the past 40 years the wide range of applications of fluorine in medicine 
has been phenomenal and for perspective a cross section of examples is giveni
below:
i
i
j perfluorodecalin (1970), blood substitute
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F C02H
F— F W  ^{
diflunisal (1977), salicylic acid analogue 
A nonsteroidal anti-inflammatory drug used in the treatment of osteoarthritis. It 
is quickly absorbed into the body and is much more effective than aspirin.
perflubron (1993), (Imagent - perflubron emulsion), oxygen transport /
sonography contrast agent
[-CH2-CF2-]n
polyvinylidene fluoride (synthesised 1960’s)
With its good thermal properties, mechanical strength and chemical inertness 
polyvinylidene fluoride can be processed into precision parts for orthopaedic 
applications (1990’s).
3.2 Fluorine the enabler
So what advantage does fluorine offer? The incorporation of fluorine into a 
molecule with the aim of improving therapeutic efficiency is based on several 
key considerations (32):
CF3(CF2)7Br
• Fluorine is the second smallest substituent after hydrogen and closely 
mimics hydrogen with respect to steric requirements at the enzyme 
receptor.
van der Waals radius [A]
CH3 = 2.1 CF3 = 2.5 CCi3 = 3.5 CCH3 = 3.5
Fluorine is the most electronegative element and it frequently alters the 
electron density, basicity and acidity of neighbouring groups and thereby 
their chemical reactivity.
Electronegativity (according to Pauling)
H = 2.1 C = 2.5 F = 4.0
The strength of the C-F bond exceeds that of the C-H bond. This 
difference often results in increased thermal and oxidative stability of the 
modified substrate. This property has been exploited in attempts to protract 
the action of a drug by blocking the sites involved in oxidative degradation.
Bond energies [kJmor1]
C-H = 416 C-F = 485 C-CI = 328
The replacement of hydrogen by fluorine increases lipid solubility. The CF3 
group is amongst the most lipophilic of all the substituents. This property 
may contribute to the absorption, transportation and delivery of the modified 
substrate to its biological target. The effective concentration of the drug in 
the target tissue can thus be increased by improving the ability of the 
molecule to penetrate the lipid bilayers.
Lipophilicity [n]
CH3 = 0.50 C2H5 = 1.00 CF3 = 1.07
Only a few higher plants and bacteria are able to metabolise inorganic 
fluoride, and naturally occurring organofluorine compounds are extremely 
rare (39-43). Therefore metabolic breakdown or transformations of the 
modified substrate, as a consequence of fluorine incorporation, is highly 
unlikely.
3.3 Fluorine containing anti-viral and antibacterial agents
In the past couple of decades medicinal chemists have been rigorously 
exploring the use of fluorine as a replacement for hydrogen at sites which are 
subject to metabolism, with a particular focus on viral and bacterial metabolic 
pathways.
With the discovery of AIDS (and the HIV virus) in the 1970’s it has in the years 
since become increasingly apparent that AIDS and other immuno-compromised 
patients are particularly vulnerable to viral and fungal infections. In many 
cases if left untreated these infections can eventually lead to the death of the 
immuno-compromised individual.
In the field of anti-viral and anti-fungal agents there exist many examples where 
a methyl group has been replaced by either fluorine or trifluoromethyl with 
retention of biological activity.
3.3.1 Fluorine containing anti-viral agents
More than three decades of focused anti-viral research (spanning the 1960s - 
1990s) have yielded only a handful of drugs approved by the FDA (Food and 
Drug regulatory Authority) for the treatment of human viral diseases.
Trifluorothymidine was the first fluorine containing anti-viral drug to be 
marketed. Trifluorothymidine was designed as a thymidine mimetic and was 
first synthesised in 1962 as part of a programme directed towards the discovery 
of anti cancer agents (44). However its biological activity is mediated through 
phosphorylated metabolites and this limits its clinical application to the topical 
treatment of the HSV (Herpes Simplex Virus) virus.
0HO
OH
trifluorothymidine
Designed as an analogue of thymidine, 3’a-fluoro thymidine was reported in 
1988 as having wide ranging anti-viral activity (45). It is more potent than AZT 
against HIV and was progressed to clinical trials in AIDS patients. 
Unfortunately development of this drug was terminated through its failure to 
produce efficacy at doses with acceptable side effect profiles (46).
Among the class of randomly screened compounds TBZ has been reported as 
possessing anti HIV activity, attributed to its ability to inhibit reverse 
transcriptase (47). However as far as I am aware this compound was never 
progressed to full scale clinical trials.
0
3’a-fluorothymidine
(AZT)
TBZ
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In the fight against AIDS the search for a more effective (even curative) anti­
viral agent with minimal to no side effects continues.
3.3.2 Fluorine containing anti-fungal agents 
Until recently the choice of anti-fungal therapies was limited (48), with 
amphotericin B being the only drug of choice in the treatment of systemic 
fungal infections. However use of amphotericin B is accompanied by several 
drawbacks including the need to administer it via slow intravenous infusion 
over several hours and the risk of adverse side effects of fever, nausea and 
renal toxicity. The discovery of the fluorine containing drug fluconazole in 1993 
by the pharmaceutical company Pfizer, marked a major step forward in the 
treatment of anti-fungal infections (49). Fluconazole can be given orally or 
intravenously and its excellent safety profile means that doses of up to 2 g per 
day are well tolerated by patients with few if any side effects. Today 
fluconazole is the global market leader in the treatment of anti-fungal 
infections.
OH
OHL  NH2
amphotericin B, anti-fungal agent
Ffluconazole (Diflucan - brand name), anti-fungal agent
3.3.3 Fluorine containing amino acids
Even if we were to disregard the unique importance of amino acids in the 
initiation of life on earth, compounds of this class possess a sufficient number 
of biological functions to be of fundamental necessity to all living organisms. 
The synthesis of amino acids and their analogues must therefore be 
considered to occupy a position of great importance in modern bioorganic 
chemistry and in the creation of new medicines.
The vigorous development of organofluorine chemistry since the 1940’s, 
together with recent advances in biochemical understanding have created a 
wave of interest in the research of fluorine containing amino acids. The 
interest in these compounds is in many respects due to the fact that most of 
them are proving to be highly selective inhibitors of 5’ pyridoxal phosphate 
dependent enzymes.
The first successful fluorination of an amino acid as part of an anti-fungal drug 
design approach came in 1970 with the discovery of the novel anti-fungal p- 
fluoro-D-alanine. This structurally simple molecule was found to be of equal 
activity to tetracycline and chloramphenicol with respect to in vivo anti-bacterial 
activity in mice. Microbiologists were later able to prove that in agreement with 
design ideas, anti-bacterial p-fluoro-D-alanine interferes with the biosynthesis 
of D-alanine via enzymatic deactivation of alanine racemase (24, 25).
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Chapter 4
Methionine and Methionine-v-lvase as Agents for Drug Design
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Summary of the rational drug design process so far
Following a rational drug design (RDD) approach, it was our aim to synthesise 
potential anti-metabolites for the therapeutic treatment of infections arising from 
anaerobic micro-organisms and helminths. As discussed in chapter 1 the first 
step of the RDD was to identify a metabolite of key significance to a biological 
process.
4.1 Kev metabolite - L-methionine
There is a great diversity of organic sulfur compounds which are of 
fundamental importance biologically. The sulfur containing amino acid L- 
methionine plays diverse biochemical and physiological roles not only as a 
constituent of peptides and proteins but also as a precursor in the biosynthesis 
of 5-adenosylmethionine. 5-Adenosylmethionine is involved in many important 
biological processes and acts as a methylating agent in the methylation of DNA 
and proteins. 5-Adenosylmethionine also plays a role in the biosynthesis of 
polyamines, essential elements in cellular growth (50, 51).
nh 2
Me
H02C
N H 2  oh  oh
5-adenosylmethionine
Thus preparation of analogues of methionine as potential anti-metabolites 
holds promise for the treatment of disease because of the metabolic 
significance of the parent compound.
4.2 Metabolic pathway of L-methionine in mammals
In mammalian cells L-methionine catabolism has been identified as following
the transaminative pathway (50, 52, 53).
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transaminative pathway showing the catabolism of L-methionine
in mammalian cells
A similar mechanism has been proposed for the catabolism of methionine in 
aerobic bacteria and fungi (54, 55).
4.3 Trichomonas vaginalis and trichomoniasis
Trichomonads, including Trichomonas vaginalis and Trichomonas foetus which 
are parasites of the urogenital tracts of humans and cattle respectively, are 
anaerobic flagellate protozoa. Cysteine and related thiol compounds are
thought to play important roles in countering oxygen toxicity and maintaining 
the cell integrity of these anaerobic flagellate protozoa.
Abortion and sterility are symptomatic of cattle infected with Trichomonas 
foetus, while Trichomonas vaginalis is responsible in humans for the sexually 
transmitted disease trichomoniasis. Although some colonies of Trichomonas 
vaginalis are assymptomatic most are not, producing in men a burning 
sensation during urination and in women an itching or burning sensation of the 
vagina accompanied by a foul smelling discharge. It is estimated that up to 
2 0 % of the human population may be or may have been infected with this 
disease. In the past trichomoniasis was usually treated using 5-nitroimidazoles 
such as metronidazole (commercially available as Flagyl, Metrogel, Metrolyl, 
Vaginyl amongst others trade names) and nimorazole. However these agents 
can give rise to resistant strains of the parasite and are suspected of having 
mutagenic effects. Thus demonstrating the need for new pro-drugs of greater 
specificity to the disease process.
It is Trichomonas vaginalis upon which our drug design discussion will centre 
on in the remainder of this chapter. Trichomonas vaginalis is known to contain 
operative amounts of the enzyme methionine^y-lyase.
4.4 Methionine-r-lvase
The enzyme methionine-y-lyase catalyses the breakdown of L-methionine to 
a-ketobutyrate, ammonia and methanethiol in some bacteria, but is apparently 
absent from mammals. The D-enantiomer of methionine is not a substrate for
N
CH2 CH£)H
metronidazole, (trade name Flagyl, etc.)
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the enzyme, nor does it inhibit competitively the enzyme’s activity. This 
indicates that the L-configuration at the a-carbon is necessary for binding of the 
substrate to the active site. The purified methionine^y-lyase of T. vaginalis has 
no activity towards the substrate cystathionine and is therefore clearly distinct 
from the mammalian enzyme y-cystathionase (56, 57). (Cystathionine purified 
from the rat liver can participates in enzyme catalysed a- and y-elimination 
reactions and is a known substrate of the mammalian pyridoxal phosphate 
dependent enzyme y-cystathionase).
cystathionine methionine
4.5 L-methionine-^y-lvase as a target enzyme for drug design
The enzyme L-methionine^y-lyase of T. vaginalis is similar in many ways to 
bacterial L-methionine-y-lyase, both enzymes catalyse y-eliminations (e.g. with 
methionine or ethionine) and p-eliminations (e.g. with S-methyl-L-cysteine) 
reactions (56, 58).
Inhibition of L-methionine^y-lyase in T. vaginalis by known inhibitors of 5- 
pyridoxal phosphate dependent enzymes such as D,L-propargylglycine 
indicates that the parasite enzyme is a pyridoxal phosphate dependant 
enzyme.
propargylglycine
When cell free extracts of 7. vaginalis were presented with a-keto-y- 
methiolbutyrate, an important intermediate in mammalian degradation of 
methionine, a low rate of catabolism was observed. This suggests that a-keto- 
y-methiolbutyrate is not an intermediate in the main route of methionine 
catabolism by 7. vaginalis. In studies it was demonstrated that 7. vaginalis 
catabolises L-methionine by simultaneous deamination and dethiomethylation 
to give a-ketobutyrate, ammonia and methanethiol (56, 59, 60).
Me L-methionine
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L-methionine catabolism in Trichomonas vaginalis
When compared with other trichomonads it is surprising to find that 
L-methionine^y-lyase is present at relatively high concentration in only 7  
vaginalis. A major difference between trichomonal and bacterial L-methionine- 
y-lyase is the lack of detectable NH3 with the trichomonal enzyme. Both these 
findings suggests the enzyme performs a function peculiar to 7. vaginalis and 
that the differences could be a source of increased specificity for the disease 
process and possible commercial exploitation.
It has been suggested that the production of methanethiol in 7. vaginalis may 
be linked to the interactions of the parasite with its host and other micro­
organisms present at the site of infection, the most important site being the 
human vagina. The production of methanethiol affects mammalian cells and
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other vaginal flora micro-organisms and is the cause of the foul smelling odour 
often a characteristic symptom of the disease trichomoniasis. Interestingly it 
has been documented that some higher plants produce volatile thiols as 
repellants against predators and parasites (52, 61-66).
L-methionine^y-lyase may play a part in the survival of the parasite within the 
host and the host bacterial environment and also in its pathogenic role. 
Support for this suggestion comes from the observation that the enzyme does 
not appear to be essential to the activity of T. vaginalis in axenic culture (a 
culture medium in which only one type of micro-organism is growing - used to 
determine basic growth requirements in microbiology).
Since L-methionine catabolism in T. vaginalis differs from that found in 
mammals and other vaginal flora bacteria, the enzyme L-methionine^y-lyase 
presents itself as a target for therapeutic attack. If the suggested role of the 
enzyme is correct, then specific inhibitors of L-methionine^y-lyase could 
significantly reduce or even cure the pathogenicity of intravaginal trichomonal 
infections.
4.6 Summary of the rational drug design process so far
Target Disease Process -------- ► trichomoniasis
Key Metabolic Process -------- ► L-methionine catabolism in
Trichomonas vaginalis
Specificity target enzyme - methionine-y-lyase
Key Metabolite L-methionine
Key metabolite (L-methionine)
transformation
▼
Anti-metabolite
Summary of identified key components in the rational drug design process
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Having now chosen, via the drug design approach, the target enzyme and key 
metabolite the next step was to transform the selected metabolite into an anti­
metabolite. The basic notion of forming an anti-metabolite is to modify the 
metabolite maximally with respect to chemical character, but minimally with 
respect to distortion of geometry, now termed isogeometric modification. The 
role of L-methionine as a methyl donor suggests that substitution of another 
group such as fluorine or trifluoromethyl for the essential methyl might prove to 
be of particular value.
The chapter that follows will discuss ways of synthesising methionine anti­
metabolites by incorporating fluorine into methionine and related compounds 
with a particular emphasis on the thiomethyl moiety.
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At the outset of this research programme and in collaboration with Professor 
G.H. Coombs’ research group at the Department of Parasitology, University of 
Glasgow, it was agreed that a suitable starting point for this project would be 
the efficient preparation of L-trifluoromethionine.
Professor G.H. Coombs’ research group was and still is developing methods to 
elucidate the metabolic pathways of trichomonads and how they interact with 
mammalian cells, focusing in particular on the mechanism of action and 
inhibition of the enzyme methionine -7 -lyase in Trichomonas vaginalis.
5.1 Historical developments in fluorine chemistry leading to the preparation 
of the first fluorinated analogue of methionine
The synthesis of fluorinated sulfur containing amino acids has been led mainly 
by developments in fluorine chemistry and the advent of more user friendly 
preparative techniques and reagents for the introduction of fluorine.
Synthesis of organic molecules containing fluorine can be achieved in one of 
two ways. One can either i) introduce fluorine directly using a fluorinating 
agent such as an alkali metal fluoride (this method often requires special 
equipment and handling expertise), or ii) one can follow an indirect route and 
use fluorinated building blocks (reagents which already have the desired C-F 
bond(s)). This second option is usually preferred by non fluorine specialists 
and has been the most popular method of choice in the reported preparation of 
fluorinated analogues of methionine.
5.1.1 Early perfluoroalkvl derivatives of sulfur and sulfur containing 
compounds
It was not until the 1950’s that the first reported perfluoroalkyl derivative of 
sulfur was made by Silvey and Cady (67). In their report they describe the 
fluorination of carbon disulfide by cobalt trifluoride to yield trifluoromethyl sulfur 
pentafluoride as the main product.
©
NH3
L-trifluoromethionine
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main product
A couple of years later in 1952, G.A.R Brandt and co-workers (6 8 , 69) showed 
that trifluoromethyl iodide and sulfur could react in a stainless steel autoclave 
at 260°C to give bis(trifluoromethyl) disulfide C2S2F6 as the main product. One 
year later, in 1953, R.N. Hazeldine and J.M. Kidd published a report (70) 
describing the synthesis of mercuric trifluoromethyl mercaptide from the 
reaction of bis(trifluoromethyl) disulfide with mercury.
5.1.2 The first synthesis of D.L-trifluoromethionine 
In 1957, taking their lead from Hazeldine and Kidd’s work on the synthesis of 
mercuric trifluoromethyl mercaptide, R.L. Dannley and R.G. Taborsky were the 
first to synthesise D.L-trifluoromethionine (71). Their synthesis involved first 
converting mercuric trifluoromethyl mercaptide to the mercaptan, then reaction 
of the mercaptan with acrolein in the presence of cupric acetate to yield 
trifluoromethyl mercapto propionaldehyde. Trifluoromethyl mercapto 
propionaldehyde was then easily converted to the D.L-trifluoromethionine in 3% 
overall yield.
260° C
8 (F3 C—  I) + Sa ► 4(F3 CS—  SCF3) + 4 l2
main product
F3 CS—  SCF3  Ha' 15°°£ (F3 CS)2 Hg
HCI /  dioxan
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F3 CSH
Cu(CH3C02 )2, CHCI3
CH2CHCHO, s j ,  1. NH4CO3, NaCN, n  EtOH, 50 - 55°C
O  2. HCI, 90°C
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HN. H20, NaOH,
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D, L-5-(P-trifluoromethylmercaptoethyl)hydantoin D, L-trifluoromethionine
At this time neither Dannley and Taborsky or any other research group 
reported any attempt to improve the yield or to test trifluoromethionine for 
biological activity. It was not until the advent of radical ion trifluoromethylation 
and its applications in the perfluoroalkylation of aliphatic hydrocarbons that the 
synthesis of fluorinated analogues of methionine was revisted.
5.2 Radical ion trifluoromethylation
In the early 1970s Bunnett and co-workers demonstrated that unactivated aryl 
halides readily enter into reactions with nucleophilic agents in liquid ammonia 
after initiation by potassium or U.V. irradiation (72-74). For these reactions 
they proposed a nucleophilic Srn1 mechanism involving the generation of the 
radical anion of the initial molecule, its conversion into a radical and 
subsequent reaction of the radical with the nucleophilic reagent.
V.N. Boiko and associates in 1977 (75), building on the earlier work of Bunnett 
and coworkers, proposed that perfluoroalkyliodides would also be capable of 
reacting with nucleophilic agents in an analogous type of reaction. This was in 
spite of the opposite polarisation of the C -l bond compared with alkyl and aryl 
iodides.
In terms of chemical characteristics perfluoroalkyl iodides differ greatly from 
their hydrocarbon analogues. This is explained by the opposite polarisation of 
the trifluoromethyliodide CF38'- I8+ to that of alkyl halides CH38+- I8‘, which gives 
rise to greater electronegativity in the CF3 compared with iodine (76, 77) As a
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result of this difference in electronegativity, perfluoroalkyl iodides do not 
possess alkylating characteristics.
Boiko and associates found that trifluoroiodomethane alkylates aliphatic, 
aromatic and heterocyclic thiols during U.V. irradiation in a pyrex flask. In 
addition their paper reports that trifluoromethylation of thiols can be realised 
not only in liquid ammonia but also in organic solvents such as methanol, 
acetone or acetonitrile in the presence of alkaline agents such as sodium 
hydroxide or sodium methoxide, although better results are obtained using 
sodium methoxide. This is probably a consequence of water formation by the 
action of sodium hydroxide on thiols.
The mechanism of trifluoromethylation of thiols used by Boiko is evidently 
consistent with the SRN1 type mechanism proposed by Bunnett and coworkers 
for the action of arylhalides on thiophenols.
SrN1 mechanism
RS0  + CF3I --------► RS* + (CF3IT
(CF3I)-  ► CF3 ♦ I0
RS0  + CF3 --------► (RSCF3f
(RSCF3f  + CF3I --------► RSCF3 ♦ (CF3I)1
5.3 Synthesis of di and trifluoromethionine
In 1989, and following an upsurge of interest in the scientific community in 
general towards fluorinated amino acids and their application in medicine, M.E. 
Houston Jr and J.F. Honek, set about investigating how they could more 
efficiently synthesise fluorinated analogues of L-methionine. In their 
communication of 1989 (78) they describe the synthesis of di and trifluoro 
analogues of L-methionine.
Houston and Honek were able to synthesise (i) L-difluoromethionine 
(previously unknown) and (ii) L-trifluoromethionine (previously prepared in 3% 
overall yield by Dannley and Taborsky) from N-acetyl homocysteine 
thiolactone.(78), affording overall yields of 24% and 26% for 
L-difluoromethionine and L-trifluoromethionine respectively. Although Houston 
and Honek had proposed to conduct biological studies on these compounds, to 
our knowledge no results were ever published.
N-acetylhomocysteinethiolactone
5.4 Synthesis of monofluoromethionine
In addition to synthesising di and trifluorinated analogues of L-methionine, 
Houston and Honek in the same paper of 1989 (78) reported the synthesis of 
L-monofluoromethionine. Their synthesis involved the direct reaction of DAST 
with the protected L-methionine sulfoxide. Their findings were that although 
isolable in the protected state, the hydrolytic instability of the FH2C- 
functionality ultimately led to its decomposition.
1 ©
NH3
L-monofluoromethionine
A similar decomposition observation was cited in an earlier paper by A.F. 
Janzen and coworkers (79). In their paper, describing the monofluorination of
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protected methionine with xenon difluoride, they found both aqueous and non- 
aqueous solutions of HF, HCI or TFA led to the decomposition of L- 
monofluoromethionine even when in the protected state condition.
It was at this point in the historical development of fluorinated analogues of 
methionine that that we decided to pursue the synthesis and biological testing 
of trifluoromethionine and other related fluoro analogues of L-methionine.
5.5 Initial aims of this research project
Our experimental starting point was to repeat the syntheses of Houston and 
Honek, via a modified and higher yielding route, and biologically test the 
difluoro and trifluoro analogues of L-methionine for growth inhibiting properties 
and or selective toxicity in Trichomonas vaginalis.
L-trifluoromethionine L-difluoromethionine
Subsequent to embarking on a programme of chemical synthesis and biological 
research, a communication was published (80), pertaining to a new and more 
convenient method of preparation of the trifluoromethyl analogues of 
methionine, cysteine and penicillamine. This work, carried out by 
V. Soloshonok and coworkers, involves the direct trifluoromethylation under 
U.V. irradiation of the unprotected and enantiomerically pure amino acid with 
trifluoromethyliodide.
In this communication Soloshonok and coworkers make no reference to the 
biological activity of any of the three compounds. It was decided to repeat their 
methods of preparation to synthesise and biologically test L-trifluoromethyl 
cysteine and D-trifluoromethyl penicillamine.
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L-trifluoromethyl cysteine D-trif!uoromethyl penicillamine
5.6 Enzyme inactivation via r2.31-siamatropic rearrangement 
In 1979 C. Walsh and R.A. Firestone published details of a novel mechanism 
based enzyme inactivation strategy (81) . Their proposal was to invoke a 
mechanism based enzyme inactivation through inducing a 2,3-sigmatropic 
rearrangement of an allyl sulfoxide to an allyl sulfenate ester in the enzyme 
active site. The allyl sulfenate ester, which is highly reactive to nucleophilic 
addition, would then serve to derivatise the target enzyme. As a result of 
derivatisation the enzyme is inactivated.
In considering potential substrates of the type imagined, Walsh and Firestone 
knew they would need to design a reagent such that the allyl sulfoxide was only 
generated in the active site of the targeted enzyme. They designed a halo (X) 
sulfoxide precursor which could undergo enzyme mediated loss of HX to 
“uncover” an allylic double bond. Their proposed reaction pathway would then 
require a minimal two step process to take place before the substrate could 
reach its ‘suicide activation’ chemistry.
Pyridoxal phosphate dependent enzymes catalyse the elimination of good
leaving groups at the y-carbon of their amino acid substrates and both
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allyl sulfoxide -> allyl sulfenate ester rearrangement
methionine-y-lyase and cystathionine^y-synthetase require bound pyridoxal 
phosphate cofactors to facilitate elimination. Therefore it is not surprising that 
Walsh and Firestone decided the bacterial enzymes methionine-y-lyase and 
cystathionine^y-synthetase would be likely candidates for generating an allyl 
sulfoxide in the enzyme active site by HX elimination.
H ©
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enzymatic pyridoxal phosphate cofactors 
facilitating y-elimination of a good leaving group (X)
Walsh and Firestone synthesised the amino acids 2-amino-4-chloro-5-(p- 
nitrophenylsulfinyl) pentanoic acid and 2-amino-4-chloro-5-(p-tolylsulfinyl)
pentanoic acid and demonstrated, via stoichiometric labelling with 3H, that y- 
chloro elimination will generate an enzyme bound allyl sulfoxide. The key 2,3 
sigmatropic rearrangement of the allyl sulfoxide to the allyl sulfenate ester then 
inactivates both methionine-y-lyase and cystothionine^y-synthetase via 
nucleophilic capture of an active site enzyme residue.
2-amino-4-chloro-5-(p-nitrophenylsulfinyl) pentanoic acid
Me.
2-amino-4-chloro-5-(p-tolylsulfinyl) pentanoic acid
Walsh and Firestone's studies showed that although 2-amino-4-chloro-5-(p- 
nitrophenylsulfinyl) pentanoic acid effected inactivation of the enzymes 
methionine-y-lyase and cystothionine-y-synthetase, 2-amino-4-chloro-5-(p- 
tolylsulfinyl) pentanoic acid did not. Walsh and Firestone postulated that in the 
case of the p-tolylsulfinyl compound, an unfavourable equilibrium shift for the 
sulfoxide -» sulfenate ester rearrangement might be the cause. Their 
postulation was in concurrence with a report by K. Mislow (82) which detailed 
the observation that although both p-tolyl and p-nitrophenyl allyl sulfoxides 
exist almost exclusively in the sulfoxide form at equilibrium (>99%), the rates at 
which they undergo reversible sigmatropic rearrangements are very different. 
Equilibration of p-nitrophenyl allyl sulfoxides could be studied at 7°C, while 
studies on the equilibration of p-tolyl allyl sulfoxide required temperatures in the
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region of 40°C - 60°C. Since Walsh and Firestone’s enzyme inhibition studies 
were conducted at 37°C one can reasonably assume that the lack of inhibiting 
activity displayed by 2-amino-4-chloro-5-(p-tolylsulfinyl) pentanoic acid was a 
result of unfavourable equilibrium kinetics.
There is some evidence to suggest that the presence of a strongly electron- 
withdrawing group attached to the sulfur will help shift the equilibrium towards 
formation of the sulfenate (82).
5.7 Synthesis of related compounds for enzyme inactivation via an allyl 
sulfoxide -> allvl sulfenate ester rearrangement 
Building on the work of Walsh and Firestone (81) it was decided to repeat the 
synthesis of 2-amino-4-chloro-5-(p-tolylsulfinyl) pentanoic acid and biologically 
test this compound in Trichomonas vaginalis.
Taking account of what has been previously postulated about equilibrium shifts 
and strongly electronegative substituents attached to the sulfur, it was decided 
to attempt the synthesis of some analogous chloro- and fluoro-compounds for 
further chemical understanding and biological testing.
It was hoped that in addition to creating a more favourable equilibrium shift in 
the direction of formation of the sulfenate ester in the active site, the presence 
of fluorine in the molecule would offer i) an improved overall yield of the desired 
compound via preferred addition during synthesis of the corresponding 
sulphenyl chloride across the double bond of the protected L-allylglycine from
ClxFyC
2-amino-4-chloro-5(fx;chloro(y^luorosulfinyl) pentanoic acid 
(X and Y are variables between 1 and 3, mono and tri)
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which it is prepared and ii) convey an increased level of toxicity to the 
bacterial enzyme through improved lipophilicity and increased susceptibility to 
nucleophilic attack by an active site enzyme residue.
RESULTS AND DISCUSSION
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Chapter 6
Fluorinated Analogues of L-Methionine
6.1 Synthesis of N-Acetyl-D, L-trifluoromethionine methyl ester
Synthesis of L-Trifluoromethionine
Biological activity of L-Trifluoromethionine
Synthesis of N-Acetyl-D, L-difluoromethionine methyl ester
Synthesis of L-Difluoromethionine
Biological activity of L-Difluoromethionine
6.2
6.3
6.4
6.5
6.6
L-T rifluoromethionine
As outlined in the introduction, the experimental starting point had been to 
repeat the synthetic procedures of Houston and Honek (78), via a modified and 
higher yielding route. It was then intended to biologically test 
L-trifluoromethionine, as a fluorinated analogue of L-methionine, for growth 
inhibition and / or selective toxicity in the anaerobic protozoan flagellate 
Trichomonas vaginalis. L-methionine is a known substrate of T. vaginalis.
However in order to synthesise L-trifluoromethionine by the chosen literature 
method, one first needed to prepare, then isolate, N-acetyl-D,L- 
trifluoromethionine methyl ester from the starting material N-acetyl-D,L- 
homocysteine thiolactone.
6 .1 Synthesis of N-Acetvl-D. L-trifluoromethionine methyl ester
NHCOMe
CC^Me
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Formation of N-acetyl-D, L-trifluoromethionine methyl ester followed an 
adaptation of M.E. Houston and J.F. Honek’s literature procedure (78).
Changes made to the literature procedure were required to achieve good yields 
of the trifluorinated intermediate product. (In our preliminary attempts following 
the literature procedure, yields of only 15-20% were realised versus the 52- 
61% quoted in the literature).
Since ring opening and esterification of N-acetyl-D,L-homocysteine thiolactone, 
by sodium methoxide in methanol, was reaching completion after 30 mins 
(confirmed by TLC) the low yielding step in the reaction sequence was 
identified as the trifluoromethylation step. The literature procedure of bubbling 
an excess of CF3I through the reaction mixture at 0°C was evidently not proving 
a satisfactory method in the equipment set up. Initial attempts to rectify the 
poor yield involved significantly reducing the flow rate of the CF3I gas through 
the reaction mixture. (This was achieved by reducing the incoming flow of N2(g) 
which would displace the CF3 l(g) from the holding vessel). However, this did not 
result in significantly improved yields. The CF3I gas (b.p. -22.5°C) could still 
be seen bubbling out of the reaction mixture almost immediately after entering 
it.
Since CF3I undergoes SN2 reactions with great difficulty, if at all, due to 
polarisation of the C -l bond (F3C*"—<-l8+) (83), the trifluoromethylation step is 
believed to follow a radical single electron transfer (SET) type reaction 
mechanism. Radical ion initiation was achieved via U.V. irradiation. Since this 
type of reaction is independent of temperature, the next plan to improve the 
reaction yield involved significantly reducing the reaction temperature during 
the trifluoromethylation step. The reaction temperature was lowered from 0°C 
to -50°C. Following this change to the literature method, the reaction yield 
improved to 64%. This was an overall 3% improvement on the literature value 
(61 %) and a 44% improvement on previous efforts.
Having shown that a 50°C reduction in temperature does not affect the reaction 
path followed, this provides further support for an S rN1 mechanism.
Srn1 mechanism
IR, 1H NMR, 13C NMR, 19F NMR spectra, m/z and micro analysis all support the 
formation of N-acetyl-D,L-trifluoromethionine methyl ester.
6.2 Synthesis of L-Trifluoromethionine
Formation of L-trifluoromethionine followed the literature procedure of M.E. 
Houston and J.F. Honek (78). Complete hydrolysis of the methyl ester of N- 
acetyl-D, L-trifluoromethionine methyl ester was achieved with aqueous NaOH 
in methanol after 50 mins at 0°C. Stereoselective amine de-protection to afford 
the L-amino acid only was effected by the enzyme porcine kidney acylase in an 
aqueous solution, at pH 7.5 and 37°C. Formation of the free amino acid was 
confirmed by the visualising of a lilac colouration upon treatment with ninhydrin 
spray in TLC spot tests. The reaction afforded a 37.7% yield of
HNCOMe HNCOMe
Me02C MeC^ C
HNCOMe HNCOMe
Me02C Me02C
HNCOMeHNCOMe
+ (CF3i rMe02C Me02C
(CF3 I)" CF3# ,0
v©
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L-trifluoromethionine (75.4% based on D,L mixture) compared with the 
literature value of 42.6%.
1H NMR, 13C NMR, 19F NMR spectra, m.p., [a]D and m/z all support the 
formation of L-trifluoromethionine.
6.3 Biological activity of L-Trifluoromethionine
G.H. Coombs and associates were able to show that L-trifluoromethionine is a 
growth inhibitor of Trichomonas vaginalis (page 168) and a substrate for 
methionine-y-lyase purified from T. vaginalis (84). Their biological testing 
demonstrated that during the enzymic reaction, L-trifluoromethionine 
undergoes an elimination reaction to produce a-ketobutyrate (84). 
Trifluoromethane thiol, which would also be a product in this reaction pathway, 
was not detected and this was presumably due to its rapid non-enzymatic 
decomposition to carbonothionic difluoride.
L-trifluoromethionine
methionine-y-lyase
(pyridoxal phosphate dependent enzyme)
O
trifluoromethane thiol a-ketobutyrate
HF elimination
F
y=S potential DNA cross-linking agent
F
Carbonothionic difluoride
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The decomposition of trifluoromethane thiol to carbonothionic difluoride had in 
1983 been postulated by T.A. Altson and H.J. Bright in reference to the 
interaction of a variety of pyridoxal phosphate dependent enzymes with 
trifluoromethionine (85).
F3C'
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Proposed mechanism for the interaction between L-trifluoromethionine and the 
pyridoxal phosphate dependent enzyme methionine-y-lyase
If carbonothionic difluoride were released into the active site of the enzyme it 
would be susceptible to attack by a nearby nucleophilic enzyme residue. 
Nucleophilic attack by an enzyme residue on carbonothionic difluoride would 
result in the formation of a covalent bond which could led to irreversible 
inactivation of the enzyme and ultimately could lead to the death of the 
organism.
In addition to being susceptible to nucleophilic attack by an active site enzyme 
residue, it has been suggested (85) that carbonothionic difluoride could also 
act as a possible DNA cross-linking agent. Following nucleophilic attack by 
different amine residues positioned on opposite strands of the DNA double 
helix and elimination of HF, carbonothionic difluoride could effectively create a 
series of covalent bonds which would form a bridge between opposite sides of 
the DNA double helix. If this were the case then the process of DNA replication 
would be halted by the inability of the double helix to fully unwind.
+
HFR
+
similarly HF
R R'
H2NR and H2NR’ represent amine residues on opposite strands of the DNA
double helix.
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Schematic representation of the possible DNA cross-linking effect of
carbonothionic difluoride.
In addition to biological tests on T.vaginalis, L- Trifluromethionine was tested 
for growth inhibiting properties in the other trichomonads; T. foetus, T. augusta 
and T. pyriforris. While T. augusta showed reduced growth, when tested under 
a variety of drug concentrations, very little and no growth inhibiting capabilities 
were observed for T. foetus and T. pyriforris respectively. In T. augusta 
although growth inhibition is observed it is not halted, even at high drug 
concentration. This suggest that although L-trifluoromethionine inhibits T. 
augusta it does so via a different route to that observed in T. vaginalis. 
Collectively these results suggest that the enzyme L-methionine-7 -lyase is 
present in only T.vaginalis and absent in the other trichomonads tested.
For comparison purposes L-trifluoromethionine was tested in a range of other 
organisms including; G. lamblia, E. invadins, C. fasciculata, H.m. muscanum,
H.m. ingenoplastis, L. donovani, L. tarenolae, L. mexicana, L. major and 
macrophage. However L-trifluoromethionine showed significant growth 
reduction in only L. donovani (after 72 hr at >10 pg ml' 1 drug concentration) and 
in C. fasciculata (after 120 hr at all drug concentrations). Although for both 
organisms nil growth was never observed. Again the observation that growth 
was not halted for any of the above organism suggests that none of them 
contained methionine-y-lyase.
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L-Difluoromethionine
For biological specificity and toxicity comparison testing versus 
L-trifluoromethionine, the analogue L-difluoromethionine was prepared. Again 
the first step in the synthetic pathway was the synthesis and isolation of an 
intermediate product, N-acetyl-D, L-difluoromethionine methyl ester, prepared 
from the starting material N-acetyl-D, L-homocysteine thiolactone.
6.4 Synthesis of N-Acetvl-D. L-difluoromethionine methyl ester
Formation of N- acetyl-D,L-difluoromethionine methyl ester followed an 
adaptation of M.E. Houston and J.F. Honek’s literature procedure (78).
Ring opening and esterification was achieved as previously described in the 
formation of N-acetyl-D,L-trifluoromethionine methyl ester. Changes to the 
literature procedure were made during the difluoromethylation step to cut down 
on the amount of difluorochloromethane required and as a consequence 
improve the overall economic feasibility of the reaction.
In the difluoromethylation step the literature procedure describes bubbling 
chlorodifluoromethane through the reaction mixture at 60°C, for a period of 
10 h. If one were to do this one would use up a great deal of, if not all, the 
available difluorochloromethane (Freon 22) supply. In considering the b.p. of 
Freon 22 (-40.7°C) and the literature reaction temperature (60°C), which is 
more than 100°C in excess of Freon 22’s b.p., it was decided to alter the 
reaction procedure in an attempt to limit the amount of unreacted Freon 22 gas 
escaping over the course of the reaction. However it was decided to do this 
without changing the temperature of the reaction. By taking advantage of the 
fluorine chemistry vacuum line one had at one’s disposal, it was decided to 
employ a pressurised closed system approach to this reaction procedure. On
NHCOMe
CO2 M6
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the vacuum line an equimolar amount of Freon 22 was condensed directly into 
an air evacuated pressure bottle. The pressure bottle having previously been 
charged with the sodium salt of N-acetyl-D, L-homocysteine methyl ester and 
methanol. The remainder of the reaction followed the literature method, 
although in an increased pressure environment (the pressure inside the 
reaction bottle was estimated to be around 2 atmospheres). The reaction 
proceeded via the SN2 displacement of chlorine to afford a 55% yield of N- 
acetyl-D,L-difluoromethioine methyl ester. This yield, although lower, is within 
comparable limits of the literature value of 61 %.
IR, 1H NMR, 13C NMR, 19F NMR spectra and m/z all support the formation of N- 
acetyl-D,L-difluoromethionine methyl ester.
6.5 Synthesis of L-Difluoromethionine
Formation of L-difluoromethionine followed the literature procedure of M.E.
acylase to effect stereoselective amine de-protection and afford the L-amino 
acid only. L-Difluoromethionine was isolated in 41.1 % overall yield (82.2% 
based on D,L mixture) compared with a literature value of 38.1%. Again 
formation of the free amino acid was confirmed by visualising of a lilac 
colouration upon treatment with ninhydrin spray in TLC spot tests.
1H NMR, 13C NMR, 19F NMR spectra, m.p., [a]D, m/z and micro analysis all 
support the formation of L-difluoromethionine.
6 . 6  Biological Activity of L-Difluoromethionine
G.H. Coombs and associates were able to demonstrate that L-
difluoromethionine does act as a growth inhibitor of T. vaginalis, although it is
Houston and J.F. Honek (78) and again employed the enzyme porcine kidney
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not as potent as L-Trifluoromethionine. (The raw data for this biological testing 
result could not be located at the time of writing up and is therefore absent from 
this thesis).
If one makes the assumption that L-difluoromethionine interacts with the 
enzyme methionine^-lyase of T. vaginalis via the same transamination route as 
found for L-trifluoromethionine, then the products formed from L- 
difluoromethionine will be a-keto butyrate and carbonothionic monofluoride. 
Carbonothionic monofluoride if released into the active site of the enzyme will, 
as has been postulated for carbonothionic difluoride (85), also be susceptible 
to attack by a nucleophilic enzyme residue. Again this could result in 
irreversible enzyme inactivation and ultimately, if present at a high enough 
concentration, could lead to the death of the organism.
Carbonothionic monofluoride would however not be able to function as a DNA 
cross-linking agent as has been suggested for L-trifluoromethionine. However 
that is not to say a reaction between carbonothionic monofluoride and an amine 
residue on one of the strand of the unwinding DNA double helix could is not a 
possibility. If this interaction were to occur then carbonothionic monofluoride 
could still interfere with the DNA replication process by instigating a DNA code 
miss-read.
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Chapter 7 
Fluorinated Analogues of L-Cvsteine and D-Penicillamine
7.2
7.1 Synthesis of L-Trifluoromethyl cysteine 
Biological activity of L-Trifluoromethylcysteine
7.4
7.3 Synthesis of D-Trifluoromethyl penicillamine 
Biological activity of D-Trifluoromethyl penicillamine
7.1 Synthesis of L-Trifluoromethvl cvsteine
Again for biological specificity and toxicity comparison testing versus 
L-trifluoromethionine, the analogue L-trifluoromethyl cysteine was prepared 
directly from the unprotected amino acid L-cysteine.
Formation of L-trifluoromethyl cysteine followed the procedure of V. 
Soloshonok and co-workers (80) with only minor changes to improve the 
overall yield;
i) The temperature of the reaction flask was maintained at -50°C for the 
duration of the reaction versus -35°C in the literature, ii) the molar excess of 
CF3I was increased from 2M to 2.60M (this was driven by the capacity of the 
vacuum line flask) and iii) the irradiation time was extended from 1 h in the 
literature procedure to 1.5h.
B
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Trifluoromethylation at the S position of the unprotected L- aminoacid was 
achieved following initiation by U.V. irradiation using CF3I in a radical Srn1 
reaction (as described earlier). The L-trifluoromethyl cysteine product was 
isolated in 73.2% yield versus a literature value of 75%.
1H NMR, 13C NMR, 19F NMR spectra, m.p., [a]D> m/z and micro analysis all 
support the formation of L-trifluoromethyl cysteine.
1.2 Biological activity of L-Trifluoromethvl cysteine
G.H. Coombs and associates (page 168) were able to demonstrate that 
L-trifluoromethyl cysteine does act as a growth inhibitor of Trichomonas 
vaginalis. However in further tests L-trifluoromethyl cysteine was found to be 
effective at reducing / halting growth in a wide range of organisms (pages 168 - 
173, 175). This finding suggest that L-trifluoromethyl cysteine may not be as 
enzyme specific in its mode of action as L-trifluoromethionine. This result could 
also suggest that the hydrocarbon chain length (distance between the a-amino 
acid moieties and the thiomethyl moiety) is crucial to the methionine^y-lyase 
enzyme recognition process.
7.3 Synthesis of D-TrifluoromethvI penicillamine
Again for biological specificity and toxicity comparison testing versus
L-trifluoromethionine, the analogue D-trifluoromethyl penicillamine was 
prepared directly from the unprotected amino acid D-penicillamine.
Formation of D-trifluoromethyl penicillamine followed the procedure of V. 
Soloshonok and co-workers (80) with only minor changes, i) the molar excess 
of CF3I used was 2.88M versus 2.0M in the literature procedure, and both ii) the
temperature and iii) the reaction times were as described above in the 
synthesis of L-trifluoromethyl cysteine.
Deprotonation of the thiol and trifluoromethylation at the sulfur of the 
unprotected L- amino acid were achieved as described for L-trifluoromethyl 
cysteine. The reaction afforded a 65.7% yield of D-trifluoromethyl penicillamine 
versus a literature value of 61%.
1H NMR, 13C NMR, 19F NMR spectra, m.p., [a]D, and m/z all support the 
formation of D-trifluoromethyl penicillamine.
7.4 Biological activity of D-Trifluoromethvl penicillamine 
G.H. Coombs and associates (page 176) were able to demonstrate that 
D-trifluoromethyl penicillamine does not act as a growth inhibitor of 
Trichomonas vaginalis. This lack of inhibiting abilility may be due either to: i) 
the steric bulk afforded by the two CH3 groups attached to the p carbon 
inhibiting D-trifluormethyl penicillamine from being recognised as a substrate 
by the enzyme methionine ^y-lyase or ii) the absence of any hydrogens bonded 
to the p carbon inhibiting this compound from taking part in the transamination 
process. If this were the case then D-trifluoromethyl penicillamine could 
reversibly attach and then detach unchanged from the active site of 
methionine^y-lyase, thus exerting no inhibitory effect on this enzyme.
The D stereochemistry of this compound is unlikely to have been responsible 
for the potential loss of enzyme specificity since the spatial arrangement of the 
C02e group, the NH3® group and the S containing side chain about the chiral 
centre remain unchanged compared to L-methionine or any of the already 
prepared fluorinated analogues.
Chapter 8
Fluorinated Analogues of L-Methionine sulfoxide 
& L-Methionine sulfone
8.1 Synthesis of L-Methionine sulfoxide
8.2 Synthesis of N-Acetyl-D, L-trifluoromethionine sulfoxide 
methyl ester
8.3 Attempted synthesis of L-Trifluoromethionine sulfoxide
8.4 Synthesis of N-Acetyl-D, L-trifluoromethionine sulfone 
methyl ester
8.5 L-Trifluoromethionine sulfone
In attempting to prepare the corresponding sulfoxide and sulfone of 
L-trifluoromethionine it was hoped to; firstly biologically test whether or not 
these two compounds were inhibitory substrates for methionine^-lyase of T. 
vaginalis and secondly whether oxidation of the sulfur in L-trifluoromethionine 
to either the sulfoxide or the sulfone had the effect of increasing the metabolic 
stability and hence potency of this compound.
8.1 Synthesis of L-Methionine sulfoxide
S CO2
0
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Having been unsuccessful in attempts to directly oxidise trifluoromethionine to 
trifluoromethionine sulfoxide with either:
i) 30% hydrogen peroxide and glacial acetic acid in ethanol or
ii) treatment with 60% perchloric acid and ammonium molybdate(VI) in water 
followed by addition of 30% hydrogen peroxide,
One decided to check the validity of the reaction procedure using the 
non-fluorinated starting material L-methionine. L-Methionine sulfoxide was 
successfully prepared from the reaction of L-methionine with 30% hydrogen 
peroxide and glacial acetic acid in ethanol. L-Methionine sulfoxide was 
isolated in an overall yield of 58.0% compared with the literature value 85.8%. 
Small amounts of unreacted L-methionine were also recovered.
A characteristic cabbage-like odour, m.p. and m/z all support the formation of 
L-methionine sulfoxide.
Since these results confirm that the method of oxidation is a reliable one, one 
can surmise that it must be the presence of the trifluoromethyl group which is 
impeding the oxidation reaction. Since it is known that the trifluoromethyl group
can exert strongly electron withdrawing effects on neighbouring atoms and that 
the S which one wishes to oxidise is adjacent to the CF3 group, it is likely that 
electronic charge is being drawn away from S and towards the CF3 group. This 
inductive effect results in a lowered electron density around the sulfur atom. 
This reduction in electron density then has the effect of reducing the potential 
for S to undergo oxidation in the above reaction.
Inductive effect of CF3 group on adjacent sulfur, 
->  indicates the direction of e~ flow
One way to overcome the reduced ability of S to participate in the reaction 
would be to employ a stronger oxidising agent such as mCPBA, which is what 
was attempted next.
Since mCPBA is a water sensitive oxidising reagent it was decided to use the 
previously synthesised and protected form of trifluoromethionine, N-acetyl-D, L,- 
trifluoromethionine methyl ester, in this reaction. Once one had successfully 
synthesised the corresponding sulfoxide, it was planned to deprotect the amino 
acid by the method previously describe for N-acetyl-D,L-trifluoromethionine to 
give L-trifluoromethionine sulfoxide.
8.2 Synthesis of N-Acetvl-D. L-trifluoromethionine sulfoxide methyl ester
NHCOMe
The experimental oxidation procedure followed that described in C. Walsh and 
R.A. Firestone’s paper (81). From the reaction of N-acetyl-D,L- 
trifluoromethionine methyl ester with mCPBA, one was able to successfully 
synthesise N-acetyl-D,L-trifluoromethionine sulfoxide methyl ester as a clear oil 
in an overall yield of 91.6%.
1H NMR, 13C NMR, 19F NMR spectra, m/z and micro analysis all support the 
formation of N-acetyl-D, L-trifluoromethionine sulfoxide methyl ester.
In particular, the 19F NMR spectrum exhibits 2 signals (-73.61, -73.64) where 
the starting material shows only 1 signal (-41.9). This experimental data 
supports the formation of a new chiral centre at the sulfur and the formation of 
2 new stereoisomers. The change in chemical shifts supports a reduction in
CC^Me
0
*  - new chiral centre
the electron density around the fluorine atoms and reflects the inductive 
electron withdrawing effect of the sulfoxide oxygen.
Additional support for the formation of the S=0 bond comes from a change in 
the chemical character, and consequently the chemical shifts, of the atoms 
adjacent to the sulfur. A shift in the CH2y 13C NMR signal (from 32.5 to 44.7) 
shows the decrease in the level of electron shielding around this carbon.
8.3 Attempted synthesis of L-Trifluoromethionine sulfoxide
CO?
Following the procedure of Houston and Honek (78) for the selective 
deprotection of N-acetyl-D,L-trifluoromethionine methyl ester, one successfully 
hydrolysed the methyl ester protecting group with an aqueous solution of 
sodium hydroxide to form the sodium salt. This reaction, as in previous tests, 
was monitored by TLC to assure completion. However on overnight treatment 
of an aqueous solution of the sodium salt with porcine kidney acylase at pH 
7.5, 37°C, no free amino acid could be either detected, with ninhydrin spray, or 
isolated by ion exchange column chromatography.
Considering this was a selective deprotection procedure which had been 
carried out successfully many times before, this result suggested that either i) 
the addition of a new chiral centre at sulfur, or ii) the presence of the sulfoxide 
oxygen; inhibit this intermediate product from being a recognised substrate for 
the enzyme porcine kidney acylase. To test this theory it was decided to 
remove the chirality variable by attempting to prepare the corresponding 
protected sulfone.
L-Trifluoromethionine sulfone
For the reasons explained earlier in the preparation of L-trifluoromethionine 
sulfoxide, it was decided to use the previously synthesised N-acetyl-D, L,- 
trifluoromethionine methyl ester in this reaction. Once one had successfully 
synthesised the corresponding sulfone, it was planned to deprotect the amino 
acid, as previously describe for N-acety-D, L-trifluoromethionine, to give L- 
trifluoromethionine sulfone.
8.4 Synthesis of N-Acetvl-D. L-trifluoromethionine sulfone methyl ester
NHCOMe
Again following the experimental oxidation procedure described in C. Walsh 
and R.A. Firestone’s paper (81), but with a greater than 2.0M excess of 
mCPBA, one was able to successfully synthesise N-acetyl-D,L- 
trifluoromethionine sulfone methyl ester as a clear oil in an overall yield of
1H NMR, 13C NMR, 19F NMR spectra and m/z all support the formation of 
N-acetyl-D,L-trifluoromethionine sulfone methyl ester.
In particular, the 19F NMR spectrum is exhibiting only one signal (-78.3), which 
is positioned upfield compared with the starting material signal (-41.9). Again a 
change in the position of the CH2y 13C NMR signal (shifting downfield from 32.5 
for L-methionine to 46.3 for the sulfone) demonstrates a decrease in electron 
shielding around the CH2y carbon.
CC^Me
0  0
87.2%.
8.5 Attempted synthesis of L-Trifluoromethionine sulfone
Again following the procedure of Houston and Honek (78) for the selective 
deprotection of N-acetyl-D, L-trifluoromethionine methyl ester, one successfully 
hydrolysed the methyl ester protecting group with an aqueous solution of 
sodium hydroxide to form the sodium salt This reaction was monitored by TLC 
to assure completion. Disappearance of the C02Chb signal from the 1H NMR 
spectrum also confirmed formation of the sodium salt. However once again, on 
overnight treatment of an aqueous solution of the sodium salt with porcine 
kidney acylase at pH 7.5, 37°C, no free amino acid could be either detected, 
with ninhydrin spray, or isolated on evaporation in vacuo.
This result supports the theory that the presence of oxygen, either in the form 
of the sulfoxide or the sulfone, inhibits this intermediate product from being 
recognised as a substrate at the active site of the enzyme porcine kidney 
acylase.
One way to overcome the effect of losing this enzyme specificity would be to 
prepare only the L-isomer of the protected amino acid, e.g. N-acetyl-L- 
trifluoromethionine methyl ester, before proceeding to the oxidation step. This 
would eliminate the need for selective deprotection using porcine kidney 
acylase in the final step of the reaction. However due to time constraints and 
higher project priorities this was not attempted.
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2-Amino-4-chloro-5-(p-nitrophenvl sulfinvh pentanoic acid
O2I
0 2 I
cc f
1
* cc f
ccf 
+
CQ2CH(C6H5)2
G>NHBoc 
NQ2
S C02CH(C6H5)2
(LrNHBoc
Cl CQ2CH(C6H5)2 
0>NHBOC
Q2N
Y l  o cq2CH(c6h5)2
Cl C02CH(C6H5); 
^(L)^NHBoc
^ 0
(LTNHBoc O2N
Cl CO2.TFA
* (L) NH2
Schematic summary of the synthetic route followed in the preparation of 
2-amino-4-chloro-5-(p-nitrophenyl sulfinyl) pentanoic acid
(★ represents the formation of new chiral centres)
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9.1 Synthesis of N-Acetvl-D.L-allvlalvcine
S A >(D .L )  J
NHAc
C02H
Following the literature procedure of S. Black and N.G. Wright (86), N-acetyl- 
D,L-allylglycine was successfully prepared from acetic anhydride and D,L- 
allylglycine under alkaline conditions. The reaction afforded an overall yield of 
74.2% compared with the literature value of 83%.
IR, 1H NMR, 13C NMR spectra, m.p. m/z and micro analysis all support the 
formation of N-acetyl-D,L-allylglycine.
9.2 Synthesis of L-Allvlalvcine
Following the literature procedure of S. Black and N.G. Wright (86), L- 
allylglycine was successfully prepared and isolated as white crystals. Selective 
cleavage of the N-acetyl group was again achieved using the enzyme porcine 
kidney acylase at 37°C to afford L-allylglycine in an overall yield of 39.4% 
(78.8% based on the D,L mixture) compared with a literature value of 35%.
IR, 1H NMR, 13C NMR spectra, m.p., [a]D and m/z all support the formation of 
L-allylglycine.
9.3 Synthesis of N-Boc-L-allvlqlvcine
©
C02
NHBoc
C02H
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Protection of L-allylglycine using the tertiary butyloxycarbonyl protecting group 
(Boc) was successfully achieved following the literature procedure of C. Walsh 
and R.A. Firestone (81). The by-product hydroxyiminophenyl acetonitrile (HO- 
N=C(CN)C6H5) was easily removed from the reaction mixture by extraction with 
ether. The reaction afforded N-Boc-L-allylglycine in an 81% overall yield from 
L-allylglycine compared with a literature value of 85.4%.
IR, 1H NMR, 13C NMR spectra, m.p., m/z and micro analysis all support the 
formation of N-Boc-L-allylglycine.
9.4 N-Boc-L-allvlqlvcine benzhydryl ester
9.4.1 Synthesis of Benzophenone hvdrazone
/N H 2
N
Following the literature procedure in Fieser & Fieser’s book of ‘Reagents for 
Organic Chemistry Synthesis’ (87), benzophenone hydrazone was successfully 
prepared from the reaction of benzophenone with hydrazine in an overall yield 
of 97.4%. This yield is a greater than 10% improvement on the literature value 
of 87%.
IR, 1H NMR spectra, m.p., m/z and micro analysis all support the formation of 
benzophenone hydrazone
9.4.2 Synthesis of Diohenvldiazomethane
Following the literature procedure in Fieser & Fieser’s book of ‘Reagents for
Organic Chemistry Synthesis’ (87), diphenyldiazomethane was successfully
prepared from benzophenone hydrazone in an overall yield of 98%, a 9%
improvement on the literature value of 89%. This reagent was freshly prepared
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before use since it could not be stored for an extended period of time without 
decomposing (i.e. beyond 2 days in a cool dry place).
During the course of the reaction mercury(ll) oxide is reduced to mercury and 
water.
Ph
Ph
> -
NH2
N HgO
©»
/-.•OH
Ph ^  H
} = N = N ^  _ K O H
Ph
Hg
Ph NH
H
> = N %  -
Ph Hg-^OH
EtOH
Ph
Ph
i
y
© © 
N=N:
Reaction mechanism for the conversion of benzophenone hydrazone to
diphenyldiazomethane
IR, 1H NMR spectra, m.p. and the characteristic crimson colour of the crystals 
formed all support the formation of diphenyldiazomethane.
9.4.3 Synthesis of N-Boc-L-allvlalvcine benzhydryl ester
NHBoc
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N-Boc-L-allylglycine benzhydryl ester was successfully prepared from the 
reaction of N-Boc-L-allylglycine with diphenyldiazomethane (liberating N2 as a 
by product) by the procedure of C. Walsh and R A  Firestone (81). The 
reaction proceeded in an overall yield of 66.7%. This was lower than expected 
compared with the literature value of 80%.
IR, 1H NMR, 13C NMR spectra, m.p. and m/z all support the formation of 
N-Boc-L-allylglycine benzhydryl ester.
9.5 Synthesis of 4-Nitrophenvlsulfenvl chloride 
After several attempts to accomplish the addition reaction of 
4-nitrophenylsulfenyl chloride with the protected L-allylglycine without success, 
It was decided to consult the literature further before continuing. (The 4- 
nitrophenylsulfenyl chloride reagent had been bought in ‘fresh’ from Aldrich, 
who claimed a purity of 99% in their catalogue). A literature search at this time 
uncovered a paper published in 1947 by R.A. Turner and R. Connor (88). This 
paper showed that 4-nitrophenylsulfenyl chloride is only stable for a few hours 
and should not be stored: It fumes in moist air and cannot be isolated free of 
the disulfide from which it is prepared. Not surprisingly the decision was made 
from then on to prepare fresh 4-nitro-phenylsulfenyl chloride prior to use.
Following the procedure of R. Katakai (89), 4-nitrophenylsulfenyl chloride was 
successfully prepared from the reaction of 4-nitrophenyl disulphide and liquid 
chlorine in the presence of a small amount of iodine. Iodine acts as a free- 
radical catalyst in this reaction via thermally induced homolytic cleavage.
The radical ion initiation step is accomplished at a lower temperature with
Cl
4-Nitrophenylsulfenyl chloride
iodine than would be required for either chlorine or the disulphide since the 
bond dissociation energy for iodine is much lower (90).
Bond Dissociation energies Kimol'1 at 25°C
S-S 226
CI-CI 242
l- l 151
The newly prepared product began to crystallise out towards the end of solvent 
evaporation step. The product was then stored in the reaction vessel in which 
it was prepared under N2 until required. The m.p. of a sample of the crystals 
was identical to the literature value given for 4-nitrophenyl sulphenylchloride at 
48°C. The estimated yield was 95% or above based on the literature 
procedure and the observation that all the disulphide had dissolved after 10 
minutes of reaction time to give a clear orange / yellow solution.
9.6 Synthesis of 2-N-Boc-4-chloro-5-(p-nitrophenvlsulfenvl)pentanoic acid 
benzhydryl ester
Cl NHBoc
Following the literature procedure of C. Walsh & R. A. Firestone, (81), 2-N-Boc-
4-chloro-5-(p-nitrophenylsulfenyl) pentanoic acid benzhydryl ester was 
successfully prepared from the reaction of N-Boc-L-allylglycine benzhydryl 
ester with p-nitrobenzenesulphenyl chloride. However as expected and 
described in the literature procedure, the product was formed along with its 
regioisomer, 2-N-Boc-5-chloro-4-(p-nitrophenylsulfenyl)pentanoic acid
benzhydryl ester. This undesirable product was the major product of the 
reaction. Integration of the. NMR spectrum shows a mixture of the two 
regioisomers in a 1:10 ratio (desired : undesired).
NHBoc
undesirable regioisomer: 2-N-Boc-5-chloro-4-(p-nitrophenylsulfenyl) pentanoic
acid benzhydryl ester
IR, 1H NMR, spectra, m/z. and microanalysis all support the formation of 
2-N-Boc-(4)5-chloro-(5)4-(p-nitrophenylsulfenyl)pentanoic acid benzhydryl 
ester.
9.7 Sulfenyl chloride addition to terminal carbon - carbon double bonds.
The addition of sulfenyl chlorides across carbon-carbon double bonds has 
been known for many years and has received considerable attention (91 - 94). 
A sulfenyl chloride could, in theory, react in at least 3 distinct ways:
1. as a source of electrophilic sulfur (I) or
2. as a source of electrophilic chlorine (II) or
3. as a source of free radicals by homolytic cleavage of the
S-CI bond (III).
rs^— c r  rs8-— c r  rs' c f
(i) (ii) (in)
Of the three possibilities two have been recognised to date, the occurrence of 
(I) electrophilic sulfur and (III) free radicals.
Most studies pertaining to the electrophilic addition mechanism have been 
conducted with 2,4-dinitrobenzenesulfenyl chloride. Due to its outstanding 
stability it makes a convenient model. This particular reagent undergoes 
RS5+-CI5" polarisation and there is no evidence that the reagent could become 
the source of Cl+ ions (chloronium ions) (95). An investigation by N. Kharasch 
and associates into the reaction of 2,4-dinitrobenzenesulfenyl chloride with 
styrene and cyclohexene revealed it to be of 2nd order kinetics (96, 97). All the 
kinetic data generated to date on sulfenyl chloride addition to alkenes is 
consistent with but does not require, the formation of an episulfonium ion 
intermediate (IV).
R
I
(IV)
episulfonium ion intermediate
Additional support in favour of the formation of an episulfonium ion intermediate 
is the almost exclusive trans-stereospecific addition observed in the reactions 
of 2,4-dinitrobenezenesulfenyl chloride with c/s- and trans-2-butenes and 
norbornane (98 -100). Particularly strong evidence against a non-rotating 
open carbonium ion is supplied by the stereospecific integrity of this addition 
reaction over a wide range of temperatures (101).
However, the almost exclusive Markovnikov orientation reported for the 
reaction of 2,4-dinitrobenezenesulfenyl chloride with both styrene and 
propylene suggests that some carbonium ion character does exist in the 
transition state.
These results are more compatible with the formation of an unsymmetrical 
episulfonium ion (V).
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(V)
unsymmetrical episulfonium ion intermediate
Previous studies (102) on this topic have clearly shown no single mechanistic 
route exists and that the course of the reaction is significantly influenced by the 
nature of the substituents on both the alkene and on the sulfenyl chloride itself.
9.7.1 Influence of the alkene substituents on the ring opening of the 
episulfinium ion
The high selectivity for anti-Markovnikov oriented products initially observed 
with alkyl substituted terminal alkenes, and in particular the increase observed 
with an increase in size of the alkyl substituent, demonstrates that steric factors 
can significantly influence the nature of the ring opening of the episulfonium ion 
intermediate (IV). The findings of W.H. Mueller and P.E. Butler ((102) and 
Table 1.), provide strong evidence for a bridged episulfonium ion intermediate. 
Their results are completely consistent with nucleophilic attack on the 
episulphonium ion by the chloride ion. These initially formed alkyl substituted 
adduct mixtures would generally then undergo rearrangement to form the more 
stable Markovnikov product in a ~90% ratio at equilibrium.
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Table 1.
REA CTA NTS %  A D D U C T RATIO
C H ,=C < RSCI
initial
H^l K  K
Cl S R  SR Cl
at eauilibrium 
h I  " K  h Y  K
Cl  SR  SR Cl
c h 2=c h c h 3 c h 3s c i 82 18 12 88
CH2=C(CH3)2 c h 3s c i 80 20 17 83
c h 2=c h c 6h 5 c h 3s c i 2 98 - -
CH2=C(C6H5)2 c h 3s c i 10 90 - -
extracts from reference (102), methane sulfenyl chloride-olefin adducts,
Note: the adduct ratios were calculated from the relative intensity of their characteristic NMR signals.
In contrast to alkyl substituents, phenyl substituents attached to the alkene 
exhibit predominantly Markovnikov adduct orientated ring opening of the 
episulfonium ion (VI). This may be explained by a lower transition state energy 
following nucleophilic attack by the chloride ion on the phenyl substituted 
carbon versus the transition state energy arising from chloride ion attack on the 
terminal carbon.
(VI) (R = CH3)
Markovnikov adduct orientated ring opening of the episulfonium ion when 
phenyl substituents are attached to the alkene
Stabilisation of the transition state is due to 7c-bond overlap of the p-orbital of 
the electron deficient a-carbon with the phenyl ring’s k cloud.
The Markovnikov addition products arising from the reaction of phenyl 
substituted terminal alkenes and sulfenyl chlorides do not show any tendency 
to rearrange to the anti-Markovnikov orientation (102).
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9.7.2 Influence of the sulfenyl chloride substituents on the ring opening of the
episulfonium ion.
The nature of the R group on the sulfenyl chloride is of equal importance to the 
alkene substituents with regard to influencing the orientation of the adduct.
Below (Table 2.) illustrates the effect of the electron withdrawing group 
CH3C(0)S on the ring opening of the episulfonium ion in the addition reaction 
of the substituted sulfenyl chloride to methylpropene. The CH3C(0)S group 
tends to destabilise the positive charge on the sulfur of the episulfonium ion. 
This destabilisation contributes to the development of an electron deficient 
centre at the substituted carbon. The net result is a predominantly 
Markovnikov addition product (VIII).
This destabilisation effect is not observed for R groups with low electron- 
withdrawing influence. This is illustrated when R is CH3, i.e. methylsulfenyl 
chloride, where formation of the anti-Markovnikov orientated adduct (VII) is 
favoured.
Table 2.
% PRODUCT DISTRIBUTION
R VII anti-Markovnikov VIII Markovnikov
c h3 80 20
CH3C(0)S 32 68
reference 102.
R
Influence of R on the ring opening of the episulfonium ion in the sulfenyl 
chloride addition reaction to methylpropene (102)
Further evidence for the important influence of R on the sulfur atom 
participating in the episulfonium ion comes from the differing tendency for 
rearrangement of the kinetically controlled (initially formed) adducts and the 
thermodynamically more stable Markovnikov product.
An example of this is highlighted in an experimental procedure of Walsh and 
Firestone (81) describing the synthesis of 2-N-Boc-(4)5-chloro-(5)4-(p- 
tolylsulfenyl) pentanoic acid benzhydryl ester. Thermal isomerization of the 
initially formed 2-N-Boc-5-chloro-4-(p-tolylsulfenyl) pentanoic acid benzhydryl 
ester (kinetic product) to the more stable 2-N-Boc-4-chloro-5-(p-tolylsulfenyl) 
pentanoic acid benzhydryl ester(thermodynamic product) could be achieved 
after 17h at reflux temperature in chloroform. However, in their separate 
synthesis of 2-N-Boc-(4)5-chloro-(5)4-(p-nitrophenylsulfenyl)pentanoic acid 
benzhydryl ester, the initially formed 2-N-Boc-5-chloro-4-(p-nitrophenylsulfenyl) 
pentanoic acid benzhydryl ester (kinetic product) could not be thermally 
isomerised to 2-N-Boc-4-chloro-5-(p-nitrophenylsulfenyl)pentanoic acid 
benzhydryl ester (thermodynamic product). Rearrangement of this regioisomer 
is much slower and on applying heat the isomerisation is accompanied by 
degradation. The isomeric rearrangement, which is believed to take place via 
the reformation of the episulfonium ion intermediate, is less easily 
accomplished in the presence of an electron withdrawing R group on the sulfur. 
In the case of 2-N-Boc-5-chloro-4-(p-nitrophenyl sulfenyl)pentanoic acid 
benzhydryl ester, the electronegativity of the 4-nitropheny! group on the sulfur 
decreases the availability of the unshared electrons and impairs the sulfur from 
participating in the intramolecular displacement of the chlorine.
c h 3c 6h 4s - c i +
NHBocNHBoc
,C02CH(C6H5)2 a (reformed episulfonium ion)
NHBoc
thermal isomerisation
(initially formed kinetic product)
l v ^ V v .C02CH(C6H5)2
Cl NHBoc 
(thermodynamic product)
Proposed mechanism for the predominant route of addition for p-tolylsulfenyl 
chloride to N-Boc-L-allylglycine benzhydryl ester
W X ~ST «§ NHBoc
02NC6H4S—Cl +
NHBoc
(no reformation of the 
episulfonium ion)
NHBoc
(initially formed kinetic product)
Proposed mechanism for the predominant route of addition for 
p-nitrophenylsulfenyl chloride to N-Boc-L-allylglycine benzhydryl ester
9.8 Synthesis of 2-N-Boc-4-chloro-5-(p-nitrophenvlsulfinvl)pentanoic acid
benzhydryl ester
C02CH(C6H5)2
Cl NHBoc
(A)
Following the literature procedure of C. Walsh & R. A. Firestone, (81), 2-N-Boc- 
4-chloro-5-(p-nitrophenylsulfinyl)pentanoic acid benzhydryl ester was 
successfully prepared by the oxidation of N-Boc-(5)4-chloro-(4)5-(p- 
nitrophenylsulfinyl)pentanoic acid benzhydryl ester with 55% mCPBA in DCM 
at 0°C. Separation of the desired regioisomer was achieved by repeated flash 
chromatography to afford an overall yield of 5.5% from the protected L- 
allylglycine. This yield is lower than the literature value of 9 -10%.
The isolated product (A) exists as 4 diastereoisomers. The creation of a new 
chiral centre has been brought about by the oxidation of the sulfur to sulfoxide.
The 1H NMR spectrum supports the formation of 2-N-Boc-4-chloro-5-(p- 
nitrophehylsulfinyl) pentanoic acid benzhydryl ester as diastereoisomers.
9.9 Synthesis of 2-Amino-4-chloro-5-(p-nitrophenvlsulfinvnpentanoic 
acid.TFA salt
,c o2h
Cl nh2.t f a
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Following the literature procedure of C. Walsh & R. A. Firestone, (81), 2-amino 
-4-chloro-5-(p-nitrophenylsulfinyl)pentanoic acid was successfully prepared 
following the simultaneous hydrolysis of the benzhydryl ester and cleavage of 
the Boc protecting group of 2-N-Boc-4-chloro-5-(p-nitrophenylsulfinyl) 
pentanoic acid benzhydryl ester by the action of anisole and trifluoroacetic acid 
(TFA). The TFA salt of the amino acid was isolated as a glassy product in an 
overall yield which exceeded 100% (102%) due to incomplete drying. This 
compares well with the literature value of 108%.
Too rigorous an evaporation of the amino acid TFA salt in aqueous solution 
tends to lead to a loss of TFA stabilisation. Loss of TFA stabilisation brings 
about decomposition of the free amino acid through intramolecular 
displacement reactions.
The 1H NMR and 13C NMR spectra both support the formation of 2-amino-4- 
chloro-5-(p-nitrophenylsulfinyl)pentanoic acid.
9.10 Biological Activity of 2-Amino-4-chloro-5-(p-nitrophenvlsulfinvl)pentanoic 
acid
G.H. Coombs and associates were unable to test this product for growth 
inhibiting properties in Trichomonas vaginalis. Unfortunately following analysis 
and evaporation only 35mgs ( 0.0065 mmol) of the prepared amino acid TFA 
salt remained. This was found not to be an adequate amount to conduct 
sufficient repeatable biological trials on T. vaginalis.
However, in the work of Walsh and Firestone (81), 2-ami no-4-chloro-5-(p- 
nitrophenylsulfinyl)pentanoic acid was found to be a time dependent 
irreversible inactivator of methionine-y-lyase (purified from Pseudomonas ovalis 
not Trichomonas vaginalis). Walsh and Firestone were able to demonstrate 
that the time dependent loss of catalytic activity ultimately led to full inactivation 
of the enzyme via nucleophilic capture following 2,3-sigmatropic rearrangement 
of the allylsulfoxide to the allylsulfenate ester.
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Pathway proposed by Walsh and Firestone (81) for methionine-y-lyase 
inactivation by 2-amino-4-chloro-5-(p-nitrophenylsulfinyl)pentanoic acid
Separation and testing of different sets of diastereoisomers of 2-amino-4- 
chloro-5-(p-nitrophenylsulfinyl)pentanoic acid did not show significantly
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different reaction kinetics compared to the results obtained for a preparation 
containing all four diastereoisomers of (A) (81). This result suggested to 
Walsh and Firestone that although (L) chirality about the a-carbon is a 
prerequisite for molecular recognition at the enzyme active site, the 
stereochemistry about the y-carbon and sulfoxide are of little importance in 
achieving enzyme inactivation or the rate at which it is accomplished.
Chapter 10
Preparation of 2-amino-4-chloro-5-(chlorodifluoromethvlsulfinvl)
pentanoic acid.TFA salt
10.1 Identifying an appropriate group of target compounds
10.2 Addition reactions of fluorochloromethanesulfenyl chloride 
to terminal alkenes
10.3 TFA stable amino acid protecting groups:
10.3.1 N-Fmoc-protection
10.3.2 Cyclohexyl ester protection
Synthesis /  attempted synthesis of:
10.4 N-Fmoc-L-allylglycine
10.5 N-Fmoc-L-allylglycine cyclohexyl ester
10.6 Difluorochloromethanesulphenyl chloride
10.6.1 Trichloromethyl-(N-diethyl)-sulfenamide
10.6.2 Difluorochloromethanesulphenyl chloride
10.7 2-N-Fmoc-4-chloro-5-(difluorochloromethyl sulfenyl) 
pentanoic acid cyclohexyl ester
10.8 2-N-Fmoc-4-chloro-5-(difluorochloromethylsulfmyl) 
pentanoic acid cyclohexyl ester
10.9 2-Amino-4-chloro-5-(chlorodifluoromethylsulfinyl)pentanoic 
acid. TFA salt
2-Amino-4-chloro-5-(chlorodifluoromethvlsulfinvl)pentanoic acid.TFA salt
(X and Y are numbers between 1 and 3 such that X + Y = 3)
10.1 Identifying an appropriate group of target compounds
The reasons for choosing this group of target compounds, as briefly discussed
at the end of chapter 5 of the introduction, are 2-fold:
1. Increased enzyme specificity and toxicity of 2-amino-4-chloro-5 
(chlorodifluoromethvlsulfinvQpentanoic acid towards the enzyme 
methionine-Y-lvase versus the previously synthesised 2-amino-4- 
chloro-5-(p-nitrophenvlsulfinvl)pentanoic acid.
i) By introducing fluorine (and or chlorine) into the molecule it was hoped to 
convey an improved lipid solubility profile. This would result in enhanced 
absorption, transportation and quicker onset of enzyme inactivation 
following patient treatment. It could also afford a reduction in the dosage 
required to effect complete enzyme inactivation.
n measurements (103):
(the 7c constant is a good indication of lipophilicity, the higher the n value the
ii) As a result of replacing the bulky p-nitrophenyl sulfinyl group with a
fluoro / chloro substituted methyl sulfinyl group, it was hoped to increase the 
incidence of molecular recognition through more effectively mimicking 
L-methionine at the enzyme active site. If this replacement did prove to be 
effective, then an increase in the enzyme specificity and / or drug potency 
could result.
Cl c o 2.tfa
tcCH3 = 0.5 7cCF3 = 1.07
more highly lipophilic the group).
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van der Waals radii (A ) (104): 
CH3 = 2.0 CF3 = 2.7
iii) Improved enzyme toxicity through an increased susceptibility of the
allylsulfenate to nucleophilic capture by an active site enzyme residue. The 
electron-withdrawing influence of the chloro / fluoromethyl group is greater 
than that of p-nitrophenyl and will enhance sulfur’s electrophiiic character.
©
c i f 2c ^ s ^ o  c i f 2c ^ s ^ o  Enz‘BJ )
N©H C02 
HHJ
2%
+
P L P
3P
©E n z - B  *>b
c i f 2 c  ^ o  )
I H  v  H  *  _
C l
2©
O
H
v w
i
' cf2ci
— ► in d ic a te s  th e  
d ire c tio n  o f  e '  f lo w
C I F 2 C .  ^ o ^
c f 2 c i
©E n z - B  9 , S ^ H ®
E n z — S  
+
O H
C F 2 C I
C O ®
.NHr^© 2©
. 0 3 P
N H
^N^^CH3 
H
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(chlorodifluoromethylsulfinyl)pentanoic acid
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2. Improved yields of the desired reaioisomers during synthesis versus the
undesirable 1:10 (Markovnikov : anti-Markovnikov ratio described in the 
synthesis of 2-amino-4-chloro-5-(p-nitrophenvlsulfinvl)pentanoic acid
In planning the synthesis and composition of this target molecule one not only 
looked into ways of improving the overall biological activity, but also improving 
the synthetic yield of the favoured regioisomers and how this might be 
increased during the addition reaction of a sulfenyl chloride to the protected 
L-allylglycine.
10.2 Addition reactions of fluorochloromethanesulfenvl chloride to terminal 
alkenes
The addition of fluorochloromethanesulfenyl chlorides to alkenes is now well 
documented (105,106). K.A. Pretrov and his associates first reported the 
reactions of CI3CSCI and CI2FCSCI with cyclohexene, propylene and allyl 
chloride in 1959 (107). In their paper they reported that these sulfenyl 
chlorides, in contrast to their hydrocarbon analogues, added to alkenes only 
with great difficulty. Later in 1985, A. Haas and co-workers (108) were able to 
show that catalytic amounts of trifluoroacetic acid (TFA) promoted the addition 
of fluorochloromethanesulfenyl chlorides to terminal alkenes and that an 
increasing degree of fluorination markedly increases the rate of addition. In the 
same paper, they were able to demonstrate that fluorochloromethanesulfenyl 
chloride alkene adducts were sufficiently stable such that they could undergo 
vacuum distillation. Resistance to isomerisation results from the electron 
withdrawing effect of the fluorochloromethyl group (as previously discussed for 
the p-nitrophenyl group in the synthesis of 2-amino-4-chloro-5-(p- 
nitrophenylsulfinyl)pentanoic acid). The electron-withdrawing effect of the 
fluorochloromethyl group renders the sulfur atom electron deficient thus making 
it inaccessible to attack by the ^ -carbon. This precludes the formation of the 
episulfonium ion, which is necessary for isomerisation to occur.
Cl :Clf
(R = ClxFyC-, where x+Y = 3)
The products afforded by the reaction of fluorochloromethanesulfenyl chlorides 
with assymetric alkenes were therefore always the kinetic products. The 
products isolated were usually a mixture of Markovnikov and anti-Markovnikov 
oriented adducts, with the exact Markovnikov : anti-Markovnikov product ratio 
greatly depending on the nature of i) the alkene, ii) the sulfenyl chloride and
iii) the reaction conditions used. Some examples are given below:
Table 3.
Terminal Alkene Sulfenvl chloride Yield
Isomeric Ratio of Adducts Produced
Markovnikov
C I
/ —RS N
anti-Markovnikov
c / ---- ^
Hex-1 -ene FaCSCI 90 60 40
Hex-1 -ene F2CICSCI 96 60 40
Hex-1 -ene fci2csci 91 70 30
BrCH=CH2 F3CSCI 95 84 14
BrCH=CH2 f2cicsci 94 87 13
BrCH=CH2 fci2csci 45 87 13
(Reaction conditions varied, with temperatures ranging from -20°C and 80°C, depending on the 
terminal alkene and sulfenyl chloride used. Full experimental details are cited in reference 
108).
On the basis of Haas and co-workers’ data (108), it was predicted that the 
addition of a fluorochloromethanesulfenyl chlorides to a protected L-allylglycine 
would afford addition products in a greater than 1 :10 Markovnikov : anti- 
Markovnikov ratio. (Provided that trifluoroacetic acid is employed as a catalyst
and the reaction conditions are favourable).
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It was decided to synthesise difluorochloromethanesulfenyl chloride first. 
Difluorochloromethanesulfeny! chloride is easier to handle than 
trifluoromethanesulfenyl chloride and more highly fluorinated, and hence more 
reactive towards the alkene addition, than fluorodichloromethanesulfenyl 
chloride.
10.3 TFA stable amino acid protecting groups
Having chosen fluorochloromethanesulfenyl chlorides as the group of sulfenyl 
chlorides one wanted to use, one then faced the issue of identifying TFA stable 
amino acid protecting groups.
Recall in Walsh and Firestone’s synthesis of 2-amino-4-chloro-5-(p-nitrophenyl 
sulfinyl) pentanoic acid (81),TFA had been employed for the simultaneous 
deprotection of both the Boc- and benzhydryl ester protecting groups as well as 
for its ability to play an important role in the stabilisation of the final product.
10.3.1 N-Fmoc-protection
The F-moc- protecting group has previously been used by L.A. Caprino and 
G.Y. Han (109), in the amine protection of the amino acid glycine. It is stable to 
TFA and reported to be cleaved under mild conditions with an amine base.
10.3.2 Cyclohexyl ester protection
Cyclohexyl esters have been used to protect carboxyl groups in aspartyl 
peptides during acidic or basic reactions (110). Cycloalkyl esters are stable to 
amines and TFA but are readily cleaved by methanesulfonic acid or HF (111).
Hence on the basis of both stability and cleavability it was decided that N-Fmoc 
protection and cyclohexyl ester protection were to be used in this synthesis.
c o 2©
( L ) N H 30
C K " ^ S C 0 2 C 6 H 1 1
(L ^ N H F rn o c
Cl
Cl > S ^ V CO2C6HH
(L) ^ N H F m o c
Cl
C I3C — S
Cl
C I3C — S
NEt2
CIF2 C— S
Cl
F
F
*
F
F
Schematic summary of the synthetic route followed in the preparation of
2-amino-4-chloro-5-(chlorodifluoromethyl sulfinyl)pentanoic acid 
(★ represents the formation of new chiral centres)
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10.4 Synthesis of N-Fmoc-L-allvlalvcine
C02H
T
Protection of L-allylglycine using 9-fluorenylmethyl chloroformate (Fmoc- 
chloride) was successfully achieved following the glycine protection literature 
procedure of L.A. Caprino and G.Y. Han (109). The insoluble by-products of 
the reaction, 9-fluoreny I methanol and dibenzofulvene, were easily removed 
from the reaction mixture by extraction with ether. Following acidification of the 
aqueous layer the reaction afforded N-Fmoc-L-allylglycine in an 85.6% overall 
yield from L-allylglycine compared with a literature value of 89%.
IR, 1H NMR, 13C NMR spectra, m/z and micro analysis all support the formation 
of N-Fmoc-L-allylglycine.
10.5 Synthesis of N-Fmoc-L-allvlalvcine cvclohexvl ester
CC^CeHn 
— fl>NHFmoc
N-Fmoc-L-allylglycine cyclohexyl ester was successfully prepared following the 
general procedure of J. P. Tam and co-workers (111) for carboxylic acid 
protection. 1,3-Dicyclohexycarbodiimide (DCC) reacts with the Fmoc-L- 
allylglycine in the presence of a catalytic amount of dimethylaminopyrimidine 
(DMAP) to form an intermediate product with a good leaving group (urea). The 
leaving group is displaced by cyclohexanol in a nucleophilic acyl substitution 
reaction to afford the cyclohexyl ester protected amino acid. The precipitated 
urea was filtered off and following further purification by column 
chromatography the reaction afforded an overall yield of 67%.
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Mechanism of activation of the -C 0 2H group by DCC and the subsequent 
nucleophilic acyl substitution reaction with cyclohexanol
IR, 1H NMR, i3C NMR spectra, and m/z all support the formation of N-Fmoc-L- 
allylglycine cyclohexyl ester.
An alternative and reportedly high yielding procedure for the esterification of 
alcohols with carboxylic acids was published in 1995 by K. Ishihara and 
associates (112). Their method, employing scandium triflate as a Lewis acid 
catalyst and p-nitrobenzoic acid anhydride, was reported to give excellent 
esterification yields, often >95%, for a wide range of aliphatic acids and 
alcohols. On following this general method for the preparation of N-Fmoc-L- 
allylglycine cyclohexyl ester from N-Fmoc-L-allylglycine and cyclohexanol, one 
was only able to attain a 62% overall yield. This was a 5% lower yield than that 
previously obtained by the general method of J.P. Tam and co-workers (111)).
10.6 Difluorochloromethanesulphenyl chloride
During the reaction of trichioromethanesulfenyl chloride with metal fluorides the 
C-S bond is broken and only fluorochloromethanes are formed (113).
However, in 1959 N-N. Yarovenko and co-workers reported that by converting 
trichloromethane sulfenyl chloride into trichloromethyl-(N-diethyl)-sulfenamide 
prior to treatment with antimony fluorides, rupture of the C-S bond can be 
avoided (114). Following fluorination the sulfenamide can then easily be 
converted back into the sulfenyl chloride on treatment with dry HCI gas.
10.6.1 Synthesis of Trichloromethvl-(N-diethvl)-sulfenamide
CI3 C—S
XNEt2
Following the procedure of H. Lecher and F. Holscheneider (115), 
trichloromethyl-(N-diethyl)-sulfenamide was prepared in 95% yield from the SN2 
displacement reaction of trichioromethanesulfenyl chloride with diethylamine. 
This yield compares well with the literature value of 97-98%.
1H NMR, 13C NMR spectra, and m/z all support the formation of trichloromethyl- 
(N-diethyl)-sulfenamide.
10.6.2 Synthesis of Difluorochloromethanesulphenyl chloride
CIF2 C—S
Cl
Following the procedure of N.N. Yarovenko and co-workers (114) 
difluorochloromethyl-(N-diethyl)-sulfenamide was prepared from the reaction of 
trichloromethyl-(N-diethyl)-sulfenamide and antimony trifluoride in the presence 
of small amounts of antimony pentachloride at 67°C.
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This reaction is very temperature dependent and at temperatures below 65°C 
practically only fluorochloromethyl-(N-diethyl)-sulfenamide is formed.
Although difluorochloromethyl-(N-diethyl)-sulfenamide is formed in a mixture 
with fluorodichloro- and trichloromethyl-(N-diethyl)-sulfenamide, due to its 
instability there was no need to isolate it in a pure form. Instead it was 
sufficient to separate the mobile liquid from the solid and tarry reaction 
products and saturate it with dry HCI gas. The difluorochloromethanesulfenyl 
chloride prepared in this way was then readily separated from trichloro- (b.p. 
149°C) and fluorodichloromethanesulfenyl chloride (b.p. 99°C) by kugelrohr 
distillation in an overall yield of 22% from trichloromethyl-(N-diethyl)- 
sulfenamide. This compares well with the literature yield of 21 %.
+  +
CIF2C . ^NEt2 CIF2C ^  XCI
^NEt2 SbF^SbCIs dry HCI ® distillation CIF2CV  ^Cl
J  ► +  ► + —  ► b
CfeFC. ^.NEt2 C f e F C ^ X I
o  S
+ +
CI3C . ^.NEt2 CI3C . ^Cl
o  S
The 19F NMR spectrum and b.p. (49°C) support the formation of 
difluorochloromethanesulfenyl chloride.
1 0.7 Synthesis of 2-N-Fmoc-4-chloro-5-(difluorochloromethvlsulfenvl) 
pentanoic acid cyclohexyl ester
S
Cl
103
Following the general procedure of A. Haas and associate (108), 2-N-Fmoc-4- 
chloro-5-(difluorochloromethylsulfenyl)pentanoic acid cyclohexyl ester was 
prepared along with its regioisomer 2-N-Fmoc-5-chloro-4-(difluorochloromethyl 
sulfenyl)pentanoic acid cyclohexyl ester in an overall 19.1% yield. This was a 
disappointing yield when compared with the literature examples for the addition 
of difluorochloromethanesulfenyl chloride to hex-1 -ene and bromoethene which 
afforded >90% yields (see table 3.). However this may have been due to the 
bulky F-moc- and cyclohexyl protecting groups retarding the approach of the 
sulfenyl chloride to the double bond resulting in a lower yield. This rationale is 
in line with the literature yields obtained in the synthesis of 2-N-Boc-4(5)- 
chloro-5(4)-(p-nitrophenylsulfinyl)pentanoic acid benzhydryl ester which were 
9-10% (81).
Alternatively, the reaction conditions employed may not have been at an 
optimum for either the alkene or sulfenyl chloride used. However there was not 
time to explore these variables.
As predicted earlier on the basis of Haas and co-workers data (108), the 
addition of difluorochloromethanesulfenyl chloride to the protected L- 
allylglycine did afford addition products in a greater than 1 :10 Markovnikov : 
anti-Markovnikov ratio. Integration of the 1H NMR signals of the unpurified 
product mixture indicated the ratio of regioisomers B : C (Markovnikov : anti- 
Markovnikov) was approximately 2 : 3.
CIF2 C^
S
NHFmoc
S CO2C6H11
Cl
NHFmoc
Cl CO2C6H11
B C
Markovnikov (2 : 3 product ratio) anti-Markovnikov 
(* indicates the new chiral centre)
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1H NMR, 13C NMR and 19F NMR spectra all support the formation of 2-N-Fmoc- 
4(5)-chloro-5(4)-(chlorodifluoromethylsulfenyl)pentanoic acid cyclohexyl ester
In particular, the proximity of the fluorine atoms to the new chiral centre in both 
the Markovnikov product B and anti-Markovnikov product C is reflected in the 
13C NMR and 19F NMR spectra. The 2 fluorine atoms in the Markovnikov 
product B are magnetically equivalent and this is supported by the observation 
of a triplet (132.2ppm, J = 337.2Hz), in the 13C NMR spectrum and a singlet 
(-25.81 ppm) in the 19F NMR spectrum. In the anti-Markovnikov product C the 
fluorine atoms are in close proximity to the new chiral centre and are 
magnetically non-equivalent. The non-equivalent fluorine atoms can be seen 
as 2 doublets (128.0 and 134.1 ppm, J = 315Hz) in the 13C NMR spectrum and 2 
multiplet signals in the 19F NMR spectrum (-25.30 and -26.88 ppm).
10.8 Synthesis of 2-N-Fmoc-4-chloro-5-(difluorochloromethvlsulfinvl) 
pentanoic acid cyclohexyl ester
Cl
Following the literature procedure described by C. Walsh & R. A. Firestone,
(81), 2-N-Fmoc-4-chloro-5-(difluorochloromethylsulfinyl)pentanoic acid 
cyclohexyl ester was successfully prepared from the oxidation of the mixed 
regioisomers 2-N-Fmoc-4(5)-chloro-5(4)-(difluorochloromethylsulfenyl) 
pentanoic acid cyclohexyl ester with 55% mCPBA in DCM at 0°C. Separation 
of the desired product D from the undesired product E was achieved by 
repeated flash chromatography and afforded an overall isolated yield of 21.2% 
from the protected L-allylglycine (53% based on the 2 : 3 ratio of B : C).
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The isolated compound D exists as 4 diastereoisomers, with the creation of the 
new chiral centre being brought about by the oxidation of sulfide to sulfoxide.
c f 2c n ^ o
*o
Cl
V yNHFmoc
CIF2 C
CO2C6H11
NHFmoc
Cl CO2 C6 H11
D E
The 13C NMR and 19F NMR spectra support the formation of 2-N-Fmoc-4- 
chloro-5-(chlorodifluoromethylsulfinyl)pentanoic acid cyclohexyl ester D as 
diastereoisomers.
In particular, in the 19F NMR spectrum a triplet at -60.2 ppm for one 
diastereoisomer (equivalent F’s being split by 2 equivalent SH’s) and a doublet 
of doublets at -54.6 ppm for a second diastereoisomer (equivalent F’s being 
split by 2 non-equivalent 8H’s) were observed. The 2 remaining 
diastereoisomers appear as overlapping multiplet signals at -58.6 ppm and -
60.2 ppm.
10.9 Synthesis of 2-Amino-4-chloro-5-(chlorodifluoromethvlsulfinvl)pentanoic 
acid.TFA salt
It was intended to sequentially deprotect the amine group followed by the 
carboxyl group of 2-N-Fmoc-4-chloro-5-(chlorodifluoromethylsulfinyl) pentanoic 
acid cyclohexyl ester, while minimising the opportunity for intramolecular 
displacement reactions, to afford the free amino acid as the TFA salt. In the 
literature the Fmoc- protecting group is cleavable under mild conditions with an
Cl CO2 H
Cl
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amine base (109). 20% Piperidine in DMF is reported to cleave the amine 
group in a matter of seconds at room temperature (the actual time required 
depends on the structure of the Fmoc- amine derivative). The cyclohexyl 
protecting group on the carboxyl is stable to base but is reported to be cleaved 
by methanesulfonic acid in 1 h at 0°C (111). Following these two general 
literature procedure for Fmoc- deprotection and cyclohexyl deprotection, one 
proceeded to attempt a sequential deprotection process. One added 20% 
piperidine in DMF and stirred the reaction mixture at room temperature for 
1 min. The reaction flask was then cooled to 0°C and methanesulfonic acid 
and 2 drops of TFA added. This was then stirred at 0°C for 1 h. The reaction 
was monitored by TLC / ninhydrin spray but unfortunately, even after a second 
attempt, no free amino acid was observed. Starting material D amounting to 
55mgs was the only product recovered.
+
u
I
H
H
R— NH2
© JH
R— n H2 =
(U NH2 (L) NH2
O ^.O H  Cl V '
f^  r ,s
Y  0
Cl
Anticipated reaction mechanism for the sequential deprotection of 2-N-Fmoc-4- 
chloro-5-(difluorochloromethylsulfinyl)pentanoic acid cyclohexyl ester
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Following Fmoc- deprotection, polymerised dibenzofulvene should have been a 
byproduct of the reaction and in theory this insoluble polymer would have 
precipitated out of solution. This was not observed. The cyclohexyl carbenium 
ion formed during the deprotection of the carboxyl group would have become 
inactivated via rearrangement to a cyclopentyl carbenium ion. Together this 
sequential deprotection process was intended to afford the free amino acid 
protected as the TFA salt.
Unfortunately due to time constraints it was not possible to ascertain whether it 
was the reaction conditions employed or the reagents used that resulted in the 
deprotection sequence not proceeding as expected.
Having run out of time no further deprotection procedures were attempted. 
However, use of a less bulky amine, such as ammonia, might have proved 
more effective in removing the Fmoc- group in this system. An alternative to 
using methanesulfonic acid for the removal of the cyclohexyl group would have 
been to try HF gas.
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EXPERIMENTAL
General Methods:
Melting points were determined on a Kofler hot stage melting point apparatus 
and are uncorrected. Short path distillations were carried out on a Buchi GKR- 
50 Kugelrohr. Recorded boiling ranges refer only to the indicated air bath 
temperature. 1H NMR spectra were recorded on a Bruker AM200SY or a 
Bruker WP200SY spectrometer both operating at 200MHz or on a Perkin Elmer 
R32 spectrometer operating at 90MHz. 13C NMR spectra were recorded on a 
Bruker AM200SY spectrometer operating at 50 MHz. 19F NMR Spectra were 
recorded on a Bruker AM200SY spectrometer operating at 188 MHz. Chemical 
shifts in the 1H, 13C and 19F NMR spectra are reported in parts per million (5) 
relative to residual proton shifts in deuteriochloroform at 7.24 ppm for the 1H 
and 19F NMR and the central signal at 77.0 ppm in the 13C NMR spectrum. 
Coupling constants (J) are quoted in Hertz. The multiplicities stated in the 
13C NMR spectra were determined by the use of DEPT spectra with pulse 
angles <|> = 90° and 135°. Data are reported using the following convention: 
s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b= broadened. 
Infrared spectra were recorded on a Perkin Elmer 983 or a Perkin Elmer P- 
1000 spectrometer. Mass spectra were obtained using a VG/Kratos MS12 
spectrometer or a VG/Kratos MS90S spectormeter for high resolution work.
The U.V. light source was supplied by a Hannovia Medium Pressure Mercury 
Lamp, 125 watts, unit number 8025. Separation of compounds was carried out 
by dry flash chromatography, under reduced pressure using Merck Kieselgel 60 
or alternatively by continuous reverse phase chromatography under positive 
pressure using Fluka reverse phase silica gel 100 Ci8 unless otherwise stated.
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N-Acetvl-D.L-trifluoromethionine methyl ester
NHAc 1. MeOH, Na, 
N2, Ooc
S (D .L )
o
2 . CF3 I, -50oC 
UV irradiation
S
NHAc
C02Me
adapted procedure of: M.E. Houston and J.F. Honek, J. Chem. Soc.;
Chem. Comm., 1989, 761
Analar MeOH (30 ml) in a Pyrex 3 neck round bottomed flask (50ml) fitted with 
a dry ice/acetone condenser and a gas inlet tube was cooled to 0°C in an ice 
bath. Sodium (0.12g, 5.2mmol) was added portionwise under N2. N-Acetyl- 
homocysteine thiolactone (0.796 g, 5.0 mmol) was added all at once and the 
solution stirred for 30min. The solution was then cooled to -50°C in a dry 
ice/acetone bath. Trifluoromethyl iodide (2.94g, 15mmol) was measured out on 
a calibrated vacuum line and trapped in a purpose built fixed volume Pyrex 
flask (see diagram). The trifluoromethyl iodide was then condensed into the 
reaction vessel and the mixture stirred and irradiated with a long wave U.V. 
lamp for 2 h at -50°C (in the literature procedure the reaction temperature was 
kept constant at 0°C for the duration of the expt.). The UV lamp was then 
removed and the solvent evaporated in vacuo. The residue was taken up in 
EtOAc (50ml) and washed with 5% NaHC0 3  solution (25ml) and brine (25ml), 
dried over Na2S04 and filtered. The filtrate was evaporated in vacuo and the 
resulting yellow oil chromatographed on silica using EtOAc/hexane (3:2) giving 
829mg (64%) of the title product as a clear oil.
TLC (3:2, EtOAc : Hexane) 
starting material Rf = 0.39
sodium salt Rf = 0.00
Product Rf = 0.57
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Vmax- (KBr disc) cm' 1 
1679, 1739, 3425
1H NMR (CDCI3) 5
2.03 (3H, s, NHCOCHs), 1.97-2.37 (2 H, m, CH2p), 2.95 
(2H, t, J = 7.6 Hz, CH2y), 3.76 (3H, s, C02CH3),
4.71 (1H, t of d, J = 8.1 Hz (t), 5.0 Hz (d), CHa),
7.17 (1H, d, J = 7.5 Hz, NHAc),
13C NMR (CDCI3) 5
2 2 . 6  ( NHCOCHs), 25.9 (CH2p), 32.5 (CH2y), 51.0, (OCH3), 52.4 (CHa),
130.8 (q, Jcf = 306.0 Hz, CF3), 170.7 (NHCOCH3), 171.9 (C02CH3)
19F NMR (CDCI3) 5 
-41.9 (CF3)
m/z
found 259.0477 (M+), 158.0816 (M+ -  CF3S) 
requires 259.0490 (M+), 158.0817 (M+ -  CF3S)
Microanalysis (%)
found C 37.24, H 4.73, N 5.39
requires C 37.06, H 4.67, N 5.41
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To measure out a known amount of reagent gas:
i) The purpose built ampoule is fitted, via tap 1, and opened to the vacuum 
line - this allows air inside the ampoule to be evacuated.
ii) Tap 1. is then closed and a known amount of reagent gas is measured out 
into the vacuum line (the supply cylinder is also attached to the vacuum line).
iii) Tap 1 . is then re-opened and, with the aid of a Liq.N2 trap, the reagent gas 
condenses into the ampoule.
iv) Once all the gas has condensed into the ampoule tap 1 is closed and the 
reagent gas is ready for use.
Cold finger - designed to fit 
easily into a Liquid N2 trap.
Cold finger
During the alkyIfluorination reaction 
both taps are use.
Tap 1 allows release of the gaseous^ volume = 0.320 Kgm-3 
reagent into the reaction vessel.
Tap 2 lets in nitrogen gas to displace 
the reagent.
purpose built (volume) vacuum line compatible pyrex ampoule 
(taps 1. and 2. are made from PTFE)
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L-T rifluoromethionine
NHAc NHAc
CO2 M6
MeOH/H20/ f*Cv 
 ► 3
NaOH(aq), 0°C
H2 0 ,acylase,
37oC
S
(L) H
procedure: M.E. Houston and J.F. Honek, J. Chem. Soc.,
Chem. Comm., 1989, 761
A single neck round bottomed flask (50ml) charged with N-acetyl- 
trifluoromethionine methyl ester (700mg, 2.70mmol) and MeOH/H20  (1:1,
25ml) was cooled to 0°C in an ice bath. To this was added an aqueous solution 
of NaOH (0.12g, 3.0mmol) and the mixture was stirred for 50min (the reaction 
was monitored by TLC to assure completion). The solvent was evaporated in 
vacuo giving the sodium salt. The sodium salt was dissolved in degassed 
distilled H20  (150ml), transferred to a conical flask and the solution adjusted to 
pH 7.5 with 0.1M HCI. Porcine kidney acylase (Grade I, 1 mg, 1,430 units, 
supplied by Sigma Product No. A3010) was added, the flask stoppered and the 
aqueous solution gently agitated overnight at 37°C in a water bath. The 
solution was adjusted to pH 5 with 6 M HCI and activated charcoal (0.5g) 
added. The mixture was heated with stirring to 60°C for 10min and filtered.
The filtrate was adjusted to pH 1.5 with 6  M HCI and extracted with EtOAc (3 x 
15ml). The aqueous layer was applied to a Dowex-50W RS03H column and 
eluted with H20  until the eluate was the same pH as the distilled H20. The
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column was then eluted with 1.0 M NH4OH and the eluate collected and 
evaporated in vacuo. The product was dissolved in distilled H20  and applied 
to a reverse phase C-18 silica column and eluted with H20. Fractions were 
monitored by TLC using ninhydrin spray to visualise free amino acid. Amino 
acid containing fractions were combined and evaporated in vacuo giving 207 
mg (37.7%, 75.4% based on D,L mixture) of the amino acid as a white solid, 
m.p. 229 - 230°C.
TLC (50% MeOH, 15% H20, 35% Et20)
Product Rf = 0.62
1H NMR (D20) 5
2.02 - 2.14 (m, 2H, CH2p), 2.92 (t, 2H, J = 7.6 Hz, CH2y),
3.67 (t, 1H, J = 6.4 Hz, CHa),
13C NMR (D20) 5
26.2 (CH2p), 31.9 (CH2y), 54.2 (CHa), 131.7 (q, JCF = 306.0 Hz, CF3),
174.4 (C02H)
19F NMR (D20) 5 
-41.6 (CF3)
[a] D22 +16.6 +0.5 (5M HCI)
literature value [a] D25 +52.3 ± 0.5 (4M HCI)
m/z
found 203.0230 (M+), 158.0235 (M+ -  COzH) 
requires 203.0228 (M+), 158.0251 (M+ -  C02H)
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N-Acetvl-D.L-difluoromethionine methyl ester
NHAc
1. MeOH, Na, 
N2) OoC
f2hc
NHAc
O C02Me
S (D ,L ) 2. CHF2CI, 60>C
adapted procedure of: M.E. Houston and J.F. Honek, J. Chem. Soc.,
Chem. Comm., 1989, 761
Analar MeOH (40ml) in a 2 neck round bottomed flask (50ml) was cooled to 
0  °C in an ice bath. Sodium (0.19g, 8.3mmol) was added portionwise under N2. 
N-Acetylhomocysteine thiolactone (1.25 g, 15.8 mmol) was added all at once 
and the solution stirred for 30min. The mixture and a magnetic stirrer were 
then transferred to a pressure bottle (100ml). The pressure bottle was attached 
to a vacuum line and the air carefully evacuated. Freon 22 
(chlorodifluoromethane) (1.38g, 16.0mmol) was measured into the calibrated 
vacuum line before being condensed directly into the pressure tube. Liquid N2 
was used as the coolant. The tube was sealed and the mixture heated to 60°C 
with stirring for 1 0 h (in the literature procedure an excess of freon 22 was 
bubbled through the reaction mixture over the course of 1 0 h at atmospheric 
pressure). The reaction mixture was then evaporated in vacuo and the residue 
taken up in EtOAc (50ml), washed with 5% NaHC03 aqueous solution (25ml) 
and brine (25ml), dried over Na2S04 and filtered. The filtrate was evaporated in 
vacuo and the resulting yellow oil chromatographed on silica using 
EtOAc/Petroleum ether (1:2) giving 1.04g (55%) of the desired product as a 
clear oil.
TLC (3:1, EtOAc: Pet ether) 
sodium salt Rf = 0.00
Product Rf = 0.31
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Vmax- (KBr disc) cm' 1 
1674, 1738, 3427
1H NMR (CDCI3) 6
2.04 (3H, s, NHAc), 1.98 - 2.30 (2H, m, CH2p), 2.86 (2H, t, J = 7.7 Hz, CH2y), 
3.75 (3H, s, C02CH3), 4.67 (1 H, t of d, J = 8.1 Hz (t), 4.8 Hz (d), CHa),
6 . 8 6  (1H, t, JHF = 56.1 Hz, CF2H), 7.32 (1H, d, J = 7.9 Hz, NHAc)
13C NMR (CDCI3) 5
22.8 (NHCOCH3), 23.2 (CH2y), 33.1 (CH2p), 51.2 (OCH3), 52.5 (CHa),
120.6 (t, JCF = 272.2 Hz, CF2H), 170.7 (NHCOCH3), 172.2 (C02CH3)
19F NMR (CDCI3) 6
-93.5 (d, Jhf = 54.6 Hz, CF2H)
m/z
found 241.0246 (M+) 
requires 241.0586 (M+)
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L-Difluoromethionine
NHAc NHAc
F2HC C02Me Me0H/H20 /
 ►
NaOH(aq), 0°C
f2hc
H20,acylase,
37oC
V
NH®
F2HC. ©
2
procedure: M.E. Houston and J.F. Honek, J. Chem. Soc.,
Chem. Comm., 1989, 761
A single neck round bottomed flask (50ml) charged with N-acetyl- 
difluoromethionine methyl ester (1.0g, 4.15mmol) was dissolved in MeOH/H20 
(1:1, 25ml) and cooled to 0°C in an ice bath. To this was added an aqueous 
solution of NaOH (0.18g, 4.5mmol) and the mixture was stirred for 50min (the 
reaction was monitored by TLC to assure completion). The solvent was 
evaporated in vacuo giving the sodium salt. The sodium salt was dissolved in 
degassed distilled H20  (200ml) and the solution adjusted to pH 7.5 with 0.1M 
HCI. Porcine Kidney acylase (1.7mg, 2,431 units, supplied by Sigma Product 
No. A3010) was added and the solution gently agitated overnight at 37°C in a 
water bath. The amino acid was purified as previously described giving 315mg 
(41.1 %, 82.4% based on D,L mixture) of the title product as a white solid, m.p. 
200°C (literature value 199 - 201 °C).
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1H NMR (D20) 5
2.03 (2H, m, CH2|3), 2.75 (2H, t, J = 7.6 Hz, CH2y), 3.63 (1H, t, J = 6.0 Hz, 
CHa), 6.88 (1H, t, J hf = 51.8 Hz, CF2H)
13C NMR (D20) 5
22.5 (CH2y), 31.4 (CH2p), 53.3 (CHa), 120.9 (t, JCF = 276.7 Hz, CF2H),
174.2 (C02H)
19F NMR (D20) 5
-96.1 (d, J hf = 56.5 Hz, CF2H)
[a]D22 +6.8 ± 0.5 (5 M HCI) 
no literature value given
m/z
found 140.0334 (M+ -  C02H), 74.0241 ( M+ -  CH2CH2SCHF2)
requires 140.0346 (M+ -  C02H), 74.0242 ( M+ -  CH2CH2SCHF2)
microanalysis (%)
found C 32.57, H 4.79, N 7.74
requires C 32.43, H 4.90, N 7.57
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L-Trifluoromethvl cysteine
NH3(liq), N2,
CF3I, -50C, 
UV irradiation
F3CS. >©'2
H
procedure: V. Soloshonok, V. Kukhar, Y. Pustovit and V. Nazaretian
Synlett., 1992, 657
Liquid NH3 (50ml) in a Pyrex 3 neck round bottomed flask (100ml) fitted with a 
dry ice/acetone condenser was cooled to -50°C in a dry ice/acetone bath. 
L-Cysteine (0.700g, 5.78mmol) was added all at once and the solution stirred 
under N2. Trifluoromethyl iodide (2.94g, 15.0mmol) was measured out using 
the purpose built flask and introduced to the reaction vessel as previously 
described. The solution was irradiated with a long wave UV lamp for 1.5h. The 
UV lamp was removed and the solvent evaporated in vacuo. The solid white 
residue was taken up in MeOH (30ml) and filtered of insoluble material. The 
filtrate was evaporated in vacuo and the residue taken up in distilled H20 
(200ml). The solution was adjusted to pH 1.5 with 6M HCI and applied to a 
Dowex-50W R S O 3H  column. The column was eluted with H20  until the eluate 
was the same pH as the distilled H20. The column was then eluted with 1.0M 
NH4OH and the eluate collected and evaporated in vacuo. The product was 
dissolved in distilled H20  and applied to a reverse phase C-18 column and 
eluted with H20. Fractions were monitored by TLC using ninhydrin spray to 
visualise free amino acid. Fractions were combined and evaporated in vacuo 
giving 790mg (73.2%) of free amino acid as a white solid, m.p. 229 - 231 °C 
(literature value 227 - 230°C).
TLC (50% MeOH, 15% H20, 35% Et20) 
Starting material Rf = 0.28
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Product Rf = 0.70
1HNMR(D20)S
3.30 (CH2), 3.86 (CH), (3H, AA’B system, Jaa' = 15.9 Hz, Jab +  Jab  = 12.0 Hz) 
(AA’ and B represents CH2 and CH protons respectively)
13C NMR (D20) 8
30.7 (CH2), 75.4 (CH), 131.1 (q, JCF = 306.0 Hz, CF3), 172.3 (C02H)
19F NMR (D20) 8 
-41.6 (CF3)
[a]D22 +18.2 + 0.5 (5M HCI)
literature value [a]o25 +24.1 ± 0.5 (4M HCI)
m/z
found 189.0061 (M+), 144.0114 (M+ -  C02H), 74.0244 (M+ -  F3CSCH2)
requires 189.0071 (M+), 144.0095 (M+ -  C02H), 74.0242 (M+ -  F3CSCH2)
microanalysis (%)
found C 25.50, H 3.19, N 7.31
requires C 25.40, H 3.20, N 7.41
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D-Trifluoromethyl penicillamine
HS
( D )
c o p CF3I, -50°C, 
UV irradiation
NH3(liq), N2,
c o p
procedure: V. Soloshonok, V. Kukhar, Y. Pustovit and V. Nazaretian
Synlett., 1992, 657
Trifluoromethylation of D-penicillamine was executed by the same method 
described for L-cysteine. The quantities used were: NH3 (50ml), 
D-penicillamine (0.777g, 5.2mmol), and trifluoromethyl iodide (2.94g, 
15.0mmol). This gave 960 mg (65.7%) of the free amino acid as a white solid, 
m.p. 209 - 210°C
TLC (50% MeOH, 15% H20, 35% Et20)
Starting material Rf = 0.47
Product Rf = 0.64
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1H NMR (D20) 6
1.61,1.27 (s,s, C(CH3)2), 3.75 (s.CHa)
13C NMR (D20) 5
28.6, 23.9 ((CH3)2), 52.1 (C(CH3)2), 63.1 (CHa), 130.8 (q, JCF = 305.0 Hz, CF3), 
171.0 (C02H)
19F NMR (D20) 5 
-  36.5 (CF3)
[a]D22 -0.79 ± 0.5 (5M HCI)
literature value [a]o25 -4.1 ± 0.5 (6M HCI)
m/z
found 172.0410 (M+ -  C02H), 71.0734 (M+ -  F3CS, C02H) 
requires 172.0408 (M+ -  C02H), 71.0735 (M+ -  F3CS, C02H)
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L-Trifluoromethionine sulfoxide
^  1 . h 2o 2, CH3CO2H, ^
F3c\ sx ^ \ / \ ; ,,,,coP  38°c F3c \ g / ' \ / \ ,,"C0^
(L )  H  II (L )  H
2. EtOH 0
product has never successfully been prepared 
general procedure: A. Lepp and M.S. Dunn, Biochemical Preparations, 1955,
Vol 4, 80
Glacial acetic acid (10ml) and trifluoromethionine (500mg, 2.46mmol) were 
mixed in a conical flask to form a slurry. Slowly with stirring 30% H20 2 (0.33ml, 
2.81 mmol) was added dropwise to the flask. Once addition was complete the 
mixture was stirred for a further 5min at room temperature. The flask was 
covered with an inverted beaker and stored in an oven at 38°C overnight. The 
reaction mixture was removed from the oven allowed to cool to room 
temperature and EtOH (5ml) was added with shaking. The flask was placed at 
the back of the fume hood (cold area) during the interval of precipitation (24h). 
The precipitate was filtered, washed with EtOH (10ml) and dried. Only starting 
material was recovered.
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L-Trifluoromethionine sulfoxide
1.60% perchloric acid 
(NH4)2Mo0 4, H20,boil
CoP
(L )  H 2. 30% H20 2, 0oC-38oC
3. ethanolamine, OoC,
EtOH
product has never successfully been prepared 
general procedure: A. Lepp and M.S. Dunn, Biochemical Preparations, 1955,
Vol 4, 81
To a round bottomed flask (5ml), 60% perchloric acid (0.27ml, 2.43mmol)), 
(NH4)2Mo0 4 (34mg, 0.17mmol) and H20  (1ml) were added. The mixture was 
boiled for 5min and hot filtered of any undissolved material. The hot filtrate and 
trifluoromethionine (160mg, 0.7 mmol) were mixed in a conical flask to form a 
slurry and cooled in an ice bath. Slowly with stirring 30% H20 2 (0.30ml, 
2.53mmol) was added dropwise to the flask. Once addition was complete the 
mixture was stirred for a further 5min at room temperature. The flask was 
covered with an inverted beaker and stored in an oven at 38°C over night. The 
mixture was neutralised to pH 5 with ethanolamine and cooled in an ice bath. 
The flask was placed at the back of the fume hood and EtOH (5ml) added. After 
24h the precipitate was filtered and washed with EtOH (10ml) and dried. Only 
starting material was recovered.
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L-Methionine sulfoxide
NH31© 1. H2O2 , CH3CO2H, 
38° C
(L) H  ------------------------------------ --
2. EtOH
NH
procedure: A. Lepp and M.S. Dunn, Biochemical Preparations, 1955, Vol 4, 80
Glacial acetic acid (25ml) and L-methionine (5.0g, 24.6mmol) were mixed in a 
conical flask to form a slurry. Slowly with stirring 30% H20 2 (4.50ml, 38.3mmol) 
was added dropwise to the flask. Once addition was complete the mixture was 
stirred for a further 5min at room temperature. The flask was covered with an 
inverted beaker and stored in an oven at 38°C overnight. The reaction mixture 
was removed from the oven allowed to cool to room temperature and EtOH
(15ml) was added with shaking. The flask was placed at the back of the fume
hood (cold area) during the interval of precipitation (24h). The precipitate was 
filtered, washed with EtOH (50ml) and dried to yield 3.02g (58.0%) of the title 
product methionine sulfoxide with a cabbage like odour, m.p. 230°C (literature 
value 232°C).
Starting material (0.87g) was also recovered.
TLC (50% MeOH, 15%H20, 35% Et20) 
starting material Rf=0.71
product Rf = 0.38
m/z
found 165.0486 
requires 165.2170
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N-Acetvl-D.L-trifluoromethionine sulfoxide methyl ester
NHAc NHAc
S
( D ,L )
mCPBA 55 %,
C02Me
product has never before been prepared 
procedure: M. Johnston, R. Raines, C. Walsh and R. A. Firestone,
J. Am. Chem. Soc., 1980, 102, 4241
A flame dried round bottomed flask (25ml) equipped with side arm and septum 
cap, under N2, was charged with trifluoromethionine methyl ester (1 .0 0 g, 
4.93mmol) in distilled DCM (25ml) and stirred at 0°C in an ice bath. A solution 
of 55% mCPBA (1.54g, 4.93mmol) in distilled DCM (25ml), with added 
activated 4A molecular sieves (2 .0 g) to reduce the overall water content, was 
added to the reaction flask via syringe over 1 h. After 30min at room 
temperature the solution was washed with NaHC03 solution (3 x 50ml), dried 
over Na2S04, and filtered. The filtrate was evaporated in vacuo to give a yellow 
oil. The oil was applied to a silica column and eluted with EtOAc to give 1.04g 
(91.6%) of the title product as a clear oil.
TLC (EtOAc)
starting material Rf = 0.70 
product Rf = 0.51
m/z
found 232.0228 (M+ -  COCH3)
requires 232.0255 (M+ -  COCH3)
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1H NMR (CDCI3 ) 5
1.97 (3H, s, NHCOCH3), 2.16 (1H, m, CH2p), 2.35 (1H, m, CH2p),
3.01 (2H, m, CH2y), 3.70 (3H, s, C02CH3), 4.67 (1H, m, CHa),
7.12 (1H, d, J = 8.0 Hz, NHAc),
13C NMR (C D C I3 )  8
22.6 ( NHCOCH3), 24.2, 24.5 (CH2p), 44.7 (CH2y), 50.7, 50.9 (OCH3),
52.6 (CHa), 125.1 (q, JCF = 331.5 Hz, CF3), 170.8 (NHCOCH3), 171.3 (C02CH3)
19F NMR (CDCI3) 6  
-73.61,-73.64 (CF3)
m/z
found 232.0228 (M+ -  COCH3) 
requires 232.0255 (M+ -  COCH3)
Microanalysis (%)
found C 35.06, H 4.28, N 5.08
Requires C 34.90, H 4.36, N 5.09
127
L-Trifluoromethionine sulfoxide
NHAc NHAc
C0 2 M©
MeOH/H20/
-------------- ► o
NaOH(aq), 0»C 5
H2 0 ,acylase,
37°C
product has never been successfully prepared 
adapted procedure: M.E. Houston and J.F. Honek, J. Chem. Soc.t 
Chem. Comm., 1989, 761
A single neck round bottomed flask (50ml) charged with N-acetyl-D,L- 
trifluoromethionine sulphoxide methyl ester (1.00g, 3.64mmol) dissolved in 
MeOH/H20  (1:1, 30ml) was cooled to 0°C in an ice bath. To this was added an 
aqueous solution of NaOH (0.16g, 4.0mmol) and the mixture was stirred for 
50min (the reaction was monitored by TLC to assure completion). The solvent 
was evaporated in vacuo giving the sodium salt. The sodium salt was dissolved 
in degassed distilled H20  (150 ml) and the solution adjusted to pH 7.5 with
0.1M HCI. Porcine kidney acylase (1  mg, 1,430 units, supplied by Sigma 
Grade 1, product No. A3010) was added and the solution gently agitated 
overnight at 37°C in a water bath. The solution was adjusted to pH 5 with 6 M 
HCI and activated charcoal (0.5g) added. The mixture was heated with stirring 
to 60°C for 10min and filtered. The filtrate was adjusted to pH 1.5 with 6 M HCI 
and extracted with EtOAc (3 x 20ml). The aqueous layer, which did not test 
positive for the presence of free amino acid in ninhydrin spray spot tests on 
TLC film, was applied to a Dowex 50W RSO3H column and eluted with H20
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until the eluate was of the same pH as the distilled H20. The column was then 
eluted with 1 .OM NH4OH and the eluate collected and evaporated in vacuo. No 
product was isolated.
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N-Acetvl-D.L-trifluoromethionine sulfone methyl ester
NHAc NHAc
CO2M6
mCPBA55 %
C02Me
DCM, N3 
0°C— r.t. (D ,L )
product has never before been prepared 
procedure: M. Johnston, R. Raines, C. Walsh and R. A. Firestone,
J. Am. Chem. Soc., 1980,102, 4241
A flame dried round bottomed flask (25ml) equipped with side arm and septum 
cap, under N2, was charged with trifluoromethionine methyl ester (1 .0 0 g, 
4.93mmol) in distilled DCM (25ml) and stirred at 0°C in an ice bath. A solution 
of 55% mCPBA (3.12g, lO.Ommol) in distilled DCM (35ml), with added 
activated 4A molecular sieves (2 .0 g) to reduce the overall water content, was 
added to the reaction flask via syringe over 1 h. After 1 h 30min at room 
temperature the solution was washed with NaHC03 solution (3 x 50ml), dried 
over Na2S04l and filtered. The filtrate was evaporated in vacuo to give a yellow 
oil. The oil was applied to a silica column and eluted with EtOAc to give 0.98g 
(87.2%) of the title product as a clear oil.
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1H NMR (CDCI3 ) 5
2.08 (3H, s, NHCOCH3), 2.26 (1H, m, CH2p), 2.50 (1H, m, CH2p),
3.45 (2H, m, CH2y), 3.79 (3H, s, C 0 2 CH3), 4.77 (1H, m, CHa),
7.28 (1H, d, J = 7.3 Hz, NHAc),
13C NMR (CDCI3 ) 5
22.6 ( NHCOCH3), 23.9 (CH2p), 46.3 (CH2y), 50.4 (OCH3), 52.8 (CHa),
119.2 (q, Jcf = 324.8 Hz, CF3), 170.9 (NHCOCH3), 171.4 (C02CH3)
19F NMR (CDCI3 ) 5 
-78 .3  (CF3)
m/z
found 291.0403 (M+) 
requires 291.0388 (M+)
L-Trifluoromethionine sulfone
NHAc NHAc
f 3c ^
( d , l )  C 0 2 M e
MeOH / H2 O /
^  (DL)
N a O H (a q ) , 0°C 0  0  1 ;O O
H2 O, acylase 
37° C
NH3©
product has never successfully been prepared 
adapted procedure: M.E. Houston and J.F. Honek, J. Chem. Soc.,
Chem. Comm., 1989, 761
A single neck round bottomed flask (50ml) charged with N-acetyl-D,L- 
trifluoromethionine sulfone methyl ester (0.98g, 3.37mmol) was dissolved in 
Me0H/H20  (1:1, 30ml) and cooled to 0°C in an ice bath. To this was added an 
aqueous solution of NaOH (0.15g, 3.74mmol) and the mixture was stirred for 
SOmin (the reaction was monitored by TLC to assure completion). The solvent 
was evaporated in vacuo giving the sodium salt. (1H NMR shows loss of the 
3.76, 3H, s, CO2CH3 signal). The sodium salt was dissolved in degassed 
distilled H20  (190ml) and the solution adjusted to pH 7.5 with 0.1M HCI.
Porcine Kidney acylase (1.3mg, 1,860 units, supplied by Sigma Grade 1, 
Product No. A3010) was added and the solution gently agitated overnight at 
37°C in a water bath. The solution was adjusted to pH 5 with 6 M HCI and 
activated charcoal (0.6g) added. The mixture was heated with stirring to 60°C 
for 10min and filtered. The filtrate was adjusted to pH 1.5 with 6 M HCI and 
extracted with EtOAc (3 x 20ml). The aqueous layer did not test positive for the
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presence of free amino acid in ninhydrin spray spot tests on TLC film. On 
evaporation of the aqueous layer in vacuo no product was isolated.
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N-Acetvl-D.L-allvlqlvcine
1 . A C 2O , N aO H (aq ) 
0°C
NHAc
2. HCI C02H(D ,L )
procedure: S. Black & N. G. Wright, J. Biological Chemistry; 1955, 39, 213
D,L-Allylglycine (10.0g, 86.9mmol) and 2 M NaOH (45ml), in a conical flask, 
were stirred at 0°C in an ice bath. Distilled acetic anhydride (12.5ml,
132.5mmol) was added dropwise to the flask over the course of 1 h. A 
saturated solution of NaOH was added during the same time period to keep the 
solution above
pH 9.5. 10M HCI (200ml) was then added and the solution extracted with 
EtOAc (3 x 150ml). The separated organic layer was dried over Na2S04, 
filtered and evaporated in vacuo. N-acetyl-D,L-allylglycine crystallised as 
rectangular plates during the latter stages of distillation. The product was 
recrystallised from hot acetone by the addition of pet-ether 40-60 giving 10.13g 
(74.2%) of product, m.p. 115°C (literature value 114-117°C).
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ymax (KBr disc) cm' 1 
921, 992, 1674, 1738, 3427
1H NMR (CDCI3) 6
1.77 (3H, s, CH3), 2.30 (2 H, m, CH2p),
4.17 (1H broad m, CHa),
4.91, 4.96, (2H, 2m, CH2 vinyl), 5.53 (1H, m, CH vinyl)
13C NMR (CDCI3) 5
22.3 (CH3), 35.7 (CH2p), 53.3 (CHa), 119.6 (CH2 vinyl), 133.4 (CH vinyl), 
175.9 (C02H), 174.8 (NHCOCH3)
m/z
found 157.0728 (M+), 112.0751 (M+ -  C02) 
requires 157.1696 (M+), 112.1518 (M+ -  C02)
microanalysis (%)
found C 53.41, H 7.03, N 8.87
requires C 53.50, H 7.01, N 8.92
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L-Allvlqlvcine
NHAc 1. H20, NaOH
acylase, 37°C
©
NH3
( D ,L )  |
C02H 2. AcOH
procedure: S. Black & N.G. Wright, J. Biological Chemistry, 1955, 39, 213
A solution of N-acetyl-D,L-allylglycine (8.73g, 55.6mmol) dissolved in degassed 
distilled water (400ml) was adjusted to pH 7.5 with NaOH solution 
Porcine kidney acylase (3.0mg, 4,290 units supplied by Sigma Grade I, Product 
No. A3010) was added, the conical flask was stoppered and the solution gently 
agitated overnight at 37°C in a water bath. The solution was adjusted to pH 5 
with glacial acetic acid and activated charcoal (1.0g) added. The mixture was 
heated with stirring to 60°C for 1 0 min before filtering. On concentration in 
vacuo, to about 50ml, the L-allylglycine began to crystallise out of solution. 
Crystallisation was completed by the addition of absolute EtOH (200ml). 
Recrystallisation from H20/EtOH (1:4) afforded L-allylglycine as white crystals 
in an overall yield of 2.52g, 39.4% (78.8% based on D,L mixture), m.p. 259°C 
(literature value 259°C).
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ymax (KBr disc) cm"1
920, 990, 1584, 1624, 2400 - 3220
1H NMR (D20) 5
2.44 (2 H, m, CH2p), 3.62 (1 H, t, J = 6  Hz, CHa), 5.09 (2 H, m, CH2 vinyl),
5.59 (1H, m, CH vinyl)
13C NMR (D20) 8
35.6 (CH2p), 54.7 (CHa), 121.3 (CH2 vinyl), 132.1 (CH vinyl), 174.9 (C02H)
[a]D2 2 -35.0 ± 0.5 (H20)
literature value [a] D24 -37.1 ± 0.5 (H20)
m/z
found 115.0635 (M+) 
requires 115.1323 (M+)
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N-Boc-L-allvlqlvcine
NH2HCI 1. H20/dioxan/10% NEta 
Boc-ON, r.t., reflux
NHBoc
0 2H 2. H20, Et20
3. HCI, 0°C
0 2H
procedure: M. Johnston, R. Raines, C. Walsh & R. A. Firestone,
J. Am. Chem. Soc., 1980, 102, 4241
To a round bottomed flask (25ml) charged with L-allylglycine (1.0g, 8.70mmol) 
and a mixed solution of H20  / dioxan / 1 0 % NEt3(aq) (1:1:1, 15ml) was added 
BOC-ON in a 10% excess (2.39g, 8.7mmol). The solution was then left to stir 
at r.t. for 4h before H20  (20ml), then ether (25ml) were added. Following 
vigorous shaking the aqueous layer was separated and washed twice with 
ether (2 x 15ml). The aqueous layer was then acidified with stirring to pH 2 
with 5 M HCI (5ml) at 0°C in an ice bath for 10min. The Boc protected amino 
acid was then extracted with EtOAc (3 x 25ml), dried over Na2S0 4  and filtered. 
The filtrate was evaporated in vacuo and the resulting yellow oil crystallised 
from ether and washed with hexane giving 1.52g (81 %) of the title product as a 
white crystals, m.p. 110°C (literature value 109 -1 10°C).
ymax (KBr disc) cm-1
912, 995, 1710, 1729, 2933, 3367
1H NMR (CDCI3) 2 0 0  MHz) 5
1.45 (9H, s, t-Bu), 2.55 (2H, m, CH2p), 4.35 (1H, br, NH),
4.88 - 5.42 (3H, m, CHa, CH2 vinyl), 5.66 (1 H, m, CH vinyl)
13C NMR (CDCI3) 2 0 0 MHz) 5
28.2 (C(CH3)3), 36.3 (CH2p), 52.7 (CHa), 80.3 (C(CH3)3), 119.5 (CH2 vinyl),
132.0 (CH vinyl), 155.5 (C02C(CH3)3), 176.7 (C02H)
m/z
found 170.1178 (M+ -  C02H) 
requires 170.2321 (M+ -  C02H)
microanalysis (%)
found C 55.62, H 7.84, N 6.50
requires C 55.81, H 7.91, N 6.51
Benzophenone hvdrazone
Hydrazine hydrate 
 ►
EtOH, reflux
procedure: Fieser & Fieser, Reagents for Organic Chemistry Preparation, 338
To a round bottomed flask (150ml) charged with distilled EtOH (23ml) was 
added benzophenone (6.12g, 33.6mol) and 100% hydrazine hydrate (6.31 g, 
12.6mol). The mixture was heated under reflux for 10h. On cooling in ice, 
colourless crystals of benzophenone hydrazone separated. 6.42g (97.4%) m.p. 
97°C (literature value 98°C).
ymax (KBr disc) cm' 1 
3202, 3422
1H NMR (CDCI3) 5
5.49 (s, 2H, NH2), 7.59 - 7.25 (m, 10H, aromatic Hs) 
microanalysis (%)
found C 79.34, H 6.18, N 14.45
requires C 79.59, H 6.18, N 14.29
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Diphenyl diazomethane
Na2S04, Et2Q 
 ►
EtOH/KOH,
HgO
procedure: Fieser & Fieser, Reagents for Organic Chemistry Preparation, 338
Benzophenone hydrazone (350mg, 1.78mmol) and anhydrous Na2S04 (0.4g, 
2.82mmol) were added to a pressure bottle (100ml) charged with distilled Et20  
(5.4ml). Sequentially EtOH saturated with KOH (0.13ml) and yellow HgO 
(0.944g, 4.36mmol) were added. The bottle was sealed and wrapped in a wet 
towel before shaking for 1 h, 15min. The solution was then filtered and 
evaporated in vacuo. The residue was taken up in pet ether 40-60 (15ml) and 
on evaporation this gave 339mg (98%) of the title product as crimson crystals, 
m.p. 31 °C (literature value 30°C).
ymax (KBr disc) cm' 1 
2020
1H NMR (CDCI3) 5
7.13 - 7.58 (m, 10H, aromatic Hs)
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N-Boc-L-allvlqlvcine benzhvdrvl ester
NHBoc Ph2CN2, NHBoc
0 2H MeCN, r.t. C02CHPh2
procedure: M. Johnston, R. Raines, C. Walsh & R. A. Firestone, 
J. Am. Chem. Soc., 1980, 102, 4241
N-Boc-L-allylglycine (3.23g, 15.0mmol) and diphenyldiazomethane (1.91 g, 9.83 
mmol) were dissolved in MeCN (175ml) in a conical flask. The solution was 
stirred at room temperature for 1 h, during which time most of the crimson colour 
faded. The solvent was evaporated in vacuo and the product began 
crystallising out. The title product was recrystallised from ether/hexane (1:1) 
giving 3.82g (66.7%) of white crystals, m.p. 80 - 82°C (literature value 79 - 
80°C).
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ymax (KBr disc) cm'1
1514, 1705, 1741
1H NMR (CDCI3) 5
1.49 (9H, s, C(CH3)3), 2.58 (2H, m, CHp), 4.58 (1H, m, NH),
5.02 ( 3H, m, CHa, CH2 vinyl), 5.60 (1H, m, CH vinyl), 6.82 (1H, s, CHPh2), 
7.18-7.28 (10H, m, Ph2)
13C NMR (CDCI3) 5
28.2 (C(CH3)3), 36.6 (CH2p), 52.9 (CHa), 77.9 (CHPh2), 79.8 (C(CH3)3),
119.3 (CH2 vinyl), 128.1 -126.5 (Ph2), 139.6 (C 131.9 (CH vinyl),
155.1 (C02C(CH3)3), 171.1 (C02CHPh2)
m/z
found 381.1955 (M+) 
requires 381.4725 (M+)
p-Nitrophenvl sulphenvl chloride
0 2N
N°2  i2, c i2, e c u ,
N2,60oc
no 2
procedure: R. Katakai, J. Chem. Soc., Perkin Trans 1., 2249 (1987)
A flame dried round bottomed flask (50ml) equipped with a three way tap, water 
condensor, N2 balloon and side arm with septum, was charged with a 
suspension of p-nitrophenyl disulphide (0.540g, 1.75mmol), iodine (0.02g, 
0.79mmol) and sieve dried CCI4 (1 0 ml). Liquefied Cl2 (in excess) in sieve 
dried CCI4 (15ml) was then added to the suspension via syringe and the 
mixture heated with stirring at 60°C in a water bath until the disulphide 
dissolved to give a yellow/orange clear solution (approximately 10min). The 
three way tap was then connected to a vacuum pump and the solvent 
evaporated. The newly prepared sulphenyl chloride crystallised out towards 
the end of evaporation and was stored under N2 until required, (yield taken as 
0.63g (95%) or above) m.p. 48°C (literature value 48°C).
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2-N-Boc-4(5)-chloro-5(4)-(p-nitrophenvl sulfenvl) pentanoic acid
benzhvdrvl ester
io 2CHPh2
(L)
compound (16)
procedure: M. Johnston, R. Raines, C. Walsh & R. A. Firestone,
J. Am. Chem. Soc., 1980, 102, 4241
A flame dried round bottomed flask (50ml) complete with side arm, septum cap 
and N2 balloon was charged with N-Boc-L-allylglycine benzhdryl ester (4.27g,
11.21 mmol) and distilled DCM (20ml). The mixture was cooled to -1 8°C with 
an ice / salt bath and p-nitrobenzene sulphenyl chloride (2.08g,
10.97mmol) in DCM (15ml) under N2 was added dropwise over 30min via 
syringe. The solution was then allowed to warm to room temperature and 
stirred overnight. The solvent was evaporated in vacuo to give 4.82g of an oily 
residue. NMR showed a mixture of regioisomers (designated as compounds 
15& 16) in a 1:10 ratio (15:16). Separation could be achieved by repeated 
flash chromatography, eluting with EtOAc:CHCI3, (50:1), but the partially 
purified mixture was usually carried forward since separation was easier at the 
sulphoxide stage. The overall yield for the mixture of regioisomers was 75.4%, 
no literature value was given.
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O2N -O -S C I, 
 ►
DCM, N2 , 
-18°C— r.t.
compound (15)
Cl c o 2 c h p ^
NHBoc
O
ymax (KBr disc) cm'1
854, 1514, 1597
NMR of 15 
1H NMR (CDCI3) 5
1.28 (9H, s, t-Bu), 2.33 (2H, m, CH2(3), 3.50 (2H, m, CH2S), 4.17 (1H, m, CHCI),
4.70 (1H, m, CHa), 5.27 (1H, m, NH), 6.93 (1H, s, CHPh2), 7.29 (10H, m, 
aromatic), 7.32 (d), 7.99 (4H, AA’BB’, J = 8.9, 8 .6 , C6H4)
NMR of 16 
1H NMR (C D C I3 )  6
1.42 (9H, s, t-Bu), 1.92 (m), 2.59 (2H, m, CH2p), 3.62 (3H, m, CH2CI & CHS),
4.70 (1H, m, CHa), 5.35 (1H, m, NH), 6.93 (1H, s, CHPh2), 7.29 (10H, m, 
aromatic), 7.32 (d), 7.99 (4H, AA’BB’, J = 8.9, 8 .6 , C6H4)
microanalysis of mixture of regioisomers 15 & 16 (%) 
found C 60.92, H 5.29, N 4.81 
requires C 61.00, H 5.26, N 4.91
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2-N-Boc-4(5)-chloro-5(4)-(p-nitrophenvl sulfinvl) pentanoic acid
benzhvdrvl ester
compound 17
Cl
NHBoc
(L)
0 2CHPhk
° 2N' Y ^
0
mCPBA 55%, 
 ►
DCM, N>,
(L)
o 2chpi^
NHBoc
Cl c o 2chpi^
NHBoc
0 2N
compound 18
procedure: M. Johnston, R. Raines, C. Walsh & R. A. Firestone,
J. Am. Chem. Soc., 1980, 102, 4241
A flame dried round bottomed flask (25ml) equipped with side arm and septum 
cap, under N2, was charged with 15 & 16 (4.82g, 8.45mmo!) in distilled DCM 
(100ml) and stirred at 0 °C in an ice bath. A solution of 55% mCPBA (2.65g, 
8.45mmol) in distilled DCM (100ml), with activated 4A molecular sieves to 
reduce the overall water content, was added to the reaction flask via syringe 
over 1 h. After 30min at room temperature the solution was washed with 
NaHC03 solution (3 x 50ml), dried over Na2S04, and filtered. The filtrate was 
evaporated in vacuo giving a yellow oil. The oil was applied to a silica column 
and eluted with EtOAc:CHCl3 (50:1) to give products 17 & 18. Separation of 17 
from 18 was achieved by repeated flash chromatography using the same 
eluants as before. Product 17 exists as two isomers I & II which were not 
separated. NMR data is given for 17 as a whole since I & II give almost the
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same spectra. Only one isomer of 18 was isolated and analysed. The overall 
yield of 17 from 14 was 360mg (5.5%).
NMR of 17 
1H NMR (CDCI3) 8
171: 1.40 (9H, s, t-Bu), 2.12 (m), 2.33 (2H, m, CH2p), 3.29 (2H, m, CH2S),
4.60 (2H, m, CHCI, CHa), 5.25 (1H, d, J = 8.89 Hz, NH), 6.87 (1H, s, CHPh2), 
7.32 (10H, s, Ph2), 7.82 (d), 8.37 (4H, AA’BB’, J = 8.74 Hz, C6H4)
1711: 2.41 (2H, m, CH2p), 3.19 (m), 3.38 (2H, m, CH2S), 4.28 (1H, m, CHCI),
4.60 (1H, m, CHa), 5.39 (1H, d, J = 8.77 Hz, NH)
NMR of 18 
1H NMR (C D C I3 )  8
1.45 (9H, s, t-Bu), 2.49 (2H, m, CH2p), 3.0 (1H, m, CHS), 3.6 (2H, m, CH2CI)
4.8 (1H, m, CHa), 5.49 (1H, m, NH), 6.91 (1H, s, CHPh2), 7.32 (10H, s, Ph2),
7.89 (d), 8.30, (4H, AA’BB’, J = 8.79 Hz, C6H4)
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2-Amino-4-chloro-5-(p-nitrophenvl sulfinvl) pentanoic acid.TFA salt
OM
NHBoc
(L)
C 02CHBz2
anisole,
TFA,
OoC
procedure: M. Johnston, R. Raines, C. Walsh & R. A. Firestone,
J. Am. Chem. Soc., 1980, 102, 4241
In a conical flask, 171 &17II (90mg, 0.153mmol) were dissolved in anisole 
(0.73ml, 6.7mmol) and treated with TFA (3.60ml, 46.7mmol) at 0°C in an ice 
bath with stirring for 12min. The reaction was monitored by TLC using ninhydrin 
spray to visualise free amino acid. Volatiles were then removed in vacuo at 
room temperature and a solution of H20 (5ml) / DCM (5ml) was added. The 
mixture was transferred to a separating funnel and shaken vigorously; the 
aqueous layer was separated and evaporated in vacuo at room temperature, 
affording 49.9mg (102%) of the title amino acid protected as the TFA salt. The 
yield was not absolute and exceeded 1 0 0 % due to the amino acid incorporating 
some water to give a glassy product.
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1H NMR (D20) 5
2.15 - 2.5 (m, 2H, CH2p) 3.25 - 3.55 (m, 2H, CH2S), 4.20 (m, 1H, CHCI), 
4.41 (m, 1 H, CHa), 7.74 (m), 8.24 , (m, 4H, C6H4)
13C NMR (D20) 5
38.2 (CH2p), 52.0 (CHCI), 52.1 (CHa), 63.0, 64.0 (CH2S),
125.6, 126.3, 148.1, 148.6, (4 signals, CH aromatic)
150.7, 150.6 (2 quaternary aromatic), 163.6 (q, TFA), 171.8 (C02H)
N-Fmoc-L-allvlqlvcine
10% Na2C03(aq), NHFmoc
Fmoc-CI, dioxan 
0 2H OoC — r.t. 0 2H
product has never before been prepared 
procedure: L.A. Carpino & G.Y. Han, J. Org. Chem., 37, 3404
In a conical flask, a mixture of L-allylglycine (1.38g, 12.0mmol) and a 10% 
Na2C03 aqueous solution (45ml) were stirred at 0°C in an ice bath. A solution 
of Fmoc-CI (3.12g, 12.06mmol) in dioxan (20ml) was added dropwise over 
30min. The mixture was stirred for a further 5min at 0°C and then allowed to 
warm to room temperature and stirred for another 2h. The solution was then 
poured into H20  (100ml) and extracted with Et20  (2  x 50ml). The aqueous 
layer was separated and cooled in an ice bath before acidifying with 10M HCI 
to pH 1. The white precipitate was extracted with EtOAc (2 x 50ml), washed 
with H20  ( 2  x 50ml), dried over Na2S04 and filtered. The filtrate was 
evaporated in vacuo to give the title compound as a white residue. 
Recrystallisation from MeN02 gave 3.46g (85.6%) of the desired product as 
white crystals, m.p. 140°C (no literature value available).
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ymax (KBr disc) cm'1
1722, 2 3 70 -3 2 00 , 3402
1H NMR (CDCL3) 5
2.53 (2 H, m, CH2p), 4.20 (1H, t, J = 6 . 8 6  Hz,CHa), 4.46 (3H, m, CHCH2 Fmoc),
5.14 (2H, m, CH2 vinyl), 5.69 (1H, m, CH vinyl), 5.44 (1H, d, J = 8.12 Hz, NH), 
7.24 -7.99 (8 H, m, CH aromatic)
13C NMR (CDCL3) 6
36.3 (CH2J3), 47.0 (CHzCH, Fmoc), 53.1 (CHa), 67.2 (CH2, Fmoc),
119.7 (CH2 vinyl), 120.0 -127.7 (4 signals, each 2 aromatic CH’s),
131.64 (CH vinyl), 141.3, 143.6 (2CH’s of the Fmoc group),
156.0 (NHC02),175.8 (C02H)
m/z
found 337.1342 (M+) 
requires 337.3757 (M+)
Microanalysis (%)
found C 70.75 , H 5.55, N 4.25
Requires C 71.22 , H 5.63, N 4.15
N-Fmoc-L-allvlqlvcine cvclohexvl ester
NHFmoc NHFmoc
DCM.DMAP,
0 2H cyclohexanol, 
DCC, OoC— r.t. A
product has never before been prepared 
adapted procedure: J.P. Tam, T. Wong, M.W. Riemen, F. Tjoeng &
R.B. Merrifield, Tetrahedron. Lett., 1979, 4033
A single neck round bottomed flask (100ml) charged with N-Fmoc-L-allylglycine 
(1.99g, 5.92mmol), anhydrous DCM (50ml), DMAP (46mg, 0.38mmol) and 
cyclohexanol (1.40g,14.0mmol) was stirred at 0°C in an ice bath. DCC (1 .2 2 g, 
5.92mmol) was added to the reaction flask and the mixture stirred for a further 
5min at 0°C and 3h at room temperature. The mixture was filtered and the 
filtrate evaporated in vacuo. The residue was taken up in DCM (30ml) and 
refiltered as necessary, washed with 0.5M HCI (2 x 25ml) and an aqueous 
solution of NaHC03 ( 2  x 25ml), dried over Na2S04 and filtered. The filtrate was 
evaporated in vacuo and the resulting yellow oil applied to a silica column, 
eluting with DCM. This gave a clear oil, which recrystallised from DCM giving 
1 .6 6 g (67%) of pure product, m.p. 105 -106 °C.
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ymax (KBr disc) cm'1
1686, 1714, 1738, 2856, 2936, 3324
1H NMR (CDCI3) 5
1.27 -1.79 (m, 1 0 H, 5 x CH2 cyclohexyl), 2.55 (m, 2H, CH20 ),
4.23 (t, 1H, J = 6.93 Hz ,CHa), 4.43 (m, 3H, CHCH2 Fmoc),
4.81 (m, 1 H, C02CHC5Hio), 5.11 (d, 2 H, J = 11.72 Hz, CH2 vinyl),
5.54 (d, 1H, J = 8.14 Hz, NH), 5.68 (m, 1H, CH vinyl),
7.21 - 7.73 (m, 8 H aromatic)
13C NMR (CDCI3) 5
23.5, 25.2, 31.4 (5 x CH2, C6Hi0), 36.3 (CH2p), 47.1 (CH2CH, Fmoc),
53.4 (CH, vinyl), 67.0(CHCH2, Fmoc), 74.0 (CH, cyclohexyl),
119.2 (CH2, vinyl), 120.0, 125.1, 127.0, 127.7 (4 signals, each 2 aromatic CH’s)
132.2 (CH, vinyl), 141.3, 143.8 (2CH’s of the Fmoc group), 155.7 (NHC02),
171.1 (C02H)
m/z
found 419.2117 (M+) 
requires 419.5214 (M+)
Microanalysis (%)
found C 74.66, H 7.19, N 3.15
Requires C 74.50, H 7.40, N 3.34
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N-Fmoc-L-allvlqlvcine cyclohexyl ester
NHFmoc
(L) N2l MeN02,
OoH cyclohexanol, 
p-nitro benzoic anhydride, 
scandium triflate, r.t.
NHFmoc
procedure: K. Ishihara, M. Kubota, H. Kurihara & H. Yamamoto,
J. Am. Chem. Soc., 1995, 117, 4413
A flame dried 50ml round bottomed flask equipped with side arm and septum 
cap, under N2, was charged with N-Fmoc-L-allylglycine (0.625g, 1.86mmol) in 
distilled MeN02 (20ml). Sequentially cyclohexanol (0.169g, 1.69mmol) in 
MeN02 (10ml), p-nitrobenzoic anhydride (0.8g, 2.5mmol) in MeN02 (15ml) and 
scandium triflate (1mg, 0.003mmol) in MeN02 (1ml) were added to the reaction 
flask via syringe. The reaction mixture was stirred overnight and in the morning 
a white precipitate could be seen. The reaction was quenched with NaHC03 
solution (40ml), the product extracted with Et20  (50ml), dried over Na2S04 and 
filtered. The filtrate was evaporated in vacuo and the crude product column 
chromatographed on silica, eluting with DCM to give 1.62g (62%) of the pure 
product.
Analytical data as before.
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TrichloromethvMN-diethvO-sulfenamide
Et20, HNEt2
CI3C Cl  L CI3C NEt2
b N2l -60°C-r.t.
procedure: H. Lecher & F. Holscheneider, Chem. Ber., 1924, 57, 755
A flame dried round bottomed flask (50ml) equipped with side arm and septum 
cap, under N2, was charged with trichloromethyl sulfenylchloride (8 .0 g, 
43mmol) in distilled Et20  (100ml). The mixture was stirred at -60°C and 
diethylamine (6.64g, 90.8mmol) was added over the course of 30min. The 
mixture warmed to room temperature and stirring continued for a further 3h. 
The white precipitate was removed by filtering and the filtrate evaporated in 
vacuo giving 9.09g (95%) of the title product as a yellow liquid.
1HNMR (CDCI3) 6
3.55, 3.34 (m, 4H, 2 x CH2), 1.24 (t, 3H, J = 7.15 Hz, CH3)
13C NMR (CDCI3l) 5 
51.8 (CH2), 14.4 (CH3)
m/z CI3CSNEt2
found 104.0534 (M+-CCI3)
requires 104.1904 (M+ -CCI3)
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Difluorochloromethane sulfenvl chloride
+
1 . SbFs/SbCIs, CIFoC. .Cl 
67°C " s " distillation
2. HCI, ice, 
r.t. — OC
+ ^  CIF2C ^ / I
s
-Cl
+
procedure: N.N. Yarovenko, S.P. Motornyl, A. S. Vasil’eva & T. P. Gershzon, 
J. Gen. Chem. U.S.S.R., 1959, 29, 2129
A 3 neck round bottomed flask (50ml) fitted with a stirrer and a thermometer 
was charged with trichloromethyl-(N-diethyl)-sulfenamide (6.9g, 31 mmol), SbF3 
(4.14g, 18.1 mmol) and SbCI5 (0.14g, 0.47mmol). The mixture was stirred at 
67°C and kept at this temperature until the lower layer became quite black (1h 
45min). The upper layer was separated from the tars, transferred to a 25ml 
conical flask and saturated with dry HCI(g) (in excess) for 2h 30min. The 
reaction mixture was then vigorously stirred and cooled in an ice bath. Finely 
crushed ice was added and the yellow oily layer was quickly separated and 
dried over CaCI2. The different sulfenyl chlorides were separated by Kugelrohr 
distillation. F3CSCI b.p. 0°C (could not be isolated), CIF2CSCI 
b.p. 49°C (1.02g (22%)), CI2FCSCI b.p. 99°C (0.38 g (11%)), CI3CSCI 
b.p. 149°C (not isolated).
CIF2CSCI
19F NMR (CDCI3) 5
-37.1 (s, 2F)
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2-N-Fmoc-4(5l-chloro-5(4)-(chlorodifluoromethvlsulfenvl)pentanoic acid
cyclohexyl ester
cif2c ^ s
NHFmoc
NHFmoc CLF2CSCI, TFA,
Cl CO2C6 H11 
(I)
+
CO2C6H11 N2, DCM, 0°C -> r.t. Cl
NHFmoc
CIF2C
CO2C6H11
(II)
product has never before been prepared
procedure: A. Haas, M. Lieb & Y. Zhang, J. Fluorine Chem., 1985, 203
A flame dried 50ml round bottomed flask with side arm, septum cap and N2 
balloon, was charged with N-Fmoc-L-allylglycine cyclohexyl ester (0.88g, 
2.10mmol) in distilled DCM (15ml) and 100% TFA (0.04g, 0.35mmol). The 
solution was stirred at 0°C in an ice bath and chlorodifluoromethyi sulfenyl 
chloride (0.31 g, mmol) in distilled DCM (10ml) was added over the course of 
30min. The mixture warmed to room temperature and stirred overnight. The 
solvent and TFA were evaporated in vacuo leaving a golden oil. Starting 
material and the two regioisomers were isolated by preparative thin layer 
chromatography using DCM / hexane (10:1) as the eluant to isolate 230mg 
(19.1 %) of regioisomer I.. Regioisomer I could not be fully isolated from the 
starting material and regioisomer II at this stage. Integration of the 1H NMR 
spectrum of the unpurified product mixture indicated that the ratio of 
regioisomers I : II was approximately 2:3.
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Compound I:
1H NMR (CDCI3 ) 8
1.25 -1.89 (m, 1 0 H, 5 x CH2 cyclohexyl), 1.90-2.59 (m, 2H, CH2p),
3.74 (m, Hz, 2H, CH2SCF2CI), 4.02 (m, 1H, CHCI),
4.22 (t, 1H, J = 6 . 8 6  Hz ,CHa), 4.30 - 4.74 (m, 3H, CHCH2 Fmoc),
4.86 (m, 1H, C02CHC5Hio), 5.52 (d, 1H, J = 8.14 Hz, NH),
7.26 - 7.79 (m, 8 H aromatic)
13C NMR (CDCI3) 5
23.6, 25.2, 31.4 (5 x CH2 cyclohexyl), 36.3 (CH2p), 44.7 (CHCI),
47.3 (CH2S), 51.7, CH cyclohexyl), 67.0, (CHCH2, Fmoc),
74.0 (CHCH2, Fmoc), 120.0, 125.1, 127.0, 127.7, (4 signals, 8  x CH aromatic),
132.2 (t, J = 337.2Hz, CF2CI), 141.3, 143.8 (2 aromatic CH’s),
155.7 (NHC02), 171.1 (C02CH)
19F NMR (CDCI3) 8  
-25.81 (s, 2F,-CH2SCF2CI)
Compound II:
1H NMR (CDCI3 ) 6
1.22 -1.81 (m, 10H, 5 x CH2 cyclohexyl), 2.28 (m, 2H, CH2p),
3.51 - 3.77 (m, Hz, 2H, CH2CI), 3.93 (m, 1H, CHSCF2CI),
4.21 (t, 1H, J = 6.80 Hz ,CHa), 4.34 - 4.70 (m, 3H, CHCH2 Fmoc),
4.83 (m, 1 H, CO2CHC5H10), 5.41 (d, 1 H, J = 8 . 8 6  Hz, NH),
7.24 - 7.77 (m, 8 H aromatic)
13C NMR (CDCI3 ) 8
23.5, 25.2, 31.3 (5 x CH 2 cyclohexyl), 34.2 (CH2 p), 45.0 (CHS), 47.10 (CHoc),
47.3 (CH2CI), 51.8, CH cyclohexyl), 67.1, (CHCH2, Fmoc),
74.6 (CH, Fmoc), 120.0, 125.1, 127.1, 127.8, (4 signals, 8  x CH aromatic),
128.0 and 134.1 (2d, J = 315Hz, CF2CI), 141.3, 143.8 (2 aromatic CH’s),
156.0 (NHC02), 170.7 (C02CH)
159
19F NMR (C D C I3 )  8
-25.30 and -26.88 (2m, 2F, CCIF2S), within the 2 multiplets we can distinguish 2 
doublets: -25.20 (d, J = 136.1 ,z -CCI(F)FS),
-27.05 (d, J = 136.1Hz, -CCIF(F)S)
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2-N-Fmoc.4(5).chioro-5(4)(chlorodifluoromethvlsulfinvl)pentanoic acid
cyclohexyl ester
NHFmoc
I
NHFmoc
n
NHFmoc
m
55% mCPBA 
 ►
N2) DCM,
CPC—- r.t
Cl
CIF2C^
NHFmoc
(L)
CO2C6H11
IV
product has never before been prepared 
procedure: M. Johnston, R. Raines, C. Walsh & R. A. Firestone, 
J. Am. Chem. Soc., 1980, 102, 4241
A flame dried round bottomed flask (25ml) equipped with side arm and septum 
cap, under N2, was charged with I & II (0.36g, 0.63mmol) in distilled DCM 
(10ml) and stirred at 0°C in an ice bath. A solution of 55% mCPBA (0.22g,
0.63mmol) in distilled DCM (10ml), with added drying sieves to reduce the 
overall water content, was added to the reaction flask via syringe over 1h. 
After 30min at room temperature the solution was washed with NaHC03 
solution (2 x 10ml), dried over Na2S04, and filtered. The filtrate was 
evaporated in vacuo giving a yellow oil. The oil was applied to a silica column 
and eluted with EtOAc:CHCI3 (50:1) to give 121 mg of product III (21.2% yield, 
or 53% based on the 2:3 ratio of I : II). Product III exists as a number of 
diastereoisomers which were not separated.
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Compound III:
13C NMR (CDCL3) 6
23.5, 25.1, 31.3 (5 x CH2 cyclohexyl), 39 - 40.6 (m, CH2(3), 41.9 (CHCI)
47.0 (CHoc), 50.6 - 51.0 (CH2SO), 51.5, (CH cyclohexyl), 67.2, (CHCH2, Fmoc),
75.1 (CHCH2, Fmoc), 120.0, 124.8, 127.1, 127.7, (4 signals, 8 x CH aromatic)
129.7 & 130.1 (2t, Ji = 2.0Hz & J2 = 2.1 Hz, C(F)FC« & CF(F)CI),
141.3, 143.4 (2 aromatic CH's), 155.6 (NHC02), 170.5 (C02CH)
19F NMR (CDCI3) 6 
-CF2CI
-54.6, (d of d, Ji = 558.5 Hz & J2 = 149.2Hz),
-60.2, (t, J = 455.9Hz),
-58.6 to -60.2 (m)
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2-amino-4-chloro-5-(chlorodifluoromethvlsulfinvl)pentanoic acid
TFA salt
c if2c ^ 0
VvNHFmocCl CO2 C6 H11
/  1. piperidine / DMF, r.t 
/  2. TfOH, 0°C
c i f2c ^  j z
nh2
Cl CQ2H .TFA salt
product has never successfully been prepared 
Procedures: L.A. Carpino & G.Y. Han, J. Org. Chem., 37, 3404 and 
J.P. Tam, Tai-Wai Wong, M.W. Rieman, Foe-S. Tjoeng and R.B. Merrifield,
Tett. Letts., 4033 (1979)
In a conical flask, lll(A) and lll(B) (100mg, 0.17mmol) were dissolved in DMF 
(5ml) and treated with a 20% piperidine / DMF solution (0.17mmol of 
piperidine) and stirred at r.t. for 1 min, the reaction vessel was cooled to 0°C 
and methanesulfonic acid (19.2mg, 0.20mmol) along with 2 drops of TFA was 
then added to the reaction flask. The reaction was stirred at 0°C for 1 h and 
monitored by TLC using ninhydrin spray to visualise free amino acid. No free 
amino acid was observed. Distilled water (5ml) was added to the reaction 
mixture and the mixture transferred to a separating funnel. After shaking 
vigorously, the layers were separated and evaporated in vacuo at room 
temperature. Starting material was recovered (confirmed by NMR). The 
deprotection was then attempted a 2nd time. Starting material III amounting to 
55mg (55%) was the only product recovered.
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BIOLOGICAL TESTING
General Methods:
Drug tests were performed in duplicate using minimum essental medium 
(designated HOMEM medium) on microtitre plates. The parasite starting 
density in each test were 104 cells ml'1. The test cultures comprised of 20pl 
drug + 180pil culture. Apart from the control leg where 20pl H20  replaced the 
20pil drug. Final cell counts were estimated using an inverted microscope.
To observe the range of activity of individual drugs a variety of parasitic 
protozoa were tested. The Trichomonads, Giardia and Entamoeba are 
anaerobic protozoa all the others tested were aerobic protozoa.
The Trichomonads were tested both anaerobically and aerobically as it is 
known that cell lines resistant to the standard drug (metronidazole) show 
resistance only when oxygen is present. However for most drugs it appears to 
make no difference.
Key to parasitic growth densities:
+2
+3 high
medium
+1 low
+ very low 
none
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L-Trifluoromethionine and L-Trifluoromethvl cysteine
Biological activity profiles versus Trichomonas vaginalis 
Growth inhibition results for T. vaginalis in the presence of varying 
concentrations of L-Trifluoromethionine, L-Trifluoromethyl cysteine and the 
known growth inhibitor Metronidazole.
Drug Metronidazole L-Trifluoromethionine L-Trifluoromethyl cysteine
Cone" jig ml-1 Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2
100 - - - - - -
50 - - - - - -
25 - - - - - -
10 - - + + - -
5 - - + + + +
2.5 - - +1 +1 +1 +1
1 + + +2 +2 +1 +1
control +3 +3 +3 +3 +3 +3
Test conditions: 20|il aqueous drug solution + 180|il culture, 24h, aerobic incubation, 37°C, 
microtitre plate. Ref (84) 9/9/93
Biological activity profile versus Trichomonas foetus
Growth inhibition results for T. foetus in the presence of varying concentrations 
of L-Trifluoromethionine, L-Trifluoromethyl cysteine and the known growth 
inhibitor Metronidazole.
Drug Metronidazole L-T rifluoromethionine L-Trifluoromethyl cysteine
Cone" mi mi1 Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2
100 - - +2 +2 + +
50 - - +2 +2 + +
25 - - +3 +3 +1 +1
10 - - +3 +3 +1 +1
5 - - +3 +3 +2 +2
2.5 - - +3 +3 +3 +3
1 + + +3 +3 +3 +3
control +3 +3 +3 +3 +3 +3
Test conditions: 20pl aqueous drug solution + 180p,l culture, 24h, aerobic incubation, 37°C, 
microtitre plate. Ref (84) 15/9/93
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Biological activity profile versus Entamoeba invadens
Growth inhibition results for E. invadens in the presence of varying 
concentrations of L-Trifluoromethionine and L-Trifluoromethyl cysteine.
Drug L-T rifluoromethionine L-Trifluoromethyl cysteine
Cone" mi mi'1 Rep 1 Rep 2 Rep 1 Rep 2
100 +1 +1 +1 +1
50 +2 +2 +2 +2
25 +3 +3 +2 +2
10 +3 +3 +2 +2
5 +3 +3 +3 +3
2.5 +3 +3 +3 +3
1 +3 +3 +3 +3
control +3 +3 +3 +3
Test conditions: 20|xl aqueous drug solution + 180|il culture, 48h, anaerobic incubation, 25°C, 
microtitre plate. Ref (84) 9/12/93
Biological activity profile versus Entamoeba invadens
Growth inhibition results for E. invadens in the presence of varying
concentrations of L-Trifluoromethionine and L-Trifluoromethyl cysteine.
Drug L-T rifluoromethionine L-Trifluoromethyl cysteine
Cone11 (ig ml*1 Rep 1 Rep 2 Rep 1 Rep 2
100 +1 +1 - -
50 +2 +2 + +
25 +2 +2 +1 +1
10 +3 +3 +2 +2
5 +3 +3 +3 +3
2.5 +3 +3 +3 +3
1 +3 +3 +3 +3
control +3 +3 +3 +3
Test conditions: 20jal aqueous drug solution + 180pl culture, 144h, anaerobic incubation, 25°C,
microtitre plate. Ref (84) 13/12/93
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Biological activity profile versus macrophages
Growth inhibition results for macrophages in the presence of varying
concentrations of L-Trifluoromethionine and L-Trifluoromethyl cysteine.
Drug L-T rifluoromethionine L-Trifluoromethyl cysteine
Concn }ig ml'1 Rep 1 Rep 2 Rep 1 Rep 2
100 +3 +3 +1 +1
50 +3 +3 +1 +1
25 +3 +3 +2 +2
10 +3 +3 +3 +2
5 +3 +3 +3 +3
2.5 +3 +3 +3 +3
1 +3 +3 +3 +3
control +3 +3 +3 +3
Test conditions: 20|il aqueous drug solution + 180jil culture, 48h, 5% C 0 2 incubation, 32°C,
microtitre plate. Ref (84) 9/12/93
Biological activity profile versus macrophages
Growth inhibition results for macrophages in the presence of varying
concentrations of L-Trifluoromethionine and L-Trifluoromethyl cysteine.
Drug L-T rifluoromethionine L-Trifluoromethyl cysteine
Cone" pg ml'1 Rep 1 Rep 2 Rep 1 Rep 2
100 +3 +3 - -
50 +3 +3 + +
25 +3 +3 +1 +1
10 +3 +3 +2 +2
5 +3 +3 +3 +3
2.5 +3 +3 +3 +3
1 +3 +3 +3 +3
control +3 +3 +3 +3
Test conditions: 20fil aqueous drug solution + 180pJ culture, 144h, 5% C 02 incubation, 32°C,
microtitre plate. Ref (84) 13/12/93
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Biological activity profiles versus Leishmania mexicana
Growth inhibition results for L  mexicana in the presence of varying 
concentrations of L-Trifluoromethionine, L-Trifluoromethyl cysteine and 
Metronidazole.
Drug Metronidazole L-T rifluoromethionine L-Trifluoromethyl cysteine
Cone" ng ml'1 Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2
100 +3 +3 - + - -
50 +3 +3 + + - -
25 +3 +3 +1 + - -
10 +3 +3 +1 +1 - -
5 +3 +3 +2 +2 - -
2.5 +3 +3 +2 +2 + +
1 +3 +3 +2 +2 + +
control +3 +3 +3 +3 +3 +3
Test conditions: 20pJ aqueous drug solution + 180jil culture, 72h, aerobic incubation, 25°C, 
microtitre plate. Ref (84) 11/10/93
Biological activity profile versus Leishmania maior
Growth inhibition results for L. maior in the presence of varying concentrations 
of L-Trifluoromethionine, L-Trifluoromethyl cysteine and Metronidazole.
Drug Metronidazole L-T rifluoromethionine L-Trifluoromethyl cysteine
Cone" fig ml'1 Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2
100 +3 +3 +1 +1 - -
50 +3 +3 +2 +2 - -
25 +3 +3 +3 +3 - -
10 +3 +3 +3 +3 + +
5 +3 +3 +3 +3 + +
2.5 +3 +3 +3 +3 +1 +
1 +3 +3 +3 +3 +1 +1
control +3 +3 +3 +3 +3 +3
Test conditions: 20^1 aqueous drug solution + 180pJ culture, 72h, aerobic incubation, 25°C,
microtitre plate. Ref (84) 11/10/93
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Biological activity profiles versus Leishmania donovani
Growth inhibition results for L. donovani in the presence of varying 
concentrations of L-Trifluoromethionine, L-Trifluoromethyl cysteine and 
Metronidazole.
Drug Metronidazole L-T rifluoromethionine L-Trifluoromethyl cysteine
Cone" ml*1 Rep 1 Rep 2 Rep 1 Rep 2 Rep 1 Rep 2
100 +3 +3 + + - -
50 +3 +3 + + - -
25 +3 +3 + + - -
10 +3 +3 +1 +1 - -
5 +3 +3 +3 +2 - -
2.5 +3 +3 +3 +3 + +
1 +3 +3 +3 +3 + +
control +3 +3 +3 +3 +3 +3
Test conditions: 20nl aqueous drug solution + 180jil culture, 72h, aerobic incubation, 25°C, 
microtitre plate. Ref (84) 11/10/93
Biological activity profile versus Leishmania tarentolae
Growth inhibition results for L  tarentolae in the presence of varying
concentrations of L-Trifluoromethionine and L-Trifluoromethyl cysteine.
Drug L-T rifluoromethionine L-Trifluoromethyl cysteine
Cone11 fig ml*1 Rep 1 Rep 2 Rep 1 Rep 2
100 + + - -
50 +1 +1 - -
25 +2 +2 - -
10 +3 +3 - -
5 +3 +3 - -
2.5 +3 +3 - -
1 +3 +3 + +
control +3 +3 +3 +3
Test conditions: 20^1 aqueous drug solution + 180pJ culture, 48h, aerobic incubation, 25°C,
microtitre plate. Ref (84) 2/12/93
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Biological activity profile versus Giardia lamblia
Growth inhibition results for G. lamblia in the presence of varying
concentrations of L-Trifluoromethionine and L-Trifluoromethyl cysteine.
Drug L-T rifluoromethionine L-Trifluoromethyl cysteine
Cone11 |ig ml'1 Rep 1 Rep 2 Rep 1 Rep 2
100 +3 +3 - -
50 +3 +3 +1 +1
25 +3 +3 +1 +1
10 +3 +3 +2 +2
5 +3 +3 +2 +2
2.5 +3 +3 +3 +3
1 +3 +3 +3 +3
control +3 +3 +3 +3
Test conditions: 20jil aqueous drug solution + 180pl culture, 48h, anaerobic incubation, 37°C, 
microtitre plate. Ref (84) 2/12/93
170
L-T rifluoromethionine
Biological activity profiles versus a variety of micro-organisms
Growth inhibition results for a variety of micro-organisms in the presence of
varying concentrations of L-Trifluoromethionine.
Drug T. augusta C. fasciculata H.m. muscanum H.m. ingenoplastis L. tarentolae T. pyriforris
Cone" jig ml'1 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2
100 +1 +1 +3 +3 +2 +2 +3 +3 > +3 +3
50 +1 +2 +3 +3 +2 +2 +3 +3 t +3 +3
25 +1 +1 +3 +3 +3 +3 +3 +3 DEAD +3 +3
10 +1 +1 +3 +3 +3 +3 +3 +3 Did +3 +3
5 +1 +1 +3 +3 +3 +3 +3 +3 Not +3 +3
2.5 +1 +1 +3 +3 +3 +3 +3 +3 Grow +3 +3
1 +3 +1 +3 +3 +3 +3 +3 +3 I +3 +3
control +3 +3 +3 +3 +3 +3 +3 +3 I +3 +3
Test conditions: 20pJ aqueous drug solution + 180pl culture, 48h, aerobic incubation, 25°C,
microtitre plate. Ref (84) 29/10/93
Drug T. augusta C .  fasciculata H.m. muscanum H.m. ingenoplastis L. tarentolae T. pyriforris
Cone" |xg ml'1 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2
100 - - + + +2 +2 +3 +3 +3 +3
50 - +3 + + +2 +2 +3 +3 t +3 +3
25 - - + + +2 +3 +3 +3 DEAD +3 +3
10 - - + + +3 +3 +3 +3 Did +3 +3
5 - - + + +3 +3 +3 +3 Not +3 +3
2.5 - - + + +3 +3 +3 +3 Grow +3 +3
1 +3 - + + +3 +3 +3 +3 I +3 +3
control +3 +3 + + +3 +3 +3 +3 I +3 +3
Test conditions: 20jd aqueous drug solution + 180jil culture, 120h, aerobic incubation, 25°C,
microtitre plate. Ref (84) 1/11/93
Kev: T = trichomonas, C = Crithdia, Hm = Herpetomonas, L = Leishmania
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L-Trifl uoromethvl cvsteine
Biological activity profiles versus a variety of micro-organisms
Growth inhibition results for a variety of micro-organisms in the presence of
varying concentrations of L-Trifluoromethionine.
Drug T. augusta C. fasciculata H.m. muscanum H.m. ingenoplastis L. tarentolae T. pyriforris
Cone" im mi*1 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2
100 +3 +3 + + + + - - +2 +1
50 +3 +3 +1 +1 + + +1 +1 t +3 +2
25 +3 +3 +2 +2 + + +3 +3 DEAD +3 +3
10 +3 +3 +2 +2 + + +3 +3 Did +3 +3
5 +3 +3 +3 +3 +1 +1 +3 +3 Not +3 +3
2.5 +3 +3 +3 +3 +2 +2 +3 +3 Grow +3 +3
1 +3 +3 +3 +3 +2 +2 +3 +3 I +3 +3
control +3 +3 +3 +3 +3 +3 +3 +3 I +3 +3
Test conditions: 20^1 aqueous drug solution + 180^1 culture, 48h, aerobic incubation, 25°C,
microtitre plate. Ref (84) 29/10/93
Drug T. augusta C .  fasciculata H.m. muscanum H.m. ingenoplastis L. tarentolae T. pyriforris
Cone" mi'1 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2 R1 R2
100 >s, + + + + - - A < +3 +3
50 +1 +1 + + - - t +3 +3
25 t +2 +2 +1 +1 + + DEAD +3 +3
10 Over­ +2 +2 +2 +2 + + Did +3 +3
5 grown +3 +3 +2 +2 +3 +3 Not +3 +3
2.5 t +3 +3 +3 +2 +3 +3 Grow +3 +3
1 +3 +3 +3 +3 +3 +3 I +3 +3
control I +3 +3 +3 +3 +3 +3 I +3 +3
Test conditions: 20pJ aqueous drug solution + 180jil culture, 120h, aerobic incubation, 25°C,
microtitre plate. Ref (841 1/11/93
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D-Trifluoromethvl penicillamine
Biological activity profiles versus Trichomonas, vaginalis 
Growth inhibition results for T. vaginalis in the presence of varying 
concentrations of D-Trifluoromethyl penicillamine
Drug D-Trifluoromethyl penicillamine
Cone" |tg ml'1 Rep 1 Rep 2 Rep 3
100 +2 +2 +2
10 +3 +2 +3
1 +3 +3 +3
control +3 +3 +3
Test conditions: 20|jJ aqueous drug solution + 180pl culture, 24h, anaerobic incubation, 37°C, 
microtitre plate. Ref (84) 29/4/94
Biological activity profile versus Trichomonas, foetus
Growth inhibition results for T. foetus in the presence of varying concentrations 
of D-Trifluoromethyl penicillamine.
Drug D-Trifluoromethyl penicillamine
Cone" |ig ml'1 Rep 1 Rep 2 Rep 3
100 +3 +3 +3
10 +3 +3 +3
1 +3 +3 +3
control +3 +3 +3
Test conditions: 20pl aqueous drug solution + 180^1 culture, 24h, anaerobic incubation, 37°C, 
microtitre plate. Ref (841 29/4/94
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